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Genomic, proteomic and other experimentally generated data from studies of biological systems 
aiming to discover disease biomarkers are currently analyzed without sufficient supporting 
evidence from the literature due to complexities associated with automated processing. 
Extracting prior knowledge about markers associated with biological sample types and disease 
states from the literature is tedious, and little research has been performed to understand how to 
use this knowledge to inform the generation of classification models from ‘omic’ data. Using 
pathway analysis methods to better understand the underlying biology of complex diseases such 
as breast and lung cancers is state-of-the-art. However, the problem of how to combine literature-
mining evidence with pathway analysis evidence is an open problem in biomedical informatics 
research. 
This dissertation presents a novel semi-automated framework, named Knowledge 
Enhanced Data Analysis (KEDA), which incorporates the following components: 1) literature 
mining of text; 2) classification modeling; and 3) pathway analysis. This framework aids 
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FROM OMIC STUDIES  
Rick Matthew Jordan, M.S. 
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iv 
researchers in assigning literature-mining-based prior knowledge values to genes and proteins 
associated with disease biology. It incorporates prior knowledge into the modeling of 
experimental datasets, enriching the development process with current findings from the 
scientific community.   
New knowledge is presented in the form of lists of known disease-specific biomarkers 
and their accompanying scores obtained through literature mining of millions of lung and breast 
cancer abstracts. These scores can subsequently be used as prior knowledge values in Bayesian 
modeling and pathway analysis. Ranked, newly discovered biomarker-disease-biofluid 
relationships which identify biomarker specificity across biofluids are presented. A novel method 
of identifying biomarker relationships is discussed that examines the attributes from the best-
performing models. Pathway analysis results from the addition of prior information, ultimately 
lead to more robust evidence for pathway involvement in diseases of interest based on 
statistically significant standard measures of impact factor and p-values. 
The outcome of implementing the KEDA framework is enhanced modeling and pathway 
analysis findings. Enhanced knowledge discovery analysis leads to new disease-specific entities 
and relationships that otherwise would not have been identified. Increased disease understanding, 
as well as identification of biomarkers for disease diagnosis, treatment, or therapy targets should 
ultimately lead to validation and clinical implementation.  
v 
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Area under the Receiver Operating Characteristic curve (AUC) – the Receiver Operating 
Characteristic (ROC) curve, is a plot of the True Positive Rate (TPR; Sensitivity or Recall) on 
the y-axis against the False Positive Rate (FPR; 1 – Specificity) on the x-axis. The area under 
the ROC curve (AUC) is a measure of a model’s discriminative performance.   
Bayesian network – is a directed acyclic graph where nodes represent variables and edges 
represent conditional dependencies. Each node has a probability attached to it which is 
conditional on the probability of the probability of its parent’s nodes. Bayesian networks can 
be used to assign a probability to an event that has not happened yet based on prior knowledge 
of other events that have occurred.  
binning – is a data pre-processing technique used to pool similar performing entities into a 
few groups. The pooled group can then be represented by one value instead of many. Binning 
can simplify large datasets into smaller groups for comparisons, however data loss usually 
results.   
BioCreative corpora - is a large and structured set of texts used to perform assessments for 
evaluating text mining and information extraction activities using gene ontology annotation 
terms of human proteins.  
 breadth-first marker propagation – algorithm for traversing or searching tree structures. It 
starts at the tree root and explores the neighbor nodes first, before moving to the next level 
neighbors. Breadth-first searches require only one pass through the tree for model training, and 
thus are faster than other methods that do not. 
conditional independencies - two events are conditionally independent if knowledge of one 
event occurring provides no information on the likelihood of the other occurring. 
cross-validation - a modeling validation process where a dataset is subdivided into smaller 
training and test sets. Different combinations of samples are created by altering the groupings 
of samples. Training and testing of different combinations of samples are performed several 
times and the accuracies averaged. Cross-validation is performed to evaluate how a model will 
generalize to other datasets.  
data mining - a bioinformatics technique for analyzing data and databases to discover 
significant patterns or relationships between biological entities such as genes or proteins 
data parameters – a model consists of variables and parameters that attempt to explain 
relationships among variables. Variables are quantities that can be measured, and parameters 
xviii 
are constants of essential properties (materials, equipment, or measures of central tendency, to 
name a few) of a given experiment. 
data transformation – is where a mathematical function is applied to each data point in a 
dataset with a given probability distribution in order to convert the entire dataset into a 
different probability distribution. 
decision rules – if/then expressions that represent a dependency between a condition and a 
decision. In modeling, these rules can be used to predict classification of subjects into groups. 
enrichment analysis – a type of analysis where groups of genes or proteins are studied 
together to assign biological meaning to the group. The group is usually clustered together as a 
result of function, location, or some other area of interest. Analyzing as groups enables new 
biological patterns to emerge, or to determine whether a subset shows similar expression of a 
biological characteristic, or might belong to similar biological pathways. 
entropy ranking methods – in literature mining, biomedical entities are ranked by frequency 
or relative entropy.  Frequency ranking orders the entities with respect to the number of 
citations. The relative entropy ranking calculates the fraction between the documents 
containing the entity in the result set and the total number of documents containing the entity 
in the complete Medline document set.  
false positive – in statistics, a false positive (type I error) occurs when the null hypothesis (H0) 
is true, but is rejected. A false positive concludes that something exists when it truly does not 
(believe a falsehood). 
feature selection – is the process of selecting a subset of the most relevant features for use in  
model construction. This is performed to eliminate redundant or irrelevant features found in 
datasets. Feature selection can be performed to reduce the amount of time computer algorithms 
spend analyzing irrelevant features. 
Gene Ontology (GO) – is a bioinformatics naming convention that organizes gene and protein 
information.  Gene Ontology provides structured terminology of gene and protein properties 
such as cellular components, molecular functions, and biological processes.  
gene symbol disambiguation – in literature mining, resolving conflicts that arise from  
ambiguous gene names. The same gene may poses several aliases, while the same identifier 
may refer to two very different biological entities, such as ER referring to estrogen receptor, or 
emergency room.  
greedy search – an algorithm that uses a heuristic that makes the locally optimal choice at 
each stage to search a space of classification models. In many cases, a greedy strategy does not 
produce an optimal solution, but may produce a locally optimal solution that approaches a 
global optimal solution in a reasonable amount of time. Finding a truly optimal solution may 
require many steps and a significant time investment. 
xix 
hypergeometric distribution- is a probability distribution that describes the probability of 
successes in  draws, without replacement, where each draw is either a success or a failure. 
The hypergeometric test uses the hypergeometric distribution to calculate the statistical 
significance of having drawn a specific number of  successes (out of  total draws). The test 
is used to identify which sub-populations are over- or under-represented in a sample.  
 local rule learning (local structure search) – used to learn Bayesian network structures. In 
local learning, one or more target variables of special interest are examined; the local structure 
of the target variable is of greater interest than the other variables. Each node in a tree model 
corresponds to an instance of a problem. At each node the local network structure is used to 
create a partial solution to the problem.  
loop condition - conditional loops are a way for computer programs to repeat one or more 
steps depending on a condition. The ‘while’ loop and ‘for’ loop are the two most common 
types of conditional loops in most programming languages. 
MEDLINE - (Medical Literature Analysis and Retrieval System Online) is a literature 
database of biomedical information maintained by the US National Library of Medicine. 
MEDLINE contains more than 18 million records from over 5,000 scientific publications from 
1950 to the present. Each MEDLINE record is manually indexed with NLM's controlled 
vocabulary, known as Medical Subject Headings (MeSH).  
NLPBA – acronym for Natural Language Processing in Biomedical Applications. 
non-small cell lung cancer – a type of lung cancer consisting of adenocarcinomas, large cell 
carcinomas, and squamous cell carcinomas. 
 oncogene  - a gene that when activated promotes tumorous cell growth. 
ontology - a naming convention used to organize information. It can be used to define how to 
represent relationships among objects, concepts, and other entities belonging to a particular 
area of expertise. Gene ontology specifies processes, functions, and cellular locations of gene 
products. 
over-fitting – occurs when a model with too many parameters produces a good fit with the 
sample data but a poor fit with new data.  
 parallel decision tree – in data mining, decision trees are tree-like models on which decisions 
are based. A decision tree is an undirected graph where edges exist between every two 
vertices. However, all attributes need to be sorted in order to choose the appropriate node at 
which to split the tree. Decision trees can require considerable amounts of time, memory, and 
computational resources when utilizing large data sets. Dividing the dataset into smaller pieces 
allows for parallel processing of trees resulting in increased speed, and fewer computational 
resource requirements. 
 PMID – acronym for PubMed Identification that is a unique identifier assigned to every article 
xx 
indexed in PubMed. 
 precision – in information retrieval, precision is the fraction of documents returned that are 
relevant. (precision = relevant / retrieved)  
pre-processing parameters - pre-processing of data is an important step in the data mining 
process, to eliminate false, missing, or noisy data values. Data pre-processing includes 
filtering, normalization, transformation, and feature selection. 
proto-oncogene – a normal gene that once mutated, has the potential to become an oncogene. 
pruning step – in computer science, a technique that reduces the size of decision trees by 
removing sections that add little information to the final classifier. Pruning reduces the 
complexity of the classifier and improves the accuracy of the prediction by reducing the 
possibility of overfitting. 
PubMed - a web-based literature retrieval service provided by the US National Library of 
Medicine. PubMed provides access to several biomedical literature databases, with MEDLINE 
being the largest. 
recall – (a.k.a. sensitivity) in information retrieval, recall is the fraction of relevant documents 
that are retrieved. (recall = relevant documents retrieved / total number of relevant documents) 
search heuristic - a heuristic is a technique for obtaining results of a search faster than 
existing methods, or for finding an immediate estimated solution when existing methods 
cannot produce a true solution. A heuristic, in general, sacrifices accuracy for speed. 
 sensitivity – (a.k.a. true positive rate) in experimental science, sensitivity of a test is the 
number of diseased people that are identified as such by the test, compared to the total number 
of diseased people tested. (sensitivity = diseased identified by test / total number of diseased 
tested). 
small cell carcinoma - a type of lung cancer that is highly malignant, composed of small 
ovoid undifferentiated cells.  
specificity – (a.k.a. true negative rate) in experimental science, specificity of a test is the 
number of healthy people identified as such by the test. (specificity = healthy identified by test 
/ total number of healthy tested). 
xxi 
PREFACE 
Many of the figures and text contained in this work can also be found in the Journal of Clinical 
Bioinformatics article titled ‘Semi-automated literature mining to identify putative biomarkers of 
disease from multiple biofluids’ (Jordan et al. 2014).
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1.0  INTRODUCTION 
In 2014, cancer surpassed heart disease as the leading cause of death worldwide, with 8.2 million 
deaths and 14.1 million new cancer cases reported (World Cancer Report 2014). Furthermore, 
worldwide cancer deaths are predicted to increase well into the future, with lung cancer currently 
being the leading cause of deaths in males, and breast cancer, the leading cause of deaths in 
females.  
Lung cancer is the leading cause of cancer deaths worldwide, and the most common 
cancer in terms of incidence. In 2008, there were 1.61 million new cases, and 1.38 million deaths 
due to lung cancer, with the highest rates occurring in Europe and North America (Ferlay et al. 
2010). The most common cause of lung cancer is long-term exposure to tobacco smoke (Merck 
Manual). Across the developed world, 91% of lung cancer deaths in men during the year 2000 
were attributed to smoking and 71% for women (Peto et al. 2006). Lung cancer carries with it an 
unfortunate prognosis, due to the fact that it is usually not discovered until symptoms arise 
(~75%). Early stage (stages 0-3) diagnoses offer 80% - 10% five year survival rates, whereas 
late-stage survival averages <10% (Collins et al. 2007). 
Breast cancer is the most common invasive cancer in women globally, comprising 22.9% 
of all cancers in women (World Cancer Report 2008). In 2008, breast cancer caused 458,503 
deaths worldwide (13.7% of all cancer deaths in women) (World Cancer Report 2008). Unlike 
lung cancer, no specific activity can be attributed to causing breast cancer, with the majority of 
breast cancer cases, >80%, being classified as non-hereditary or sporadic. However, increases in 
1 
incidence vary significantly around the world being lower in less-developed countries and 
greater in the well-developed countries; modern lifestyles have been implicated in causation 
(Laurance 2006). Breast cancer conveys much better prognoses compared to lung cancer, as it is 
more often discovered earlier, with early stage (stages 0-3) diagnoses providing 93% - 41% five 
year survival rates, while late stage survival averages 15% (Imaginis Corporation 2006). 
  While the number of worldwide cancer deaths have been increasing annually, cancer 
rates have decreased due to awareness and early detection methods. Early detection or screening 
is vital to surviving cancer. The most common lung cancer screening methods include low-dose 
spiral (helical) CT (Computed Tomography) chest scans, chest x-ray, and sputum cytology. Of 
these, helical CT appears to show the most promise as 20.3% fewer lung cancer deaths occur 
among those who were screened with low-dose helical CT compared with those who were 
screened with chest x-rays (http://www.cancer.gov/images/DSMB-NLST.pdf). This is due to 
helical CT using X-rays to obtain a multiple-image scan of the entire chest, while a standard 
chest X-ray produces a single image of the whole chest in which anatomic structures overlie one 
another (http://www.cancer.gov/news-events/press-releases/2011/NLSTprimaryNEJM). The 
most common breast cancer screening methods include self-exams, mammograms, clinical 
exams, and breast imaging via CT and MRI (Magnetic Resonance Imaging). In one study, breast 
cancer screening and management programs have been shown to improve survival rate ~18% 
(Kalager 2009). However, while current screening methods have led to better survival rates, 
millions of people still succumb to cancer each year; and room for improvement on current 
screening methods remains.  
More recent disease screening methods have shown promise in the areas of molecular 
genomic/proteomic (‘omic’) testing for individual gene mutations, proteins and gene panels. 
 2 
Biomarkers, which can be any measurable biological characteristic or substance that indicates a 
particular condition or process, now play a crucial role, with the emergence of personalized 
medicine. Individual biomarkers are currently tested for early detection of hereditary breast 
cancer (BRCA1/breast cancer 1, BRCA2/breast cancer 2, ESR1/estrogen receptor, 
PGR/progesterone receptor, HER2/erb-b2 receptor tyrosine kinase 2, and PARP/poly (ADP-
ribose) polymerase 1); and heterogeneous nuclear ribonucleoprotein (hnRNP), a tumor-
associated antigen found in what appears to be normal lung epithelium in lung cancer cases.  
Moreover, the relatively new field of Pharmacogenomics analyzes an individuals’ genetic 
makeup to determine how they will metabolize or respond to certain drugs. This relatively new 
field combines pharmacology and genomics to develop effective, safe medications and doses that 
will be uniquely tailored to a given individual 
(https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics). Examining the allelic 
makeup of individual genes can help physicians with disease management and treatment.  
Multi-biomarker panels such as OncotypeDx (Lyman et al. 2007) for breast, colon, and 
prostate cancers; and PAM50 (Parker et al. 2009) for breast cancer, have become more common 
as increases in US Food and Drug Administration (FDA) approval have occurred. Since 2003 the 
FDA has cleared or approved ~1000 biomarker-based tests, including 139 tests that measure two 
or more biomarkers (http://www.amplion.com/biomarker-trends/biomarker-panels-the-good-the-
bad-and-the-ugly/). However, with an average of less than 100 biomarker tests per year being 
approved for thousands of diseases, new methods of discovering biomarkers are desperately 
needed.  
 Biomarkers have been discovered in many different ways, ranging from clinical 
observation, to literature/data mining, disease modeling, gene clustering, and analysis of disease-
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related biological pathways. Literature mining provides a wealth of information as the amount of 
scientific knowledge continues to grow exponentially; however, the amount of information can 
also be a hindrance due to its enormity. Data mining identifies differential gene or protein 
expression in numerous disease states, but the findings are only representations of a moment in 
time when the sample was taken. Disease modeling provides precise measurements such as 
accuracy, sensitivity, and specificity, but a given model may not generalize to other/larger 
populations. Pathway analysis allows for visualization of biological processes and protein 
interactions, but is a snapshot of only one pathway in an intertwined biological network of 
pathways that interact and depend on one another. Hence, knowledge discovery (the process of 
discovering useful knowledge from a collection of data) frameworks which improve 
experimental findings by utilizing information obtained from several methods should be more 
desirable, reliable, and accurate. More accurate experimental findings should lead to more likely 
biomarker possibilities and better disease understanding at the molecular level, and ultimately in 
clinical improvements in prevention, maintenance, and treatment.  
1.1 THE PROBLEM 
New approaches are needed to improve methods which ultimately lead to biomarker discovery. 
One possibility is combining prior scientific knowledge from literature mining and experimental 
data to improve knowledge discovery, and subsequent disease modeling and pathway analysis. 
Prior knowledge can exist in many different forms such as facts, theories, beliefs, diagrams, 
charts, measurements, and calculated values. Several challenges are encountered when 
attempting to organize prior knowledge from literature mining: 1) obtaining and organizing 
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information, 2) combining prior knowledge with experimental data, and 3) interpreting 
downstream results. Organizing and presenting others’ findings into a single format is non-
trivial. A carefully designed plan which can accommodate all types of reported findings is 
needed. Converting the prior knowledge in a way that will attribute a weighted significance to 
prior knowledge in relation to experimental data poses another issue. Lastly, many other issues 
arise in the interpretation of modeling and pathway analysis results.   
 
1.1.1 Obtaining and organizing prior information from literature mining 
In organizing prior knowledge several issues must be accounted for: 1) information source, 2) 
search space, 3) experimental design, and 4) scoring method. All of these issues will affect the 
outcome of the study, and must be clearly defined to allow accurate downstream interpretation. 
Information source 
Determining the type of text, as well as the source is an important first step in obtaining prior 
knowledge. Many types of information exist, such as meta-data, clinical reports, original 
research articles, review articles, opinion papers, books, and editorials. A researcher needs to 
determine which type of information can reveal the most relevant findings. Text availability is of 
concern because the full-text of all articles are not freely available; those that are not must be 
purchased from the publisher. Performing an exhaustive search of a substantial-sized corpus of 
full-text articles is currently cost-prohibitive ranging from $10-$40 per article, on average. 
Abstracts on the other hand, are easily-acquired and freely-available, and their size enables easy 





Clearly defining a search space will allow for a truly representative and exhaustive search. 
Defining the search space provides the study specificity by limiting the information included to 
only that which is truly relevant. Without defining a search space, calculated values pertaining to 
system’s performance measures such as accuracy, recall, and precision, cannot be correctly 
determined and could actually be incorrect. Many filters can be applied during this step to limit 
unwanted information from being obtained. Additional factors which may or may not be 
included in a search, not mentioned previously include: disease, disease stage, tissue type or 
biofluid, tumor type, gene or protein of interest, location in the body, treatments, age, sex, and 
diet.  
Experimental design 
Careful experimental design is crucial for any scientific study. All aspects of a study must be 
clearly defined such as: sample size, sample stratification, analysis method and relevant 
calculations, reporting of results, and others. Common issues known to occur in most 
experiments must be taken into account such as how exceptions, biases, confounding, and false 
positives will be handled. For example, in literature mining, false positives may be eliminated by 
using a set of articles not pertinent to the topic at hand (also known as the ‘negative set’). An 
error in the experimental design phase may be fatal to the entire study.  
Scoring method 
Quantifying evidence from literature about disease-biomarker associations in the form of prior 
knowledge as numeric scores is challenging for several reasons. Defining what constitutes 
positive and negative findings is not a trivial process. Common practice in literature mining 
employs the use of a ‘gold standard’. Gold standards may include previously established lists or 
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dictionaries, actual expert assessments, or comparison of results to a previously annotated 
corpus. Obtaining a gold standard source can be quite difficult when studying less-researched 
diseases, or in new method assessments. Determining how mentions of one or more biological 
entities will be counted presents another issue. The question arises, should each mention be 
counted independently, or should all redundant mentions of an entity in one abstract be pooled 
together to provide a single count? Additional complications include score normalization, 
gene/protein ambiguity, the use of abbreviations versus full-length terms, as well as negation.  
 
1.1.2 Combining prior knowledge with experimental data 
Obtaining information and assigning a score to that information constitutes the first step in the 
process. Converting scores into meaningful values and incorporating those values into datasets 
follows. Transforming the values into prior probabilities poses a challenge as many possibilities 
exist such as using raw values, ranking the scores, weighting, or binning. Similarly, several 
options exist in incorporating knowledge into the dataset, such as including the values as a 
separate column in the data, adding or multiplying the experimental data values by the prior 
value, or any combination of the transformation and incorporation methods mentioned.  
 Additionally, the type of experimental data being used also comes with additional 
concerns. Array based data (microarray, protein array) is a common type of experimental data 
produced by researchers today. This allows for examination of thousands of biological entities 
(genes, proteins, miRNAs, and SNPs) simultaneously. However a statistical anomaly exists when 
comparing thousands of entities among tens or hundreds of samples in what is called the 
‘multiple comparison problem’. This problem results in an increase in the false discovery rate 
when the set is considered as a whole (Benjamini & Hochberg 1995). Missing data 
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measurements presents another problem, with possible solutions being to remove the entire 
entity from analysis, or use other measurements to impute a number to fill in the blank. None of 
the possible solutions are ideal. Lastly, many data analysis software packages were not created to 
handle millions of values simultaneously. This creates further issues with the best solution being 
feature selection. In feature selection, entities that do not appear to be relevant are removed from 
the analysis, thus decreasing noise and speeding up the analysis.  
 
1.1.3 Interpreting downstream results 
Machine learning algorithms have the ability to learn data patterns and use that information to 
make predictions. Modeling algorithms have been used to predict the stratification of patient 
samples by examining biological or environmental metrics. Standard models are usually 
accompanied by measures of accuracy, sensitivity, and specificity, in order to assess the models 
strengths and weaknesses in its classifications. While these classifiers have greatly enhanced the 
ability to make predictions, they are somewhat complicated; to many, they are a black box, 
which could lead to incorrect interpretation of important results. A concern exists in examining 
hundreds or thousands of entities; a model may appear to achieve desired levels of accuracy, 
sensitivity, and specificity, but may use so many modeling attributes that the findings may be a 
result of overtraining and the results may be biased. Another issue is that a model that correctly 
classifies samples using one dataset does not mean it will generalize well to other datasets, or the 
general population.   
Pathway analysis provides a visual interpretation of known biological pathways and 
protein-protein interactions. However, many pathway analyses are misunderstood and enable 
some to draw false conclusions. A target gene/protein found to be upstream in a disease pathway 
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or process may be thought to cause or influence other important downstream genes/proteins, but 
this may not be the case. Also a possibility exists that pathway information may not be 
sufficiently updated enough to reflect an entire process. Additionally, not every pathway may be 
represented, interactions between pathways may not be known, and only known pathways can be 
examined. Very few tool exist to predict new pathways. 
Both, classification modeling and pathway analyses require follow-up and validation 
studies, requiring additional time and financial investment. For all of the reasons presented, one 
can see why biomarkers are lacking for many diseases. Different approaches and out-of-the-box 
thinking are needed to take biomarker discovery processes into the future. Defined methods or 
frameworks that can save time and obtain the most up-to-date and relevant information, which 
can then be utilized by well-informed researchers are highly desirable.   
1.2 THE APPROACH 
This dissertation provides a framework for combining prior knowledge with experimental 
datasets to ultimately aid in biomarker discovery. The overall goal is to speed up the time 
investment required to obtain prior knowledge, and then use this knowledge to uncover new 
relationships via classification models and identify pathway genes/proteins that otherwise would 
be missed by conventional analyses.  
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Figure 1. The KEDA framework components and information flow. The semi-automated 
text-mining component of KEDA takes as input positive and negative sets of abstracts returned 
from keyword searches of literature databases. The text-mining component outputs gene/protein 
names and counts obtained from all abstracts in each abstract set. The counts are transformed 
into prior probabilities; and preprocessed datasets are obtained. For classification modeling, the 
priors are incorporated into the datasets and used as input into a modeling algorithm, which 
outputs classifiers, model accuracy values, and the markers used to build the models. For 
pathway analysis, the datasets are analyzed first to obtain a single expression score per 
gene/protein. Each score is multiplied by the prior probability to obtain an updated expression 
value reflecting prior knowledge. These values accompany the gene/protein names in a list that is 
input into pathway analysis software which outputs pathway impact factors, p-values, and 
diagrams for each pathway. 
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The Knowledge Enhanced Data Analysis (KEDA) framework as shown in Figure 1 
incorporates the following components: 1) text-mining of literature; 2) classification modeling; 
and 3) pathway analysis. The generalized flow of information is described in Figure 1. The 
current implementation of the KEDA framework is described as follows: in text-mining of the 
literature, research abstracts from PubMed (http://www.ncbi.nlm.nih.gov/pubmed) were 
examined for gene/protein mentions, scores were produced for each entity, and the scores 
transformed into prior probabilities.  
Publicly-available datasets were normalized if needed, and features were selected using 
the J5 method (Patel et al. 2004) in caGEDA (Patel & Lyons-Weiler 2004). Remaining feature 
data was matched with prior probabilities, the datasets formatted if needed, and input into the 
Bayesian Rule Learner algorithm (Gopalakrishnan et al. 2010) for disease modeling exercises. In 
the modeling step, Bayesian networks (BNs) containing target nodes with zero parents are 
examined initially. Variables are added to the BN’s as parent nodes and scored. The best-scoring 
BN’s are retained on a beam for further analysis, stored by score. In this way, only the highest 
scoring BN structures that retain the ability to improve are explored. The beam is checked for 
models where the score can be improved by the addition of another parent variable. Greedy 
searches are performed by adding one more variable as an additional parent of the target, and 
scores are recalculated to see if the score of the model improved with the addition of a new 
parent variable. The process continues until Bayesian scores cannot improve further and the best 
scoring model is presented to the user in the form of a rule model (Gopalakrishnan et al. 2010). 
Model performance measures (accuracy, sensitivity, and specificity) were analyzed to determine 
the method’s performance. Attributes of the best-performing models were compared to known 
disease biomarker lists to uncover novel relationships.  
 11 
In the pathway analysis step, prior probabilities were multiplied to post-data analysis J5 
results and input into Pathway Express. Pathway performance measures (number of input genes 
in pathway, impact factor, and p-value) were analyzed to determine the method’s performance. 
Each pathway was visually examined to compare the number of genes and individual 
genes/proteins that were identified by the different methods examined.  
1.2.1 Theses 
The central thesis is that the KEDA Framework is sufficient for incorporating knowledge from 
literature mining into disease modeling from omic datasets and to enhance the results from 
pathway analyses. 
Based on experiments performed on several array-based lung and breast cancer publicly 
available datasets of various experimental types, complexity, and sizes, the following specific 
claims are made:  
Claim 1:  The text-mining component in KEDA is a sufficient method of obtaining 
putative biomarkers, assigning a prior knowledge score per biomarker, and 
estimating biomarker specificity for biofluids. 
Claim 2: A) Incorporation of prior information from literature mining does not degrade 
classifier modeling performance, on average. 
B) Analyzing the attributes used to build the best-performing classification
models leads to new biological relationships being uncovered. 
C) Incorporation of prior information enhances pathway analysis results by
identifying more input genes in disease-relevant pathways. 
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1.3 SIGNIFICANCE 
From a bioinformatics perspective, this work is significant for a number of reasons: 
 A framework is developed and evaluated that utilizes a semi-automated text-mining 
method to produce a list of documented putative biomarker/biofluid relationships from millions 
of abstracts. If desired, researchers can apply the described methods to their own diseases of 
interest. The list of known disease-specific biomarkers, created as the gold standard, is novel, 
and was compiled from several databases for this work. Researchers now have a list to use for 
validation of their own work, when researching breast and/or lung cancer. Very few published 
works examine more than one or two biofluids at a time, whereas this work examines 14 
biofluids simultaneously. Additionally, ranked, newly discovered biomarker-disease-biofluid 
relationships are presented; as well as biomarker specificity across biofluids. The genes/proteins 
presented are assumed to be disease specific (breast and lung cancer), and their accompanying z-
scores are also novel. Researchers looking for values to use as informed priors now have a 
resource, and do not have to invest the time and effort to produce them, as it has already been 
done for them.  
A new method of identifying possible biomarker relationships by examining the 
attributes from the best-performing models is described. Pathway analysis results were enhanced 
by the addition of prior information. Improved pathway analysis should ultimately lead to more 
robust disease-specific biomarkers, as well as improved disease-specific knowledge discovery. It 
is not apparent the extent to which others have investigated prior knowledge incorporation in 
pathway analysis. The pathway results presented here may be the first to show the improvement 
obtained by incorporation of prior knowledge. 
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1.4 DISSERTATION OVERVIEW 
The rest of this work is organized as follows: Chapter 2 provides background information 
concerning lung and breast cancer, text-mining phases, modeling, pathway analysis, and current 
use of prior knowledge in molecular biology.  Chapter 3 discusses the methodology used. 
Chapter 4 discusses the experimentation and evaluation methods, and examines the results. 
Chapter 5 is a discussion section focusing on conclusions and future work. 
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2.0 BACKGROUND 
In this chapter, as this work centers on lung and breast cancer, background statistics are provided 
and a molecular perspective included. Additional background is given on the several phases of 
literature mining, as it is the process used to obtain prior knowledge. An introduction to Bayesian 
modeling is also presented, as this is the modeling method chosen for this work. Last, summary 
of the numerous ways that prior knowledge is currently being used in molecular biology is given. 
2.1 STATISTICS & MOLECULAR ASPECTS OF LUNG AND BREAST CANCER 
Lung Cancer 
Lung cancer is characterized by uncontrolled cell growth in lung tissues. Most primary lung 
cancers are carcinomas, which are derived from epithelial cells. The two major forms of lung 
cancer are non-small cell lung cancer (NSCLC; 85% of total lung cancer cases) and small cell 
lung cancer (SCLC; 15% of total lung cancer cases). Non-small cell lung carcinomas (NSCLC) 
can be stratified into squamous cell lung carcinoma, adenocarcinoma, and large cell lung 
carcinoma subtypes. Squamous cell lung carcinomas account for 25% of lung cancers (Travis 
2002), usually start near a central bronchus (Figure 2), and often grow more slowly than other 
cancer types (Vaporciyan et al. 2000).  Adenocarcinoma accounts for 40% of non-small cell lung 
cancers (Travis 2002), and usually originate in peripheral lung tissue. Most cases of 
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adenocarcinoma are associated with smoking, but adenocarcinoma is the most common form of 
lung cancer (Subramanian & Govindan 2007) among non-smokers as well (Horn et al. 2012).  
Figure 2. Diagram of the lung (www.abc.net.au). 
Most small-cell lung carcinomas (SCLC) arise in the larger airways (primary and 
secondary bronchi; Figure 2) (Collins et al. 2007), grow quickly and spread early. 60–70% of 
SCLCs have metastatic disease at presentation, and are strongly associated with smoking (Horn 
et al. 2012).  
Non-smokers account for 15% of lung cancer cases (Thun et al. 2006, 2008), which can 
be attributed to genetic factors (Gorlova et al. 2007; Hackshaw et al. 1997), radon gas 
(Catelinois et al. 2006), asbestos (O'Reilly et al. 2007),  and air pollution (Kabir et al. 2007; 
Coyle et al. 2006; Chiu et al. 2006) including secondhand smoke (Carmona 2006; WHO, 2002). 
Second-hand smoking is a major cause of lung cancer in non-smokers. Studies have shown a 
significant increase in relative risk among those exposed to secondhand (passive) smoke (CDC 
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1986; Boffetta et al. 1998; Department of Health 1998; NHMRC 1994). Recent research of 
passive smoke suggests that it may be more dangerous than direct smoke inhalation (Schick & 
Glantz 2005). Radon is a colorless, odorless gas created from the breakdown of radium, which is 
the decay product of uranium. Radiation decay products can ionize DNA, causing mutations that 
can turn cancerous. Radon exposure is the second major cause of lung cancer, after smoking 
(Catelinois et al. 2006). Radon levels vary by location due to the composition of the soil and 
rocks. The Environmental Protection Agency (EPA) estimates that one in 15 homes in the U.S. 
has radon levels above the recommended guideline (EPA 2006). Asbestos, a silicate material, 
can cause a variety of lung diseases, including lung cancer. In the UK, asbestos accounts for 2–
3% of male lung cancer deaths (Darnton et al. 2006). Asbestos can also cause mesothelioma. 
Outdoor air pollution has a small effect on increasing the risk of lung cancer. Fine particulates 
and sulfate aerosols, which may be released in traffic exhaust fumes, are associated with slightly 
increased risk (Alberg & Samet 2010; Chen et al. 2008). Outdoor air pollution is estimated to 
account for 1–2% of lung cancers (Alberg & Samet 2010).  Factory and power plant emissions 
also pose potential risks (Kabir et al. 2007; Chiu et al. 2006). 
The lung is a common place for metastasis from other parts of the body. Primary lung 
cancers most commonly metastasize to the adrenal glands, liver, brain, bone (Vaporciyan et al. 
2000; Tan & Zander 2008), opposite lung, and kidneys (Greene 2002).  
Non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC) 
prognoses are usually poor. The overall five-year survival for patients with SCLC is about 5% 
(Horn et al. 2012). Patients with more advanced SCLC have an average five-year survival rate of 
less than 1%. The median survival time for early-stage disease is 20 months, with a five-year 
survival rate of 20% (Merck Manual). According to the National Cancer Institute, the median 
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age at diagnosis of lung cancer in the United States is 70 years (SEER 2010), and the median age 
at death is 72 years. Lung cancer, is the second most common cause of cancer-related death in 
women, causing ~12.0% of cancer deaths in women annually (Catelinois et al. 2006). The age 
group most likely to develop lung cancer is over-fifty with a history of smoking. The mortality 
rate in men has been declining for more than 20 years, while women's lung cancer mortality rates 
have been rising steadily over the last decades, but have recently begun to stabilize (Jemal et al. 
2004). Eastern Europe has the highest lung cancer mortality among men, while northern Europe 
and the U.S. have the highest mortality among women. Lung cancer incidence is currently less 
common in developing countries (WHO 2004). With increased smoking in developing countries, 
the incidence is expected to increase in the next few years, notably in China (Zhang et al. 2011) 
and India (Behera & Balamugesh 2004). 
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Figure 3. Mutated pathways in lung adenocarcinomas (Harris & McCormick 2010) 
The main causes of any cancer include carcinogens (such as those in tobacco smoke), 
ionizing radiation, and viral infection. Exposures cause cumulative changes to the DNA in the 
epithelial lining of the lungs, and as more tissue becomes damaged, cancer develops (Vaporciyan 
et al. 2000). Also, nicotine seems to depress the immune response to malignant growths in 
exposed tissue (Sopori 2002). There is a genetic predisposition to lung cancer. In relatives of 
people with lung cancer, the risk is increased 2.4 times, and may be due to genetic 
polymorphisms (Kern & McLennan 2008). Lung cancer is initiated by activation of oncogenes 
(genes enabling susceptibility to cancer) or inactivation of tumor suppressor genes (Fong et al. 
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2003). Proto-oncogenes turn into oncogenes when exposed to particular carcinogens (Salgia & 
Skarin 1998). Mutations in the K-ras/Kirsten rat sarcoma viral oncogene homolog proto-
oncogene are responsible for 10–30% of lung adenocarcinomas (Herbst et al. 2008; Aviel-Ronen 
et al. 2006). The EGFR/epidermal growth factor receptor regulates cell proliferation, apoptosis, 
angiogenesis, and tumor invasion. Mutations and amplification of EGFR are common in non-
small-cell lung cancer (Figure 3) (Herbst et al. 2008). Chromosome damage can lead to loss of 
heterozygosity, and can cause inactivation of tumor suppressor genes. Damage to chromosomes 
3p, 5q, 13q, and 17p are common in small-cell lung carcinoma (Qaiser 2012). The TP53/tumor 
protein p53 tumor suppressor gene, located on chromosome 17p, is affected in 60-75% of cases 
(Devereux et al. 1996). Other genes that are often mutated or amplified are MET/MET proto-
oncogene, receptor tyrosine kinase, NKX2-1/NK2 homeobox 1, STK11/serine-threonine kinase 
11, PIK3CA/phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha, and 
BRAF/B-Raf proto-oncogene, serine/threonine kinase (Herbst et al. 2008).  
 
Breast Cancer 
Breast cancer is a type of cancer that originates from breast tissue, most commonly from the 
inner lining of milk ducts or the lobules that supply the ducts with milk (Sariego 2010). Cancers 
originating from ducts are known as ductal carcinomas; those originating from lobules are 
known as lobular carcinomas (Figure 4). While the majority of cases are women, men can also 
develop breast cancer. 
 
 20 
Figure 4. Diagram of the breast. (www.impressive-breast.com/blog/anatomy-female-breast/) 
A woman's risk of breast cancer is increased if her mother, sister, or daughter had breast 
cancer, and the risk becomes significant if at least two close relatives had breast and/or ovarian 
cancer (Medew 2010). Family history accounts for ~10% of the cases, in general. In hereditary 
breast cancer syndrome, 10-20% of patients with breast cancer have a first- or second-degree 
relative with this disease. The most well-known of these, the BRCA1 and BRCA2 mutations, 
confer a 60-85% lifetime risk of breast cancer (http://www.cancer.gov/about-cancer/causes-
prevention/genetics/brca-fact-sheet). Approximately 2% of the female population carries the 
BRCA1 or BRCA2 gene mutation (Wooster & Weber 2003). The inherited mutation in BRCA1 
or BRCA2 genes can interfere with or inhibit the repair of DNA cross links and DNA double 
strand breaks (Patel et al. 1998; Marietta et al. 2009; Theruvathu et al. 2005). Because of repair 
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deficits, the risks from carcinogens and ionizing radiation can increase (Friedenson 2000; 
Friedenson 2012),  allowing more mutations, which can lead to uncontrolled division, lack of 
attachment, and metastasis to distant organs (Dunning et al. 1999).  
A woman who has had breast cancer in one breast is at an increased risk of getting a 
second breast cancer. Later age of first birth and not having children account for ~30% of U.S. 
breast cancer cases. Factors correlated with higher income contributed to 19% of cases (Madigan 
et al. 1995). Atypical hyperplasia and lobular carcinoma in situ (LCIS), which are found in 
benign breast conditions, are correlated with an increased breast cancer risk. Those with a normal 
body mass index (BMI) at age 20 who gained weight as they aged had nearly double the risk of 
developing breast cancer after menopause, compared to women who maintained their weight 
(NCI 2010). Hormone replacement therapy significantly increases the incidence of breast cancer 
(Sulik 2010). Additional risk factors include: being female (Giordano et al. 2004), choosing not 
to have children or breastfeed (Collaborative Group on Hormonal Factors in Breast Cancer 
2002), increased hormone levels (Yager & Davidson 2006; Santoro et al. 2009), race, iodine 
deficiency (Venturi 2001; Aceves et al. 2005; Stoddard et al. 2008), high-fat diet (Chlebowski et 
al. 2006), alcohol intake (Boffetta et al. 2006), obesity, estrogen exposure (Cavalieri et al. 2006), 
radiation exposure (ACS 2005; Feig & Hendrick 1997; National Research Center for Women & 
Families 2009), shiftwork (WHO 2007), and other risk factors (Begg et al. 2008).  
Breast cancer is around 100 times more common in women than in men, but males 
usually have poorer outcomes due to delays in diagnosis (World Cancer Report 2008; NCI 
2011). Pre-menopausal women tend to have a worse prognosis than post-menopausal women 
(Peppercorn 2009). Unfortunately, sometimes breast cancer is not discovered until it has already 
metastasized. Common sites of breast cancer metastasis include bone, liver, lung and brain 
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(Lacroix 2006). The World Cancer Research Fund estimated that 38% of breast cancer cases in 
the US are preventable through reduced alcohol intake, increased physical activity, maintaining a 
healthy weight, and breastfeeding of children (Eliassen et al. 2010; American Institute for 
Cancer Research/ World Cancer Research Fund). Carcinogens take advantage of deficiencies in 
biological pathways that require normal BRCA1 and BRCA2 function. Avoiding these 
carcinogens reduce the risks for BRCA1/2 mutation carriers (Friedenson 2010).  
Figure 5. PI3K/AKT pathway diagram (journal.frontiersin.org). 
Normal cells commit apoptosis when they are no longer needed. Until then, they are 
protected from cell suicide by several protein pathways. Two of the protective pathways are the 
PI3K/AKT pathway (Figure 5) and the RAS/MEK/ERK pathway (Figure 6). If the genes in these 
protective pathways are mutated, turning them permanently "on", the cell is incapable of 
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committing suicide when it is no longer needed (SABCS 2009). Normally, the 
PTEN/phosphatase and tensin homolog protein turns off the PI3K/AKT pathway when the cell is 
ready for apoptosis. In some breast cancers, the gene encoding the PTEN protein is mutated, 
rendering the PI3K/AKT pathway being stuck in the "on" position, and the cancerous cell can no 
longer commit suicide (SABCS 2009).  
Figure 6. RAS/MEK/ERK pathway diagram (www.medchemexpress.com). 
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Breast cells have receptors on the surface, in the cytoplasm and on the nucleus. 
Hormones bind to these receptors causing cellular changes. Breast cancer cells may have 
estrogen receptor (ESR1), progesterone receptor (PGR), and HER2 receptors, or any 
combination of the three. Cells without these receptors are called triple negative, however they 
may possess other hormone receptors such as androgen and prolactin receptors. 
2.2 LITERATURE MINING 
Scientific information has become overwhelming in its extent and size, creating querying 
difficulties for scientists and physicians, as the literature mining process can be described as 
tedious at best. Many literature mining methods have been described (Adamic et al. 2002; 
Hirschman et al. 2002; Leonard et al. 2002; Novichkova et al. 2003; Srinivasan 2004; Wren et 
al. 2004; Cohen & Hersh 2005; Hristovski et al. 2005; Jensen et al. 2006; Xuan et al. 2007; and 
Krallinger et al. 2008, among others), and have created a solid foundation for future literature 
mining researchers.   
Figure 7. Literature mining process. Information retrieval - identify subset of articles from a 
much larger collection; Entity recognition - identifying biological entities (genes/proteins); 
Information extraction - identify relationship between a pair of biological entities; Knowledge 
discovery – aka ‘hypothesis generation’; drawing connections for novel relationships; Integration 
- integrate literature findings with other data types; potential for making biological discoveries. 
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Literature mining consists of several activities:  information retrieval, entity recognition, 
information extraction, knowledge discovery, and integration. Delineation of the boundaries 
between the components is sometimes difficult, especially between information extraction and 
knowledge discovery (Figure 7).  
INFORMATION RETRIEVAL 
‘Information retrieval’ is the term given to the process of identifying relevant information. This 
information may be articles, abstracts, full text papers, or book chapters. Information retrieval is 
used to identify a subset of articles from a much larger collection. In text mining, information 
retrieval can be used to automatically extract features of interest from a set of documents. These 
features can in turn be used in combination with other algorithms to separate documents into 
relevant (positive) and non-relevant (negative) sets.  
The two most common types of information retrieval techniques are, ‘Boolean’ and 
‘Vector Model’. The Boolean method retrieves all documents that contain user-defined keywords 
using the Boolean logic operators ‘AND’, ‘OR’, and ‘NOT’. In the vector model, each term is 
assigned a value according to a frequency-based weighting scheme (Jensen et al. 2006). 
 Vector documents can be compared to a query that specifies the relative importance of 
each query term. Vectors can also be used as input for machine learning methods trained to 
discriminate between positive and negative documents by word content (Jensen et al. 2006). 
PubMed (http://www.pubmed.org) uses both the Boolean and vector models. Google Scholar 
(http://scholar.google.com) uses a ranking system for retrieval that ranks based on weighting of 
the full text, title, author, publication, and other citations in the literature (Beel & Gipp 2009).
26 
Information retrieval has been heavily studied (Wilbur & Yang 1996; Stapley & Benoit 
2000; Donaldson et al. 2003; and Kayaalp et al. [online]). MedMiner (Tanabe et al. 1999) 
(http://www.discover.nci.nih.gov/host/1999_medminer_abstract.jsp), XplorMed (Perez-Iratxeta 
et al. 2001) (http://bioinformatics.ca/links_directory/tool/10185/xplormed), Textpresso (Muller 
et al. 2004) 
(http://www.textpresso.org), PubFinder (Goetz & von der Lieth 2005) 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160190/), and GeneInfoMiner (Xuan et al. 
2005) are tools that have all been developed to aid in information retrieval from scientific 
literature. 
NEGATIVE ABSTRACT SETS 
False positive elimination from text mining findings can be aided by the use of negative abstract 
sets, which are abstracts that are not specifically about the relationship of interest.  Descriptions 
of the implementation and use of negative sets of abstracts is sparse in the literature. This fact is 
somewhat puzzling due to the standard use of control sets in experimental design, in general. 
Nonetheless, the use of negative abstracts has been implemented in this work. This is a 
significant contribution of this work that not many others have explored in text mining. One of 
the benefits of using a negative set is the elimination of having to use other computational 
methods to minimize false discovery. A drawback is that bias that may exist in abstract selection. 
A literature search identified only a few biomedical text mining papers that describe the 
use of negative sets of abstracts (Andrade & Valencia 1998; Adamic et al. 2002; Al-Mubaid & 
Singh 2005; Deyati et al. 2012; and Younesi et al. 2012). 
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Adamic (2002) described a statistical approach for finding novel gene-disease 
relationships. A frequency of occurrence count was discussed for relevant abstracts compared to 
a random set. Gene pairs and gene symbol disambiguation results were compared to a manually-
edited breast cancer gene database. 
Al-Mubaid and Singh (2005) covered a method for discovering protein-disease 
associations from MEDLINE abstracts. They employed a protein/disease dictionary and 
“positive” and “negative” abstract sets. The positive set was disease-relevant abstracts, 
determined by a PubMed keyword search; the negative set was a random set of abstracts that did 
not mention the disease. Their method identified disease-relevant proteins by comparing the 
frequency distributions of protein names in the positive set and the total set (union of the positive 
and negative sets), and selected proteins where the frequency distributions were statistically 
significantly different. 
Andrade and Valencia (1998) annotated biological functions of protein sequences. In this 
article, the ‘treatment of text with statistical methods’ was discussed. The authors estimated word 
significance from a protein family set of abstracts by comparing each word’s abundance and 
distribution to a background set of protein family abstracts. 
Younesi et al. (Younesi et al. (2012); Deyati et al. 2012) divided the biomarker 
terminology into six concept classes (clinical management; diagnostics; prognosis; statistics; 
evidence; and antecedent). This extra level of stratification significantly reduced the number of 
retrieved relevant documents. Frequency and entropy ranking methods were used for acquired 
genelists with frequency ranking performing better than entropy ranking.  
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ENTITY RECOGNITION 
Named entity recognition (NER), is the term given to the process of identifying biological 
entities (genes/proteins) mentioned in text. While the process may sound simple enough, a closer 
look reveals difficulties that exist. One of the main problems is a lack of standardization (Jensen 
et al. 2006). A complete dictionary of all biological entities does not exist. A given biological 
entity may have several names, abbreviations, or multi-word names. Similarly, the same word or 
phrase can refer to different entities (Cohen & Hersh 2005). Dealing with such ambiguity is not 
trivial. NER is possibly the most difficult task in biomedical text mining and is a prerequisite for 
both information extraction (IE) and information retrieval (IR) (Jensen et al. 2006). 
NER systems are typically measured in terms of precision (P; correct predictions/total 
predictions) and recall (R; correct predictions/number of named entities in the text) (Cohen & 
Hersh 2005). Precision and recall often are combined into a F-score (F = 2PR / [P+R]) (Perez-
Iratxeta et al. 2005), or can also be reported by balancing precision and recall levels (Cohen & 
Hersh 2005). 
Rule-based methods (Fukuda et al. 1998; Narayanaswamy et al. 2003; and Tanabe & 
Wilbur 2002) and machine-learning algorithms using gene and protein tagged corpora (Tanabe & 
Wilbur 2002) (AbGene, P=85.7%, R66.7%); Collier et al. 2000; Zhou et al. 2004 (P=66.5%, 
R=66.6%); McDonald & Pereira 2005; and (Settles 2005; ABNER, 
http://www.cs.wisc.edu/~bsettles/abner, P=74.5%, R=77.8%) have been described. Dictionary 
(lexicon)-based methods (Donaldson et al. 2003; Chiang et al. 2004; Yu & Agichtein 2003; 
Cohen 2004; Liu & Friedman 2003; Yu et al. 2002; Schwartz & Hearst 2003; Chang et al. 2002) 
primarily used for synonym and abbreviation extraction have been extensively studied. 
Combinations of dictionaries with rule-based/statistical methods (Leonard et al. 2002; Mika & 
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Rost 2004; Finkel et al. 2005; and Chang et al. 2004 (GAPSCORE, 
http://bioinformatics.oxfordjournals.org/content/20/2/216.full.pdf+html, P=74%, R=81%) have 
been developed to reduce false positives. Other methods have been used to resolve ambiguity in 
biological names (Narayanaswamy et al. 2003; Eriksson et al. 2002; Hanisch et al. 2005) (IHOP; 
http://www.ihop-net.org/UniPub/iHOP/help.html). 
Overall, the performance of state-of-the-art gene and protein NER systems achieve F-
scores between 75 and 85 percent. While performance measures have not increased over the past 
few years, investigators are obtaining very consistent results using a variety of different 
approaches on different data sets (Cohen & Hersh 2005). 
INFORMATION EXTRACTION 
The goal of information extraction is to identify a relationship between a pair of biological 
entities. While the entity type is usually very specific (genes, proteins, and drugs) the 
relationship type can be general (biochemical association) or specific (regulatory relationship) 
(Cohen & Hersh 2005). Two methods of information extraction are common, co-occurrence or 
frequency-based scoring methods and NLP-based methods which combine analysis of semantics 
and syntax. 
Manual template-based methods use patterns (usually in the form of regular expressions) 
generated by domain experts to extract concepts connected by a specific relation from the text 
(Yu et al. 2002). Automatic template methods utilize patterns from the text surrounding concept 
pairs that are known to have the relationship of interest (Yu & Agichtein 2003; Cohen 2004). 
Statistical methods identify relationships by looking for concepts that are found in combination 
with each other more often than predicted by chance (Lindsay & Gordon 1999). 
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Mining and mapping text from MEDLINE and UMLS Metathesaurus has been the focus 
of much of the work in this area (Hristovski et al. 2005; Srinivasan 2004; Stapley & Benoit 
2000; Blaschke et al. 1999; Hristovski et al. 2001; Weeber et al. 2000; Weeber et al. 2003; Ding 
et al. 2002; Stephens et al. 2001). The UMLS Metathesaurus is the largest biomedical thesaurus, 
and provides biomedical knowledge consisting of concepts that are classified by semantic type 
and also employs hierarchical and non-hierarchical relationships among the concepts (Aronson 
2001). MEDLINE is the National Library of Medicine (NLM) journal citation database. It was 
created in the 1960s, and now provides more than 22 million references to biomedical journal 
articles dating back to 1946. MEDLINE contains citations from more than 5,600 journals. The 
MEDLINE database can be accessed through PubMed as well as other services. What sets 
MEDLINE apart from the rest of PubMed is being able to use the NLM controlled vocabulary, 
Medical Subject Headings (MeSH), to index citations 
(https://www.nlm.nih.gov/pubs/factsheets/dif_med_pub.html). 
PubMed has been publicly available since 1996. It contains more than 25 million 
references including the MEDLINE database and additional citations: 1) in-process citations; 2) 
articles that are out-of-scope (general science and chemistry journals) from MEDLINE, 3) pre-
print citations of MEDLINE indexed journals; 4) citations that precede the MEDLINE indexing 
of a journal; 5)  citations that have not been updated with current MeSH headings and have not 
been converted to MEDLINE; 6) citations to added life sciences journals that submit full-text to 
PubMed Central (PMC); 7) citations to manuscripts published by NIH-funded researchers; 8) 
citations for the majority of books available on the NCBI Bookshelf 
(https://www.nlm.nih.gov/pubs/factsheets/dif_med_pub.html).  
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Frequency-based methods usually produce better recall, but worse precision when 
compared to NLP-based methods. Frequency-based methods are unable to extract directional 
relationships, and also have difficulty distinguishing between direct and indirect relationships 
(Jensen et al. 2006). 
NLP-based methods perform a substantial amount of sentence parsing (Stanford parser; 
http://nlp.stanford.edu/software/lex-parser.html) to break down the text into a structure where 
relationships can be easily extracted (Friedman et al. 2001). 
Several different approaches have been described to identify interactions between genes 
and proteins based on frequently seen verbs in MEDLINE abstracts (Sekimizu et al. 1998); for 
automatic extraction focusing on protein-protein interactions (Blaschke et al. 1999); for 
combining a syntactic/semantic grammar in a single parsing process to extract a variety of gene 
pathway relationships (McDonald et al. 2004); to use dictionaries of proteins and interaction 
terms to identify protein-protein interactions within a sentence (Albert et al. 2003); to use NLP to 
extract causal relations between genes and diseases (Freudenberg & Propping 2002); for using a 
corpus (GENIA; semantically annotated; http://www.geniaproject.org/) for text-mining 
information extraction (Kim et al. 2003); and others (Andrade & Bork 2000; Hirschman et al. 
2004; Yeh et al. 2004). 
One common NLP-method uses a tree structure for each sentence to delineate noun 
phrases and represent interrelationships. A set of rules is then used to extract relationships based 
on the tree and semantic labels. One negative aspect of using NLP-based methods is that it is 
extremely difficult to extract relationships that span several sentences (Jensen et al. 2006). 
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KNOWLEDGE DISCOVERY 
‘Knowledge discovery’ or ‘hypothesis generation’ is the next step in the literature mining 
process. Articles have been written about drawing implicit connections from separate literatures 
by extracting facts from different publications to infer new previously undiscovered 
relationships. Swanson and others (Zhu et al. 2006; Frijters et al. 2010; and Li & Liu 2012) have 
published numerous articles describing the implicit connections they uncovered. Several 
examples include: showing that fish oil can help patients with Raynaud syndrome (Swanson 
1986), eleven neglected connections of migraine and magnesium (Swanson 1988), implicit 
connections between Somatomedin C and arginine (Swanson 1990), and connections linking 
estrogen to Alzheimer’s disease (Smalheiser & Swanson 1996). The software ARROWSMITH 
(http://arrowsmith.psych.uic.edu) which is a computer-assisted approach for formulating scientific 
hypotheses by identifying words shared between articles was also created (Smalheiser & 
Swanson 1998) to aid in this type of discovery process. It is quite probable that other novel 
relationships exist and are waiting to be discovered.  
The main driver of development of hypotheses has been co-occurrence of terms from 
MEDLINE (Xuan et al. 2007; Hristovski et al. 2005; Srinivasan 2004; Stapley & Benoit 2000; 
Blaschke et al. 1999; Hristovski et al. 2001; Weeber et al. 2000; Weeber et al. 2003; Ding et al. 
2002; Stephens et al. 2001.) Others have developed interesting methods for discovery as well. 
Jensen built a network of human genes (Jensen et al. 2006); Freudenberg described a similarity-
based method for genome-wide prediction of disease-relevant human genes by clustering 
diseases based on their phenotypic similarity (Freudenberg & Propping 2002); Xuan developed 
MarkerInfoFinder to identify relationships between genetic markers and disease incorporating 
cytoband location, sequencing annotation, and diseases from OMIM (Xuan et al. 2007); and 
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Turner created POCUS to mine genomic sequence annotations to predict disease genes based on 
over-representation of annotation between loci for the same disease (Turner et al. 2003).   
INTEGRATION 
An integration framework combines data-mining approaches that integrate literature with other 
data types and has great potential for making biological discoveries (Jensen et al. 2006).  Several 
methodologies are described here but overall, integration of text and data mining results has not 
been as extensively studied as the other literature mining components. 
Perez-Iratxeta et al. (2002) described a method relating genes to inherited diseases using 
fuzzy relations in data mining, and established G2D as a tool for mining genes associated to 
disease (http://g2d2.ogic.ca/) (Perez-Iratxeta et al. 2005). Van Driel et al.’s (2003) method 
showed that given positional and expression/phenotypic data, it is possible to integrate data from 
several databases to produce an overview of interesting genes. Tiffin et al. (2005) integrated text- 
and data-mining using ontologies to successfully select disease gene candidates. Lustgarten et al. 
(2008) created the EPO-KB database to assist with identification and coordinate knowledge of 
validated biomarkers and their links to proteins, peptides, modifications, and disease. Further, 
they showed that ‘using EPO-KB as a pre-processing method for biomarker selection found only 
in the biofluid of the proteomic dataset creates an increase in performance over no or random 
variable selection’ (Lustgarten et al. 2009). 
2.3 CLASSIFICATION MODELING 
Classification is a supervised learning approach to biological data analysis which utilizes a 
training-set of samples to determine a specific set of measures or rules to use in placing new 
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individuals in groups. Once the training of the model has been performed, the learned rules will 
be applied to a new set of samples, called the test set. Modeling performance measures can be 
calculated based on the correctness in placing the new samples into the correct groups. An 
algorithm which implements a mathematical function for classification is known as a classifier. 
Classification can also be referred to as modeling. Many modeling algorithms exist, with logistic 
regression (Cox 1958; Walker & Duncan 1967), Bayesian modeling (Bayes 1763; Pearl 1998), 
support vector machines (Vapnik & Chervonenkis 1964; Boser et al. 1992; Cortes & Vapnik 
1995), decision trees (Quinlan 1983; 1987), and neural networks (McCulloch & Pitts 1943), 
being the most common. Classification is distinguished from clustering or unsupervised learning. 
Clustering is an unsupervised learning approach to biological data analysis where the 
grouping of subsets of entities (genes or proteins) is accomplished by using a similarity measure. 
Once clustered, the members of the group will be more similar to each other than to entities in 
other groups, based on the similarity measure implemented. Cluster analysis encompasses many 
different clustering algorithms, with hierarchical (Sibson 1973; Defays 1977), k-means (Forgy 
1965; Lloyd 1982), and density-based (Martin et al. 1996), being the most commonly used.   
2.3.1     Bayesian analysis  
Bayesian analysis is a statistical method which uses Bayes' theorem to assess the probability of 
an event occurring based on prior knowledge. Hypotheses are tested through probability 
distributions of scientific data. These distributions depend on unknown quantities called 
parameters. In Bayesian analysis, knowledge about model parameters is expressed by a 
probability distribution on the parameters, called the "prior distribution".  
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Prior probability is an assumption. Uncertainty may exist in using a prior, and may have 
an unknown effect on the results and subsequent conclusions. This uncertainty can be eliminated 
by using uniform or uninformed priors, or by not using prior information at all. However, 
including previous information in addition to experimental data may add another level for model 
building. Care must be taken, in creating priors, when attempting to attach a value to previously 
known information. 
Uniform priors or ‘un-informed’ priors may be used when not much previous knowledge 
is available, or when a large amount of experimental data is available. No assumptions are made 
concerning the data, and a constant value is input for all entities, relegating the prior values to 
relatively irrelevant status. In this case, the greater importance is placed on the obtained 
experimental data, ignoring previous knowledge. 
Informed prior probabilities can be used when previously known information is available, 
and when experimental data is limited. Additional effort is required to produce values, but the 
new information can be added to the experimental data, in hope of producing more informative 
results, with greater accuracy than when using uniform priors or no priors at all.  
Prior information regarding model parameters is expressed as a ‘likelihood’, which is 
proportional to the distribution of the data given the model parameters. This information is 
combined with the prior to produce an updated probability distribution called the ‘posterior 
distribution’, on which all Bayesian inference is based (https://bayesian.org/Bayes-Explained). In 
Bayes' Theorem (Equation 1), the occurrence of an event given an observation (P(E|F)) is 
calculated by the probability of the occurrence of that observation given the event (P(F|E)), times 
the probability of the event (P(E)), divided by the probability of the observation (P(F)).  
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𝑃𝑃(𝐸𝐸|𝐹𝐹) =  
𝑃𝑃(𝐹𝐹|𝐸𝐸)𝑃𝑃(𝐸𝐸)
𝑃𝑃(𝐹𝐹)
Equation 1. Bayes Theorem. 
where P(E|F) is the conditional probability, the numerator P(F|E)P(E) is the joint probability, and 
the denominator P(F) is the marginal probability (Neapolitan 2004). 
A Bayesian network (BN) is a directed acyclic graph consisting of a structure and 
probability parameters (Neapolitan 2004). Bayesian modeling requires learning the structure and 
parameters of the model. Variables are represented as nodes, and relationships between the 
variables are represented as directed arcs. The BN consists of a child variable (target), and parent 
variables (of that target). Probability can be assigned to the child node based on the probability 
of the parent nodes. The probability distributions for all variables represent the joint probability 
distribution over all of the variables (Pearl 1998).  
Figure 8. A hypothetical Bayesian Network example. (Neapolitan 2004) 
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For example, examine the BN (Figure 8) borrowed from Neapolitan 2004. Each node Xi 
has a conditional probability distribution P(Xi | Parents (Xi)) that calculates the effect of the 
parents on the node. Probabilities of each child node can be calculated based on the known 
probabilities of the parent node. The parameters are the probabilities in the conditional 
probability tables. Using a Bayesian network to calculate probabilities is known as Bayesian 
inference. Real-world or hypothetical conditions of any kind can be calculated using Bayesian 
inference, as long as the conditional probabilities are known.  
Bayesian procedures can be utilized in classification modeling by enabling the 
calculation of group membership probabilities, which provide more information than just 
assigning a group-label to each new observation. There are several reasons that Bayesian 
methods are becoming more popular. Bayesian modeling is preferred because it is centered on 
probability theory; expert opinion and data are used to build models; model uncertainty is 
accounted for; and models can be updated when new knowledge is obtained.  
On the other hand, prior probabilities are subjective and some statisticians see this as a 
drawback. However, powerful computational tools allow Bayesian methods to tackle complex 
statistical problems with relative ease (https://bayesian.org/Bayes-Explained).  
Bayesian analysis utilizes prior knowledge to improve classification results. Several 
works described below utilize Bayesian methods and prior knowledge to improve performance 
measures compared to other methods.  
Zhou & Zheng (2013) improved predictive performance and identified discrepancies 
between data, and achieved a prior known graph structure by examining network structures that 
represent biochemistry interactions. They proposed a Bayesian random graph-constrained model, 
38 
rGrace that combines a priori network information with empirical evidence, to be used for 
pathway analysis.  
Zhao et al. (2012) correctly identified the pathways reported to play essential roles in 
controlling bone mass by applying a Monte Carlo Markov Chain algorithm to a microarray data 
set, to improve understanding of the gene expression profile of osteoblasts at defined stages of 
differentiation. Their method used novel Bayesian models to integrate microarray data with 
KEGG pathway structures and gene-gene interactions from the literature.  
Hill et al. (2012) achieved competitive variable selection performance using empirical 
Bayes with pathway-based priors. Prior biological knowledge was incorporated as weighted 
informative prior distributions over variable subsets using an empirical Bayes formula. The 
empirical Bayes method aided in variable selection and guarded against misspecification of 
priors.  
Kim et al. (2012) proposed a Bayesian approach for identifying pathways related to 
different types of outcomes. They incorporated prior knowledge into a Bayesian hierarchical 
model and achieved more accurate coverage probability than likelihood-based approaches, 
especially when the sample size is small compared with the number of genes being studied. They 
suggested analyzing gene sets created based upon prior biological knowledge, as opposed to 
common statistical methods for microarray analysis that only consider one gene at a time, and 
may miss small gene-level changes.  
Stingo et al. (2011) identified markers that would have been missed and improved the 
prediction accuracy of a Bayesian model by incorporating pathway and gene network 
information into analysis of DNA microarray data. The information was used for pathway 
summaries, specifying priors, and structuring the Markov chain Monte Carlo (MCMC) moves to 
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fit the model. By integrating biological knowledge into the analysis they achieved a better 
understanding of underlying molecular processes. 
Kim et al. (2011) inferred a signaling pathway related to lung cancer using Reverse 
Phase Protein Microarray (RPPM), which provided information about post-translational 
phosphorylation. The pathway was inferred by learning a Bayesian network and Protein-Protein 
Interaction (PPI) prior knowledge that was incorporated into a new scoring function based on the 
minimum description length (MDL) (Rissanen 1978). Their cluster-based Linear Programming 
Relaxation can search for optimal networks.  
Parikh et al. (2010) discovered dependencies among genes while reducing the 
computational resources needed in processing high-throughput datasets by using a Bayesian 
framework to incorporate prior biological knowledge. The single-gene expansion algorithm 
ranked genes from a large gene-expression repository, as potential new members in search of 
new constituents of the known pathway. Inferring Bayesian networks from expression data is a 
powerful tool for learning complex genetic networks, since incorporation of prior knowledge can 
uncover dependencies among genes.  
Jenkinson et al. (2010) produced statistical methods for estimating rate constants of a 
biochemical reaction system from time series data using perturbations. They introduced a 
Bayesian analysis approach for computing rate constants of a closed biochemical reaction system 
from experimental data and used a prior probability density function that integrated biophysical 
and thermodynamic knowledge. 
Husmeier and Werhli (2007) improved reconstruction of gene regulatory networks 
from microarray data by integrating biological prior knowledge expressed as energy functions, 
from which a prior distribution over network structures were obtained as a Gibbs distribution. 
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The hyperparameters of this distribution represent the weights associated with the prior 
knowledge relative to the data.  
2.4 PATHWAY ANALYSIS 
Pathway analysis has become an important step in the biological data analysis process. Pathways 
provide a visual representation of gene/protein interactions in physiological processes. High-
throughput experimental profiling analyses produce lists of differentially expressed 
genes/proteins. Grouping long lists of genes/proteins into smaller sets of related genes/proteins 
implicated in similar pathways reduces the complexity of analysis from thousands of 
genes/proteins to hundreds of pathways (Khatri et al. 2012). Additionally, identifying pathways 
that differ between two conditions can have more illustrative power than a simple list of 
differentially expressed genes or proteins (Glazko & Emmert-Streib 2009). Knowledge-based 
pathway analysis identifies pathways that may be affected in a condition by associating 
information in a pathway database with gene expression patterns for the disease of interest. The 
result is differential expression of a set of genes or proteins rather than a list of individual genes 
(Khatri et al. 2012).  
Pathway tools have been created to aid researchers in biological experimental data 
interpretation. By providing a visual representation, pathway tools allow researchers to 
determine upstream and downstream genes/proteins that affect or are affected by a gene/protein 
of interest, which ultimately may allow for discovery of targets for disease treatment.  
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Table 1. Pathway analysis tools. Names, access, and sources of common pathway analysis tools 
are provided. (Adapted from Khatri P, Sirota M, Butte AJ. Ten Years of Pathway Analysis: 
Current Approaches and Outstanding Challenges. PLoS Comput Biol 2012, 8(2): e1002375). 
Several generations of pathway analysis approaches have been described in the literature. 
First-generation pathway approaches utilize Over-Representation Analyses (ORA). ORA 
methods evaluate the fraction of genes in a pathway that are found among the set of differently 
expressed genes (Table 1) (Khatri et al. 2012). ORA methods create an input list using a 
threshold or criteria (differentially expressed genes for a condition at a false discovery rate 
(FDR) of 5%). Then, for each pathway, input genes are counted. Every pathway is then tested for 
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over or underrepresentation in the list of input genes. (Khatri et al. 2002; Draghici et al. 2003; 
Berriz et al. 2003; Beissbarth & Speed 2004; Boyle et al. 2004; Castillo-Davis & Hartl 2002; 
Martin et al. 2004; Doniger et al. 2003). The most commonly used tests are based on the 
hypergeometric, chi-square, or binomial distribution (Khatri et al. 2012). Comparisons of ORA 
tools can be found in Khatri & Draghici 2005; and Huang et al. 2009.  
Second-Generation pathway approaches employ Functional Class Scoring (FCS). FCS is 
based on the premise that large changes in individual genes as well as smaller changes in 
functionally related gene sets (pathways) may have significant effects (Khatri et al. 2012). Most 
FCS methods use three steps (Ackermann & Strimmer 2009): Step 1) a gene-level statistic is 
calculated by computing differential expression of individual genes or proteins from 
experimental measurements. Gene-level statistics include: correlation of molecular 
measurements with phenotype (Pavlidis et al. 2004), ANOVA (Al-Shahrour et al. 2005), Q-
statistic (Goeman et al. 2004), signal-to-noise ratio (Subramanian et al. 2005), t-test (Al-
Shahrour et al. 2005; Tian et al. 2005), and Z-score (Kim & Volsky 2005).  
Step 2) gene-level statistics of all pathway genes are combined into a single statistic. The 
statistic can represent interdependencies among genes (Kong et al. 2006; Lu et al. 2005; Xiong 
2006; Hummel et al. 2008; Klebanov et al. 2007) or it can ignore them (Tian et al. 2005; Jiang & 
Gentleman 2007). The pathway-level statistic can depend on the number of differentially 
expressed genes, the size of the pathway, and the gene correlation within the pathway (Khatri et 
al. 2012).  
Step 3) statistical significance of the pathway statistic is determined. Null hypothesis 
testing can be broken down into two categories: 1) competitive null hypothesis and 2) self-
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contained null hypothesis (Goeman & Buhlmann 2007; Ackermann & Strimmer 2009; Tian et al. 
2005; Efron & Tibshirani 2007). A competitive null hypothesis permutes gene labels in the 
pathway, and compares the gene set in the pathway with another gene set not in the pathway. A 
self-contained null hypothesis permutes class labels (phenotypes) for each sample and compares 
the pathway gene set with itself, ignoring genes not in the pathway (Khatri et al. 2012).  
Third Generation pathway approaches are Pathway Topology (PT)-Based. These 
approaches utilize protein-protein interaction databases in a given pathway, how the proteins 
interact, and where they interact within the cell. The databases include KEGG 
(www.genome.jp/kegg/pathway.html; Ogata et al. 1999; Kanehisa & Goto 2000), MetaCyc 
(Karp et al. 2002), Reactome (www.reactome.org/PathwayBrowser/; Joshi-Tope et al. 2003;  
Joshi-Tope et al. 2005), RegulonDB (Huerta et al. 1998), STKE 
(http://dictybase.org/STKE.htm), BioCarta 
(http://cgap.nci.nih.gov/Pathways/BioCarta_Pathways), and PantherDB (Thomas et al. 2003). 
ORA and FCS methods only depend on the number of pathway genes or gene co-
expression to identify significant pathways. They do not incorporate additional information. 
Therefore, as long as they contain the same set of genes, the two methods will produce the same 
results. Pathway topology (PT)-based methods utilize the additional information as well. PT-
based methods are the same as FCS methods, but also incorporate the use of pathway topology to 
compute gene-level statistics (Khatri et al. 2012).  
Pathway Express (vortex.cs.wayne.edu/Projects.html; Khatri et al. 2005; Khatri et al. 
2007, Draghici et al. 2007) is a third generation pathway analysis approach that calculates an 
impact factor (if) in the analysis. The impact factor encapsulates the entire pathway by 
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incorporating biological factors such as gene expression, types of interactions, and location of 
genes within the pathway (Draghici et al. 2007; Khatri et al. 2007). Impact factor analysis 
represents a pathway as a graph, with the nodes representing genes and edges signifying 
interactions between the nodes.  
A perturbation factor (PF) for a gene is calculated as a sum of its differential expression 
and factors of all genes in the pathway (Equation 2). The impact factor is the sum of all 
perturbation factors for all genes in a pathway (Equation 3). Impact factor analysis was improved 
to address the effect of differential expression on the perturbation factor and the high false 
positive rate observed for small lists of input genes (Tarca et al. 2009). 
Impact Factor Analysis 
Impact factor analysis (Draghici et al. 2007; Khatri et al. 2007) computes a perturbation factor 
for each gene in each pathway as follows (Equation 2, Khatri et al. 2012): 
Equation 2. Pertubation factor 
∆F(gi), represents the normalized change in expression of gene gi. The second term 
accounts for the topology of the pathway, where gene gj is upstream of gene gi. Bji represents the 
interaction between gi and gj. If gj activates gi, Bji = 1, and if it inhibits gi, Bji = -1. The PF of 
gene gj is then normalized by the number of downstream genes it interacts with, Nds(gi). The 
second term is repeated for every gene that is upstream of another gene. After computing PF for 
each gene, the impact factor (IF), is computed using Equation 3 (Khatri et al. 2012): 
45 
Equation 3. Impact factor 
In the first term, Pi is the probability of obtaining a statistic as extreme as the one 
observed for a true null hypothesis. In order for the IF to be large for severely impacted pathways 
(with small p-values), the first term uses 1/pi rather than pi. The log function converts the 
exponential scale of the p-values to a linear scale. The second term sums up all of the PFs for all 
genes in the pathway Pi, and is normalized by the number of differentially expressed genes in the 
pathway.  
After computing the PFs for all genes in the pathway, Equation 3 is used to calculate the 
impact factor for each pathway. The impact factor of each pathway is then used to assess the 
impact of the gene expression data set on all of the pathways (with higher impact factors 
equating to the more significant the pathway) (Khatri et al. 2012). 
2.5 PRIOR KNOWLEDGE USE IN BIOINFORMATICS 
Many molecular biological experiments performed are exploratory in nature, examining 
thousands of genes or proteins at once with the goal of uncovering an individual or panel of 
biomarkers for a disease or condition. Bioinformatics techniques such as machine learning 
(Solomonoff 1957), pattern recognition (Carvalko & Preston 1972), image analysis (Exner & 
Hougardy 1988), or information retrieval are then performed to group genes/proteins or predict 
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sample classifications. Lastly, incorporating experimental results with current scientific 
knowledge and pathway analysis allows for conclusions to be drawn and more-targeted 
experiments to follow.  
 Only recently has prior knowledge incorporation during analysis with other types of data 
become common. The use of prior biological knowledge can improve the classification results 
such as accuracy, reproducibility and interpretability. The addition of prior knowledge into tried-
and-true molecular techniques has improved results, as well as enabled more creativity and 
produced some very innovative and intriguing concepts in many different areas of biological 
research. The following section describes the different types of prior knowledge and how they 
are used for different purposes in molecular biology analyses.  
Bioinformatic Tools 
Bioinformatic tools have been developed to aid researchers in processing and analysis of 
enormous amounts of information. These tools expedite the time investment, and streamline 
results based on relevancy.  
Sun et al. (2015) developed the Drug-specific Signaling Pathway Network (DSPathNet) 
which combines prior drug knowledge and drug-induced gene expression via random walk 
algorithms. Drugs exert their effects through interconnected networks of multiple signaling 
pathways, but it is difficult to incorporate interwoven pathways into one network. DSPathNet 
can be used to construct drug-specific signal transduction networks and produce models for 
exploring signaling pathways, to assist in the understanding of drug action, disease pathogenesis, 
and identification of drug targets. 
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Johannes et al. (2011) introduced pathClass, which is a collection of different SVM-
based classification methods to improve gene selection and classification performance. The 
methods contained in pathClass rely on gene expression data and also exploit gene network data. 
Yang et al. (2007) introduced GS2PATH, a tool for gene-set enrichment from prior 
knowledge, such as gene ontology (GO) and pathway databases. GS2PATH can estimate gene 
set enrichment in GO terms from KEGG and BioCarta pathways, and allows users to compute 
and compare functional over-representations. Gene-set enrichment can be useful in metabolism, 
signal transduction, genetic and environmental information processing, cellular processing, and 
drug development.  
Causal Pathways 
Causal pathways can be used to map events or changes that can lead to disease. Four examples of 
causal pathways utilizing prior knowledge incorporation are provided: Causal networks 
constructed from individual relationships from scientific literature aid in gene-expression data 
interpretation.  
Kramer et al. (2014) developed a method to predict downstream effects on biological 
functions and diseases.  They presented tools for deducing and scoring regulator networks 
upstream of gene-expression data-based on a large-scale causal network derived from the 
Ingenuity Knowledge Base (IPA; http://www.ingenuity.com).  
Catlett et al. (2013) described Reverse Causal Reasoning (RCR), a reverse engineering 
method to infer hypotheses from molecular profiling data. RCR aids in interpretation of gene 
expression profiling and provides an approach to the development of models of disease, drug 
action, and drug toxicity. Their methodology requires literature-curated cause-and-effect 
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relationship prior knowledge that can link an upstream mechanism to downstream quantity. 
Whistle, can be used for the analysis of gene expression data using prior knowledge expressed in 
Biological Expression Language (BEL).  
Silver et al. (2012) detected multivariate trait gene pathways, and used them to identify 
causal pathways that produce structural changes in the brains of Alzheimer's disease (AD) 
patients. The method known as pathways sparse reduced-rank regression (PsRRR) uses group 
lasso penalized regression to model the effects of genome-wide SNPs that are grouped into 
functional pathways using gene-gene interaction prior knowledge.  
Martin et al. (2012) introduced Network Perturbation Amplitude (NPA) scoring. The 
NPA scoring method interprets high-throughput measurements and a priori literature-derived 
knowledge of cause and effect relationships in the form of network models to characterize the 
activity of biological processes at high-resolution. The relationships were used to create network 
models of biological processes, such as inflammation or cell cycle progression.  
Clustering 
Hierarchical clustering groups similar performing genes/proteins together based on function or 
expression. A similarity measure or metric is used to determine “closeness” of genes in relation 
to other genes. The addition of prior knowledge into clustering exercises has been shown to 
improve clustering results.  
Milone et al. (2014) improved clustering of biological data by prior knowledge 
incorporation in a novel training algorithm that evaluated the biological connections of the data 
points while self-organizing maps (SOMs) clusters and biologically-inspired SOMs (bSOM) 
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were being formed. Inclusion of biological information during training increased the biological 
value of the clusters, improved the results, and simplified further analysis.  
Hwang et al. (2012) significantly improved the classification of disease phenotypes and 
disease pathway genes in experiments testing disease phenotype-gene associations in OMIM and 
KEGG. Phenotypes and genes were co-clustered to simultaneously detect associations between 
phenotype clusters and gene clusters. The algorithm created a phenotype-gene association matrix 
utilizing phenotype similarity and protein-protein interaction prior knowledge, disease classes 
and biological pathways.  
Gene enrichment 
In gene enrichment analysis, groups of genes are studied together to assign biological meaning to 
the group, as opposed to gene expression analysis where each gene is studied individually. The 
gene group is usually clustered together as a result of expression analysis, function, protein 
family, or some other area of interest using prior knowledge. Analyzing groups of genes enables 
new biological patterns to emerge, or to determine whether a subset shows similar expression of 
a biological characteristic, or might belong to similar biological pathways. Researchers now 
combine pathway, gene enrichment analysis and network-based approaches to identify 
relationships between different molecular mechanisms.  
Huang et al. (2012) developed the Pathway and Gene Enrichment Database (PAGED), to 
enable disease-specific pathway, gene signature, microRNA target, and network queries by 
integrating gene-set prior knowledge from the genome, transcriptome, and proteome. PAGED 
explores relationships between gene-sets as gene-set association networks. This shows promise 
for developing tools which will perform even better than third-generation pathway analysis 
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approaches, allowing for the discovery of molecular phenotypes for disease-associated pathway 
and gene enrichment analysis. 
Gene-gene interaction 
Gene-gene interaction (epistasis) occurs when the activity of one gene is dependent on the 
presence of other genes. Certain interactions among gene products or mutations within genes can 
result in downstream effects that can drastically alter biological processes.  
Gomez-Vela and Diaz-Diaz (2014) developed GeneNetVal to assess the biological 
validity of gene networks using gene-gene interactions in KEGG metabolic pathways. 
Converting KEGG pathways into a gene association network with a distance measure of gene-
gene interactions was proposed. 
Ma et al. (2012) identified and validated an interaction affecting a complex trait in multi-
ethnic populations, based on a knowledge-driven analysis of epistasis. Gene-gene interactions 
that affect lipid levels were tested, using prior knowledge of established GWAS hits, protein-
protein interactions, and pathway information.  
King et al. (2005) identified a "nexus" of genes that are attractive candidates for 
therapeutic targeting by using pathway techniques to study atherosclerosis as an integrated 
network of gene interactions. They describe their pathway development approach which is based 
on connectivity from language parsing of published literature, and ranking by differentially 
regulated genes in the network. The discussed a systems biology approach that accounts for gene 
interactions in atherosclerosis, incorporates non-transcriptionally regulated genes, and integrates 
prior knowledge. The results of their work show the advantages of a systems-based approach to 
analyzing complex diseases.  
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Genome-wide Association Studies  
Genome-wide association studies (GWAS) can be used to examine genetic data as well as 
demographic data or other types of information or prior knowledge to determine if a variable is 
associated with a phenotype, condition, or disease. GWAS studies can be used to investigate an 
entire genome for single-nucleotide polymorphisms (SNPs) and variants associated with a 
disease.  
Brenner et al. (2013) used a two-stage approach to investigate associations between 
variants in inflammatory pathway genes and lung cancer risk genes. Variants were identified 
using keyword and pathway searches of Gene Cards and Gene Ontology databases. Hierarchical 
modeling (HM) was used to incorporate variant prior information. A matrix of priors was 
constructed using: gene role in inflammation and immune pathways; physical properties such as 
location, conservation scores and amino acid coding; linkage disequilibrium (LD) with other 
variants; and heterogeneity.  
Li et al. (2012) described a hybrid set based test (HYST) that combined the extended 
Simes' test and scaled chi-square test. The test combination of tests was used to produce a set of 
genome-wide association signals at multiple SNPs in order to determine the significance of 
association at gene/pathway levels. HYST can be used to examine SNP-sets based on prior 
biological knowledge, as well as evaluate statistical significance for protein-protein interactions 
to increase the power for detecting disease-susceptibility genes.  
Liu et al. (2012) detected previously not-significant genes and determined novel drug 
targets and disease biomarkers using prior biological knowledge to restrict the set of candidate 
SNP pairs to be tested. They examined interactions among genomic loci (epistasis) as potential 
sources of missing heritability in genome-wide association studies, and presented four 
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approaches to detect interactions involved in complex diseases: ‘(1) for each gene, a gene-
specific set of SNPs produced a gene-based interaction model, (2) for each pathway, a pathway-
specific gene-set of SNPs provided a pathway-based interaction model, (3) a disease-related 
gene-set of SNPs resulted in a network-based interaction model, and (4) a SNP function 
framework.’  
Jia et al. (2011) tested GWAS association data integrated with human protein-protein 
interaction (PPI) network prior-knowledge using a dense module searching (DMS) method that 
identified gene-sets for complex diseases. Proteome studies were used to examine interactions 
between genes and the pathogenesis of complex diseases. Functional enrichment analysis 
showed that genes identified by DMS have higher association signal. 
Chen et al. (2011) presented a GWAS framework that was more effective in identifying 
disease-associated genes than a single gene-based method. The Markov Random Field (MRF) 
model incorporated pathway topology for association analysis.  
Being that GWAS usually focus on the analysis of single markers, which lack power to 
detect small effect sizes of most genetic variants, pathway-based approaches utilizing prior 
biological knowledge allow for more powerful analyses. Wang et al. (2010) reviewed the 
development of GWAS pathway-based approaches, and suggest that pathway-based approaches 
may also be useful for GWAS of sequencing data. 
Metabolomics 
Metabolomics studies specific cellular processes in cells, and provides a snapshot of cell 
physiology at the time the sample is taken.  Van den Berg et al. (2009) explored relations 
between metabolome data and related metabolites, and an amino acid biosynthesis pathway.  
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They described consensus principal component analysis (CPCA) and canonical correlation 
analysis (CCA). CPCA searches for common metabolite concentrations. CCA identifies 
correlations between relevant metabolites and the rest of the metabolome. CCA and CPCA are 
complementary data analysis tools that can focus data analysis on metabolite groups.  
Microarray / Gene Expression Analysis 
In microarray/gene expression experiments, thousands of DNA/RNA/protein probes are affixed 
to a solid surface (slide or chip), as the sample is placed on the slide. The contents of the sample 
are allowed to interact and bind to the probes. The remaining unbound probe is washed away, 
and the amount of sample bound to the probes measured. This technology allows for tens of 
thousands of probes to be analyzed simultaneously however, issues arise in analyzing several 
thousand entities for a small number of samples. While incorporation of prior knowledge into 
data analysis has been deemed important, in practice, it has been extremely limited.  
Yuryev (2015) advocated for causal reasoning methods to calculate cancer pathway 
activity signatures. Causal reasoning algorithms can transform microarray data into a small 
number of cancer hallmark pathways. They offer this as a solution for the 'curse of 
dimensionality’, which occurs when only a small number of samples are available for training 
sets, and a large number of genes are being measured, as happens often in the use of microarrays. 
Chen et al. (2014) described a model that demonstrated better fitness than the state-of-
the-art model, which relied on an initial random selection of genes, and showed the advantage of 
combining gene interactions from the literature with microarray analysis for generating gene 
regulatory networks. A genetic algorithm was used to optimize the strength of interactions using 
microarray data and an artificial neural network fitness function. Invasive ductile carcinoma 
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(IDCA) of the breast was used to query the literature and a microarray set containing gene 
expression changes in these cells over several time points was evaluated.  
High-dimensional microarray datasets contain high levels of noise, causing problems for 
machine learning methods. Feature selection removes most of the irrelevant genes, and thus 
much of the noise. The most common feature extraction method is principal component analysis 
(PCA) (Hotelling 1933). Hira et al. (2014) proposed an a priori manifold learning method for 
finding a representative set of microarray data infused with KEGG pathway data. Manifold 
learning algorithms, such as Isomap (Tenenbaum et al. 2000) project data from a higher 
dimensional space to a lower dimension. The new manifold produced better classification results 
than either PCA or Isomap.  
Chen and Wang (2009) showed that the prediction models constructed of gene-sets (prior 
knowledge integrated with gene expression values) outperformed prediction models of single-
gene expression values, with improved prediction accuracy and interpretability. Gene id’s were 
linked with annotation databases such as Gene Ontology (GO). ‘Supergenes’ for each category 
were constructed from outcome-related genes using a modified PCA method. These supergenes 
from each gene category represent the ability to predict survival outcome.  
Kuffner et al. (2005) derived from the literature interpretations of expression measures 
with biological hypotheses. Gene clusters that exhibit significant gene expression as well as a 
coherent literature profile were identified, and were shown to be more sensitive and more 
specific than Gene Ontology categories of the same data. Their approach generalizes to real 
applications and does not rely on controlled vocabularies or pathway resources. 
55 
microRNAs 
MicroRNAs (miRNA) are small RNAs that function in RNA silencing and gene expression 
regulation. MiRNAs can base-pair with complementary sequences in messenger RNAs 
(mRNAs), altering their function. Thousands of miRNAs are encoded in the human genome; and 
miRNAs are identified by the genes they affect. Qiu et al. (2011) developed the miR2Gene tool 
to examine gene patterns by analyzing prior knowledge of miRNA regulators. MiR2Gene is a 
useful tool that integrates miRNA knowledge for protein-coding gene analysis, and can be used 
for single, or multiple genes, as well as KEGG pathways. Sets of miRNAs were integrated with 
miR2Gene according to function, disease, and tissue specificity; and their enrichment evaluated.  
Networks 
Biological networks consist of many overlapping processes and pathways which make up the 
complicated systems involved in life. Recently, network-based approaches utilizing gene 
interaction information have emerged.  
Barter et al. (2014) compared single-gene, gene-set, and network-based methods using 
gene expression microarray data from melanoma and ovarian cancer. Informative genes were 
identified using gene expression and network connectivity information combined with prior 
knowledge of protein-protein interactions; as well as informative sub-networks (small networks 
of interacting proteins from prior knowledge networks). The different methods tested were 
correctly classifying alternate subsets of patients in each cohort, in novel and patient-level 
analyses, leading to the conclusion that 'combination' classifiers that are capable of identifying 
which patients will be more accurately classified by one method or another are needed.  
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Hur et al. (2014) pushed for an integrative multiple analysis approach consisting of 
biochemical and pharmacological networks, and transcriptomic signatures for understanding 
drug safety and gene-drug interactions. Integrated pharmacology and biochemical networks 
could describe drug-induced rhabdomyolysis by incorporating prior knowledge with publicly 
available data. A list of rhabdomyolysis-inducing drugs (RIDs) was compiled. Proteins 
interacting with RID pharmacological targets were significantly enriched in cell cycle regulation, 
apoptosis, and ubiquitination functions. Transcriptomic analysis of RIDs revealed that multiple 
pathways are also perturbed by RIDs.  
Jin & Zou (2013) identified new interactions among inflammatory factors and biological 
pathways by combining nonlinear ordinary differential equation (ODE)-based optimization with 
mutual information. They constructed an inflammatory regulatory network (IRN) during 
Influenza A virus (IAV) infection by integrating gene expression data with prior knowledge.  
Ante et al. (2011) exhibited the role of spindle checkpoint-related pathways in breast 
cancer by performing validations of relevant pathways by creating a signaling network from 
TRANSPATH and a metabolic network from KEGG LIGAND, and incorporating Serial 
Analysis of Gene Expression (SAGE) expression data from breast cancer.  
Pathway Intersections 
In order to combine individual pathways into larger networks, similar entities need to exist in 
multiple pathways or in close proximity to several pathways in order to “link” them together. 
These linking entities may be genes, proteins, or similar processes, and are vital for network 
biology studies. The use of pathways and gene interaction networks has allowed for better 
understanding of the differences in gene expression profiles between samples from a systems 
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biology perspective. The usefulness and accuracy of pathway analysis depend on understanding 
how genes interact with one another. That knowledge is continuously improving due to advances 
in next generation sequencing technologies and computational methods. While most approaches 
treat each genes or proteins as independent entities, pathways actually coordinate to perform 
essential functions in cells.  
Liang et al. (2015) state that Sparse regression compares favorably to Weighted 
Correlation Network Analysis when gene association signals are weak. Sparse regression was 
used to find genes that are intermediary to and interact with at least two pathways. A gene is 
considered a shared neighbor of two pathways if it can be determined to interact with at least one 
gene in each pathway. Each pathway gene is modeled using a predictor gene-set, and a 
connection between the pathway gene and predictor gene occurs when the sparse regression 
coefficient is non-zero.  
Francesconi et al. (2008) studied of networks of pathways. The networks were 
reconstructed based on significance of single pathways (nodes) and the intersection between 
them (edges). Groups of genes that interface between different pathways can be considered 
relevant even if the pathways they belong to are not significant alone. 
Protein-Protein Interaction 
Protein–protein interactions (PPIs) refer to known interactions between two or more proteins in 
biochemical events. Proteins must interact in a specific way in order for a process to be 
successful. If an important protein is missing or altered, the biological process will not be 
successfully completed, which could lead to disease or death. Protein interactions have been 
studied extensively, and databases of protein interactions exist. Being aware of these interactions 
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has led to the creation of pathways and networks which improve the understanding of biological 
process and disease understanding, and can also lead to the discovery of possible drug targets. 
Chronic obstructive pulmonary disease (COPD) is a highly-complex human disease with  
high mortality. Incorporation of network or pathway information into biomarker discovery might 
improve prediction performance. Hua and Zhou (2014) combined protein-protein interactions 
(PPI) information with a support vector machine (SVM) (Cortes & Vapnik 1995) (Ben-Hur et al. 
2001) method to identify potential COPD-related genes that would enable determination of 
severe emphysema from mildly emphysematous lung tissue. When compared with another SVM 
method which did not use the prior PPI information, the prediction accuracy was significantly 
enhanced (AUC (Fawcett 2006) increased from 0.513 to 0.909). This shows that incorporating a 
prior knowledge network into gene selection can potentially significantly improves classification 
accuracy. 
Zhao et al. (2014) showed that both the average accuracy (correctly predicted pathways / 
total number of pathways to which all the target genes were annotated) and the relative accuracy 
(percentage of the genes with all the annotated pathways being correctly predicted) for pathway 
predictions were increased with the number of the interacting neighbors. Protein-protein 
interactions and Gene Ontology (GO) databases were integrated for use as prior knowledge. 
KEGG pathways with interacting neighbors of target genes were chosen as candidate pathways. 
Pathways to which the target gene belonged were determined by testing whether genes in the 
candidate pathways were enriched in GO terms to which the target gene was annotated. Protein-
protein interaction data obtained from the Human Protein Reference Database (HPRD; 
http://www.hprd.org/) and Biological General Repository for Interaction Datasets (BioGRID; 
http://thebiogrid.org/) was used to predict the pathway attributions of the target gene.  
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Kirouac et al. (2012) found that widely used pathway databases are highly inconsistent 
with respect to constituents and interactions. They assembled a network from multiple on-line 
resources of pathway and interactome databases (Cancer CellMap, GeneGo, KEGG, NCI-
Pathway Interactome Database (NCI-PID), PANTHER, Reactome, I2D, and STRING) utilizing 
knowledge of proteins and protein interactions involved in inflammatory signaling networks. 
Wide inconsistencies among interaction databases, pathway annotations, and the numbers and 
identities of nodes associated with a given pathway pose major challenges in deriving causal 
insight from network graphs. As such, it is difficult to identify biologically meaningful pathways 
from interactome networks a priori; however by incorporating prior knowledge, it is possible to 
build out network complexity with increasing confidence.  
SNPs/Variants 
Different variations of a nucleotide at a given locus are called alleles. A single nucleotide 
polymorphism (SNP), is a variation at a given nucleotide at a given location in the genome, 
which occurs at least in 1% of the population. The possible alleles of a SNP are usually well-
known. In contrast, a variant can be any variation (allele) at a given locus, but does not have to 
meet the qualification of being present in 1% of the population. SNPs have been extensively 
studied, to the point that the NCBI has created a database of SNPs called dbSNP. Over 10 
million SNPs exist in a human genome, and many diseases such as sickle-cell anemia are known 
to be caused by SNPs.  
Lin et al. (2014) proposed an efficient method that is less sensitive to neutral variants and 
direction effect of causal variants, and can zero in on a genomic region or a chromosome to a 
disease associated region. Genetic variants were scanned to identify the region most likely 
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harboring a disease gene with rare or common causal variants. A score is given to each variant, 
and aggregate scores are used to identify regions with disease association. Using a Parkinson's 
case-control dataset, the proposed method has better power than three other tested methods, and 
also well-controlled type I error. The association of SNCA/α-synuclein gene with Parkinson's 
disease (p = 0.005) was also confirmed.  
Li et al. (2011) indicated that the integration of network biology and genetic analysis 
provides bridges between genetic variants and candidate genes or pathways. Using a two-step 
approach, they detect differentially inherited SNP units from a SNP network. SNP-SNP 
interactions were identified using prior biological knowledge, such as chromosomal location or 
functional relationships of their genes. Disease-risk SNP units were ranked by their differentially 
inherited properties in IBD (Identity By Descent) profiles of affected and unaffected sib-pairs.  
Namkung et al. (2011) showed that modeling local rather than global ancestry may be 
beneficial when controlling the population structure effect in rare variant association analysis. 
They evaluated different methods of rare variant analysis, including single-variant, gene-based, 
pathway-based analyses, and analyses that incorporate biological information. Using a Bayesian 
network and a collapsing receiver operating characteristic curve improved risk prediction for 
diseases caused by many rare variants.  
Chen et al. (2011) summarized state-of-the-art approaches involved in integration of 
biological knowledge into rare variant association studies. The methods fell into three categories: 
(1) hypothesis testing of index scores by aggregating rare variants at the gene level, (2) variable 
selection techniques incorporating prior information, and (3) novel approaches that integrate 
prior information, such as pathway and single-nucleotide polymorphism (SNP) annotations. 
Similarities found between the methods were that gene-based analysis of rare variants was 
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advantageous to single-SNP analysis and that the minor allele frequency threshold used to 
identify rare variants may influence the power of the test. A consistent increase in power was 
identified by considering only non-synonymous SNPs. It was demonstrated that integrating 
biological knowledge into statistical analyses enabled subtle improvements in the performance of 
statistical method applied to simulated data.  
Other techniques 
Pathway analysis incorporates prior biological knowledge to analyze genes/proteins in a 
biological context. However, hypotheses are often 1D in space. Yang et al (2014) developed 
direction pathway analysis (DPA), to test hypotheses in high-dimensional space to identify 
pathways that display distinct responses. DPA was used to study insulin action in adipocytes 
which regulates protein movement from the cell interior to the surface membrane. DPA 
determined that several insulin responsive pathways involved in plasma membrane trafficking 
are only partially dependent on the insulin-regulated kinase AKT. The findings were validated by 
targeted analysis of key proteins using immunoblotting and live cell microscopy.  
Park et al. (2013) described functional knowledge transfer (FKT), and explain that 
state-of-art machine learning algorithms that utilize FKT improve accuracy in pathway 
membership prediction. FKT can help biologists integrate prior knowledge from diverse systems 
to direct targeted experiments. They showed that functional genomics can complement sequence 
similarity to improve gene annotation transfer between organisms. Their method transfers 
annotations when determined by genomic data and can be used with a prediction algorithm to 
combine transferred gene function knowledge with high-throughput data enabling function 
prediction.  
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Minn et al. (2012) identified components of the Raf kinase inhibitory protein (RKIP) 
signaling pathway, which can inhibit breast cancer metastasis, by utilizing statistical analysis of 
clinical data integrated with experimental validation. They showed how prior biological 
knowledge can be combined with genome-wide patient data to identify regulatory mechanisms 
that may control metastasis.  
Cun and Frohlich (2012) showed that Reweighted Recursive Feature Elimination 
(RRFE) (Johannes et al. 2010) and average pathway expression led to clearly interpretable 
signatures; whereas on average, incorporation of pathway information or protein interaction data 
did not significantly improve their classification accuracies, but did affect the interpretability of 
gene signatures compared to other classical algorithms.  
Morris et al. (2011) discuss a method that trains a protein pathway map, summarizing 
curated literature to context-specific biochemical data. They showed that fuzzy logic (cFL), can 
convert a prior knowledge network (from literature or interactome databases) into a model 
describing protein activation values across multiple pathways.  
Zhu (2009) presented an algorithm designed to identify signaling pathways of low and 
concordant gene expression variation.  The semi-supervised gene clustering algorithm extended 
and generalized the gene-shaving algorithm, so that prior knowledge of signaling pathways could 
be incorporated. Using pathway gene-sets as prior knowledge, the algorithm formed tight gene 
clusters with minimal variation across samples.  
Pathway modeling may require the integration of multiple data types including prior 
knowledge. Guo et al. (2006) indicate information-based measures outperform graph structure-
based measures for stratifying protein interactions. They assessed Gene Ontology (GO)-derived 
similarity measures for the characterization of direct and indirect interactions within human 
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regulatory pathways. GO biological process and molecular function annotation measures can be 
used alone or together for the validation of protein interactions involved in pathways. Protein 
functional similarity within regulatory pathways decays rapidly as the path length increases.  
In the section above, an extensive review of the current literature was performed. Many 
of the ways that prior biological knowledge is being implemented were described above. 
However, with all of this ongoing research on the different ways that prior knowledge is 
currently being utilized, no manuscripts have been identified that describe incorporating prior 
knowledge into datasets for use as input to enhance pathway analysis. The KEDA framework 
described herein provides insights into a set of methods developed and evaluated for this 
purpose, and complements extant methodologies. 
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3.0 IMPLEMENTATION OF KEDA FRAMEWORK 
This section describes the KEDA Framework, and details the processes of literature-mining and 
the transformation of its results into priors leading to their use in modeling, and pathway 
analysis. The datasets used for modeling and pathway analysis were obtained from Gene 
Expression Omnibus (www.ncbi.nlm.nih.gov/geo/index.cgi) and are discussed. The Bayesian 
Rule-Learner algorithm (Gopalakrishnan et al. 2010) for modeling and the Pathway Express 
(vortex.cs.wayne.edu/Projects.html; Khatri et al. 2005; Khatri et al. 2007, Draghici et al. 2007) 
utility for pathway analysis are also examined.  
3.1 KEDA FRAMEWORK OVERVIEW 
The KEDA Framework (Figure 1) utilizes a semi-automated literature mining method to parse 
lung and breast cancer abstracts obtained from PubMed, to discover putative biomarkers in 
specific biofluids. Gene and protein mentions from millions of abstracts were tallied and 
transformed into prior probabilities. These ‘priors’ are incorporated with experimental data for 
use in the BRL to determine the best performing models. A comparison between the effects of 
prior information on model development from ‘omic’ datasets using informed prior, uniform 
prior and no prior results is performed. Additionally, pathway analysis is performed, and priors 
are incorporated into experimental data and a comparison made between results from prior 
information only, experimental data only, and prior information + experimental data combined. 
These subsequent results can be used to develop new methods of biomarker research/discovery. 
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3.2 DESCRIPTION OF KEDA COMPONENTS 
The following sections describe the methodology behind the KEDA components: 1) literature 
mining, 2) classification modeling, and 3) pathway analysis. 
3.2.1     Literature mining methodology 
Computational methods for mining of biomedical literature can be useful in augmenting manual 
searches of the literature using keywords for disease-specific biomarker discovery from 
biofluids (Jordan et al. 2014). By counting the mentions of a gene/protein in disease-specific 
abstracts, a picture begins to emerge of what is already known in the scientific community about 
a given disease. Counts of gene/protein abstract mentions can be transformed into new 
knowledge, which can be used to further disease understanding. Verified findings from such 
exercises can contribute to the current body of knowledge, and possibly lead to new methods or 
areas of study for biomarker research and discovery. 
In this work, breast and lung cancer searches were further stratified by biofluid mentions 
to increase the amount of relevant information. Added stratification enables us to not only 
determine genes and proteins involved breast and lung cancer, but also to discover within which 
biofluids the proteins may be found. This knowledge has potential clinical implications, by 
reducing the invasiveness of the method for obtaining a biofluid for testing. For example, there 
would be no reason to undergo the painful procedure for obtaining cerebrospinal fluid, if the 
same protein could be attained from blood or urine. This is very important knowledge, which has 
only recently been further pursued for lung and breast cancer (Veenstra et al. 2005; Zhou et al. 
2005; Nicholas et al. 2006; Alterovitz et al. 2008; Xu & Veenstra 2008; Delaleu et al. 2008; 
Tyson & Ornstein 2008; Lee & Wong 2009; Gao et al. 2009; Sugimoto et al. 2010; Oumeraci et 
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al. 2011; Nolen &  Lokshin 2011; Lau et al. 2012; Aboud & Weiss 2013; Ramshankar & 
Krishnamurthy 2013; Tredwell et al. 2014; Jordan et al. 2014; Qin et al. 2015).  
3.2.1.1     Information retrieval     Defining the search space: It is important to examine all 
abstracts, both relevant (positive) and non-relevant (negative), within a given pre-defined search 
space, so that the results are exhaustive and so statistical significance measures can be accurately 
calculated. Figure 9 provides an example of defining a search space using ‘urine’, ‘breast cancer’ 
and/or ‘lung cancer’.   
Figure 9. Defining the search space. The search space of all PubMed abstracts returned using 
the keyword ‘urine’. Within those abstracts are those which also contain ‘lung cancer’/’breast 
cancer’, or both. Abstracts containing the terms ‘urine’ and ‘lung cancer’ and/or ‘breast cancer’ 
make up the positive set; the others make up the negative set. 
Database searching 
In literature mining, two primary search methods exist: subject heading and keyword. Due to 
strengths and weaknesses of both methods, some combination of the two are usually employed to 
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achieve optimal results. In general, subject heading searches utilize a defined 
dictionary/thesaurus of controlled terms. MEDLINE terms are referred to as Medical Subject 
Headings (MeSH). Subject headings assemble possible synonyms and variations of a given term. 
For example, the term ‘cancer’ may also be described in articles as neoplasms, malignant, 
benign, tumor, or tumorous. MEDLINE (described earlier in the information extraction section), 
uses ‘neoplasm’ to return all variations of the term ‘cancer’. However, subject heading searches 
are more specific as irrelevant articles will not be returned 
(http://researchguides.uvm.edu/). 
Keyword searches return all records containing the term or phrase. Keyword searching is 
useful in identifying citations missed by subject heading searches if the term is not found in the 
dictionary/thesaurus. Keyword searches usually return more information than subject heading 
searches, but the additional information may or may not be relevant.  
PubMed utilizes a combination of the two methods. An example is provided. Entering the 
terms ‘serum AND lung cancer’ produces the following search scheme: ("serum"[MeSH Terms] 
OR "serum"[All Fields]) AND ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND 
"neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("lung"[All Fields] AND 
"cancer"[All Fields]) OR "lung cancer"[All Fields] AND (hasabstract[text] AND 
"humans"[MeSH Terms] AND English[lang]).  
In this work, the keyword ‘perspiration’ was used in addition to ‘sweat’; ‘stool’ with 
‘feces’; ‘phlegm’ and ‘sputum’ in combination with ‘mucus’; and ‘lacrima’ with tears. PubMed 
(www.ncbi.nlm.nih.gov/pubmed) queries were performed with the following limits: Abstracts, 
English, and Human, to retrieve breast and lung cancer abstracts. Query results for diseases-
biofluid combinations are found in Table 2. An abstract consists of a journal entry, title, authors, 
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affiliations, text, copyright, and PMID. The sets of abstracts were obtained using criteria from 
the positive or negative queries (defined below).  
Table 2. Size of the abstract sets returned from breast and lung cancer PubMed queries. 
CSF = cerebrospinal fluid; SF = synovial fluid. 
Positive Abstract Sets 
A positive abstract set is defined as the set of abstracts obtained by using the keywords, ‘breast 
cancer AND (biofluid)’, for example breast cancer AND plasma; or ‘lung cancer AND 
(biofluid)’. From this point forward, all positive abstract sets will be referred to as “positive 
set(s)”. Positive set queries for breast cancer were performed on 4-29-2013 and for lung cancer 
on 5-2-2013.  An assumption is made that a biomarker mention in these abstract sets is related to 
both disease and biofluid. PubMed queries output large text files, which were processed using 
the PittCAPv3 Python script.  
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Negative Abstract Sets 
A negative abstract set is defined as a set of abstracts obtained by using the keywords ‘(biofluid) 
NOT breast cancer’ or ‘(biofluid) NOT lung cancer’. From this point forward, all negative 
abstract sets will be called “negative set(s)”. Negative set queries for breast cancer were 
performed on 4-29-2013 and for lung cancer on 5-2-2013.  
Figure 10. Diagram of the KEDA text-mining process. 
An overview of the KEDA text-mining process is shown in Figure 10. More than 5.3 
million abstracts were obtained from PubMed and examined for biomarker-disease-biofluid 
associations (34,296 positive and 2,653,396 negative for breast cancer; 28,355 positive and 
2,595,034 negative for lung cancer). Biological entity mentions in all positive abstracts were 
tagged and tallied, and compared to the same findings from negative abstracts. The counts were 
used to calculate ratios and z-scores for each entity.  
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Abstract output file 
PubMed exports one large text file of all returned abstracts. Once the large files were 
downloaded from PubMed, JRSplitFile Pro (www.spadixbd.com/jsplit/index.htm) was used to 
split the large file into smaller 25 MB sized-files. A Python script entitled 
RandAbstractMaker2.0 was used to subdivide the smaller files even further, creating one 
individual file per positive abstract. At this point, a list of abstract files was created for input into 
PittCAPv3.0 (Appendix A).  
3.2.1.2     Named entity recognition     ABNERv1.5 “A Biomedical Named Entity Recognizer”; 
(Settles 2005; pages.cs.wisc.edu/~bsettles/abner/) was chosen to perform the entity recognition 
because of its batch processor which is extremely valuable when processing large numbers of 
files, and its proven performance pertaining to biological information. Individual abstract files 
were input to ABNER to tag mentions of proteins, DNA, RNA, cell lines, and cell types in the 
positive and negative sets.  Version 1.5 trains on the NLPBA and BioCreative corpora. 
Documented ABNER performance measures range from 65.9-77.8 for protein recall and 68.1-
74.5 for protein precision. The process described in this work only makes use of entities tagged 
as “Protein”, “DNA”, and “RNA”.  
3.2.1.3     Entity extraction     The PittCAPv3 Python script was developed to reduce manual 
effort and eliminate errors involved in tallying the number of gene/protein mentions from the 
returned abstracts. The script takes as input a list of abstract file names and the dictionary 
filename, and performs the following functions: 1) identify tagged entities from the .sgml files 
output by ABNER and compare mentioned entities to the dictionary; 2) filters out unwanted 
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characters, text, tags and duplicate biomarker mentions; 3) tallies the final count of all biological 
entity mentions; and 4) produce one final export list containing all confirmed biological entities 
and their individual counts. Additionally, relevant PMID’s were retained for tracking and 
verification purposes.   
 
 
3.2.1.4     Dictionary     A dictionary file was utilized in order to identify molecular entities of 
interest, as well as merging the results obtained from different gene/protein aliases under one 
name. The Protein Nomenclature file was downloaded from the Human Protein Reference 
Database (HRPD) www.hprd.org/; Copyright © 2002-09, Johns Hopkins University and The 
Institute of Bioinformatics, for use as the dictionary file. This file contains 19,327 unique protein 
IDs. The format consists of the HPRD ID, gene symbol, RefSeq ID, and aliases (separated by 
semi-colons). The gene symbol was used for the consensus name for all accompanying aliases. 
Found entities were mapped to the dictionary via the PittCapv3 Python script (Appendix A). 
 
3.2.1.5     Z-score calculation     Counts were performed at abstract level, with a mention of a 
biomarker being given a count of 1, regardless of the number of mentions within the abstract. Al-
Mubaid & Singh (2005) scoring method was adopted and modified for this work. Each z-score 
corresponds to a point in a normal distribution and can be associated by its deviation from the 
mean. The z-scores were computed as follows:  
   
S1 is the positive abstract set (i.e. disease/biofluid), S1 = {A1, A2, …, An}.  
A is a given abstract,  
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Sp is the set of markers mentioned in the dictionary and found in the positive set S1, Sp = {P1, P2, 
…, Pm}.  
S2 is the negative abstract set.   
For each marker Pi in Sp, compute the abstract frequency (af) of Pi in both sets S1 and S2 as: 
af1(Pi) = number of S1 abstracts in which Pi is mentioned, 
af2(Pi) = number of S2 abstracts in which Pi is mentioned, 
aft(Pi) = af1(Pi) + af2(Pi).  
For each marker in Sp compute expectation (ex) and evidence (ev) values: 
  ex(Pi) = [aft(Pi)/|S1 + S2|] * |S1|,     and                      ev(Pi) = af1(Pi)    
Equation 4. Expectant calculation                    Equation 5. Evident calculation
ex calculates the expected number of mentions of Pi in the positive abstracts set S1;  
ev is a count of the S1 positive set abstracts that Pi appears in.  
The larger the difference in observed and expected abstract frequencies, ev(Pi) – ex(Pi), the more 
likely that the marker Pi and the disease are significantly associated. 
The difference is normalized by:  
      f(Pi) = (ev(Pi) – ex(Pi)) / aft(Pi)  
Equation 6. Normalization calculation
The z-score is calculated by: 
Z(Pi) = [f(Pi) – mean(f)]/SD(f)
Equation 7. Z-score calculation 
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where mean(f) = the mean of all f values of all proteins in Sp and SD(f) = the standard deviation 
of the f values. 
A threshold value of 1.0 was established as a significance cut-off based on the results shown in 
Figure 18. The z-score values were ranked to determine the significance of the putative 
biomarkers, and to provide measures of disease specific relevance.  
Table 3. Breast cancer-related genes from the text-mining final table. Examples measures 
from breast-cancer/blood final table show how the z-score calculation changes based on the 
number of positive and negative abstract counts. S1 = # of positive abstracts examined; SP =  # 
of total positive markers; S2 = # negative abstracts examined; af1 = # of mentions in positive 
abstracts; af2 = # of mentions in negative abstracts; aft = # of mentions in all abstracts; ex = 
expected number of positive mentions; ev = actual number of positive mentions; f(Pi) = (ev-ex) / 
aft; mean = average f(Pi) of all biomarkers in table; SD = standard deviation of all biomarkers in 
table; Z(Pi) = calculated z-score. 
The final table (Table 3) was created once the final tally lists were output from 
PittCAPv3.0. The information in this table was used to calculate z-scores and ratios, for use as 
prior knowledge, in subsequent KEDA processes (modeling and pathway analysis). Final tables 
for all biofluids examined can be found in Appendix C. 
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3.2.1.6     Verification of relationships     Manual verification of relevant abstracts was 
performed to assess our method’s performance, and to confirm true positive findings.  Al-
Mubaid & Singh 2005 removed from the abstract pool, ‘verification documents’ (specifically 
pertaining to a disease-protein relationship), and used these abstracts for verification. The 
verification described in this work, does not remove these abstracts, and verification instead, is 
performed by comparing found results to disease-specific known biomarker lists (Tables 4 & 5). 
The lists were created from the following sources: OMIM (O; www.ncbi.nlm.nih.gov/omim/; 
Wheeler et al. 2007), cancer gene annotation system for cancer genomics (CAGE(C); 
mgrc.kribb.re.kr/cage/pageHome.php?m=hm; Park et al. 2012) , NCBI’s Genes & Disease ((G); 
www.ncbi.nlm.nih.gov/books/NBK22183/ ; NCBI 1998), NCI’s Early Detection Research 
Network (EDRN (E); edrn.nci.nih.gov/; Wagner & Srivastava 2012), an expert provided list (X) 
of validated cancer markers, (Bigbee et al 2012), and a recently released breast cancer paper ((P) 
Cancer Genome Atlas Network 2012)). Markers found in one of these lists, in addition to the 
HPRD dictionary were considered verified. The breast cancer list was compiled using OMIM, 
CAGE, Genes & Disease, the expert provided list, and the paper. The lung cancer list was 
compiled using OMIM, CAGE, EDRN, and the expert provided list.  













Table 4. Known Breast Cancer Biomarkers. O = OMIM; C = CAGE; G =  NCBI’s Genes & 
Disease; E = EDRN; X = expert provided list of validated cancer markers (Bigbee et al 2012);     





Table 5. Known Lung Cancer Biomarkers. O = OMIM; C = CAGE; G =  NCBI’s Genes & 
Disease; E = EDRN; X = expert provided list of validated cancer markers (Bigbee et al 2012);     





3.2.1.7     Error rate determination     In order to assess the performance of our text-mining 
method, an error rate metric was sought. A true positive rate is currently unattainable as a 
comprehensive pool of breast or lung cancer biomarkers does not exist. To calculate the error 
rate of our method findings, the following equation was used:    
        Error = TP / (TP + FP)  
Equation 8. Error rate calculation
where TP are true positives and FP are false positives. 
The use of negative abstracts inherently eliminates some false positives. However, it was 
determined that manual examination of abstracts would be required to ensure that the results 
obtained were not false positives. Tracking the PubMed ID allowed for manual verification of 
relevant abstracts. In tracking the abstracts, three criteria were used to determine a pass/fail 
outcome. Abstracts were examined for mentions of biofluid, disease, and biomarker. All three 
criteria were required to be acceptable and counted as a TP. Synonyms or root words were also 
deemed acceptable. FN’s would include those genes/proteins that appear in the final list, but 
were missing one of the aforementioned criteria.   
3.2.2       Classification modeling methodology 
Prior information can be combined with experimental data and included in modeling exercises to 
add an additional level of confidence in modeling results. Gene-level experimental data was used 
due to informed prior ratios being developed at the gene-level. To ensure that findings were not 
experimental-type or platform-specific, several different breast and lung cancer datasets were 
examined. While discretization could yield a larger number of value ranges for a variable, 
thereby increasing the number of rules generated by BRL (Gopalakrishnan et al. 2010), it was 
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not used in this work. Comparisons were made between datasets that either included informed 
priors, uniform priors, or no priors at all (data only). The following sections describe the datasets 
used, how the data was processed, and the implementation of the BRL modeling algorithm. 
3.2.2.1     Experimental datasets     In this section, a description of the ‘omic’ datasets used for 
model development and testing of the KEDA framework are presented. Publicly available breast 
and lung cancer experimental datasets were acquired via the Gene Expression Omnibus (GEO; 
www.ncbi.nlm.nih.gov/geo/index.cgi; detailed dataset descriptions can be found in Appendix B). 
GEO currently houses 3848 datasets (7-4-15). Several different types of data and platforms were 
examined to ensure the obtained results were not specific for a certain type of experiment or 
platform.  
Datasets of interest were found using the following keyword search: human, gene 
expression whole blood, lung or breast cancer. Datasets containing the greatest number of 
samples were given highest priority, and subsequently downloaded and analyzed.  
Figure 11. Diagram of the KEDA classification modeling process. 
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Figure 11 provides a diagram of the KEDA modeling process. All subsequent sections 
will utilize the datasets and platforms mentioned earlier. 
The following section provides a more in-depth description of the GEO datasets used in 
this work. The summaries accompanied the datasets and were provided by Gene Expression 
Omnibus.   
Gene Expression 
DNA which contains an organisms’ blueprint in located in the cell’s nucleus, which is 
encased in a membrane. DNA molecules are too large to leave the nucleus, so copies of sections 
(genes) of the DNA are ‘transcribed’. These copies are messenger RNA (mRNA) transcripts. 
The mRNA molecules are small enough to leave the nucleus and enter the cytoplasm. In the 
cytoplasm, the mRNA will encounter ribosomes, where the mRNA sequence is ‘translated’ into 
proteins. Proteins are created in response to the cellular environment, and engage in controlling 
cellular behavior. Gene expression studies are important in determining which genes are active 
given certain environmental conditions. 
Gene expression microarrays measure the specific amount of mRNA transcripts in a 
sample. Arrays vary in their technology, but generally speaking a microarray consists of 
thousands of gene-specific probes (DNA gene sequences or complimentary sequences) being 
hybridized to a surface (usually called a ‘chip’). The mRNA in a cell is captured and labelled 
with an illuminescent that will emit light when activated by a laser. The mRNA that match the 
gene sequence will bind to the probes, with the unbound sequences being washed away. The chip 
is then exposed to the laser and the brightness of each spot is captured and calculated to produce 
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an intensity value. The greater the intensity value, the more copies of the mRNA are believed to 
be found within the cells. In this way, researchers can determine which genes are ‘active’ or ‘on’ 
and which genes are ‘not active’ or ‘off’. Conclusions can be made based on comparing intensity 
values from one cell type vs. another, or one environmental condition vs. another. In this work, 
one breast cancer and one lung cancer microarray dataset was examined, enabling several 
different comparisons to be made (see Table 6): 
 
 
Table 6. Breast and lung cancer dataset summary. Gene-level data was used for comparisons. 
Several different comparisons could be made from one dataset. Norm = normalization method; 




Breast Cancer Microarray (Aarøe et al. 2010) 
This dataset is titled: Gene expression profiling of peripheral blood cells for early 
detection of breast cancer (GSE16443). It utilized expression profiling by array. The 
platform is the ABI Human Genome Survey Microarray Version 2 (GPL2986). Multiple 
comparisons were performed with this dataset: Blood Healthy vs. Cancer, Menopause 
Status, ESR1 positive vs. ESR1 negative (see section 2.1), and Tumor Grade 1v3 and 
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2v3. Various sample sizes were used for the different comparisons with the largest 
sample size being 67 cancer bloods vs. 54 normal bloods. 11217 probes covering 10678 
genes were analyzed. 
 
Lung Cancer Microarray (Rotunno et al. 2011) 
This dataset is titled: A gene expression signature from peripheral whole blood for stage I 
lung adenocarcinoma (GSE20189). It utilized expression profiling by array. The platform 
is a commercial [HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array 
(GPL571) with in situ oligonucleotides. Several comparisons were performed for this 
analysis: Stages 1-4; small cell carcinoma to adenocarcinoma; smoking histories (never, 
former, current); and case-control (cancer vs. normal) status. Varying sample size was 
available for each comparison with the largest sample size being 73 adenocarcinoma 
samples vs. 80 control samples. 22277 probes covering 14355 genes were analyzed. 
 
Copy number 
Each organism contains a specific number of chromosomes in each cell. For example, humans 
are known to have 23 pairs or 46 total chromosomes that make up their ‘genome’. Occasionally, 
or over time, the chromosome number can deviate from the norm due to deletions, insertions, 
inversions, and duplications which may result during cell replication. As a result, some cells may 
contain extra or limited numbers of certain chromosomes or chromosomal regions or genes.  
Copy number variation arrays measure chromosomal aberrations which may ultimately result in 
changes in the physical arrangement of genes on chromosomes (Feuk et al. 2006). Copy number 
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is important because many medical complications can occur when chromosomal aberrations 
exist. 
Polymerase chain reaction (PCR) is a molecular biology technique that is used to amplify 
regions of DNA exponentially, over and over again, ultimately resulting in millions of copies 
from minimal starting material. DNA usually exists in nature as a double-stranded molecule, 
with the two strands being held together by hydrogen bonds. Heating DNA to temperatures of 
95°C ‘denatures’ the DNA by breaking the hydrogen bonds that hold the molecule together, 
which results in 2 molecules of single-stranded DNA. Once the DNA is denatured, the 
temperature is lowered to around 50-60°C, for the primers to ‘anneal’ or to bind to the single-
stranded DNA molecules. Primers are short segments of DNA (~20-25 base pairs) that are 
complimentary to the DNA sequence that will bind to the DNA, and allow for an enzyme called 
DNA polymerase to bind. The temperature is raised to 75°C which is optimal for the enzyme to 
bind to the primer, and the ‘elongation step’ will occur where DNA polymerase will add 
nucleotides that are complimentary to the single-strand DNA molecule to create a complimentary 
DNA strand. In doing so one DNA molecule is replicated into two molecules. Thirty or so 
rounds of heating and cooling (thermal cycling) resulting in replication take place resulting in 
exponential numbers of the same DNA molecules.  
Copy number variation assays utilize a real-time PCR system. Real-time PCR (qPCR) 
tracks the number of DNA molecules during the PCR process by labelling the DNA molecules 
with fluorescent dyes. In doing so it can determine if the number of molecules is more or less 
than expected. If the number is greater than expected, one can conclude that there were more 
than the normal number of copies (two copies of each gene total, one from father, and one from 
mother) of the DNA present initially. If the number is less than expected, one can conclude that 
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there was less than the normal number of copies present initially. In this work, one breast cancer 
and one lung cancer copy number dataset was examined (see Table 6): 
 
Breast Cancer Copy Number (Mathiesen et al. 2012) 
This dataset is titled: High-resolution analysis of copy number changes in circulating and 
disseminated tumor cells in breast cancer patients (GSE27574). It utilized genome 
variation profiling by array. The platform is the Agilent-014693 Human Genome CGH 
Microarray 244A (GPL9128). Circulating tumor cells were compared to normal cells, 
across 155840 probes covering 23288 genes. 
 
Lung Cancer Copy Number (Starczynowski et al. 2011) 
This dataset is titled: DNA copy number and gene expression profiles of resected non-
small cell lung cancer tumors (GSE31800). It utilized genome variation profiling by 
genome tiling array. The platform is custom-commercial Custom Rosetta-Affymetrix 
Human platform [rmhu01aa520485] (GPL14189) with spotted oligonucleotides. The 
comparison was small-cell carcinomas vs. adenocarcinomas. 14839 probes covering 
11950 genes were analyzed. 
 
RT-PCR 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) is a molecular biology technique 
used to determine gene expression using RNA as a template and converting it into cDNA using 
an enzyme called reverse transcriptase. The cDNA is then amplified using the classical PCR 
technique.  
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A reaction mix containing nucleotides, primers, RNA, and enzyme is created. The 
reaction mix undergoes thermal cycling with the first cycle being the reverse transcription step 
which synthesizes single-strand cDNA. Inactivation of reverse transcriptase follows. Many 
cycles of denaturation, annealing and elongation occur which amplify the cDNA. Results are 
assessed by gel electrophoresis. In this work, one breast cancer RT-PCR dataset was examined 
(see Table 6): 
 
Breast Cancer RT-PCR (Magbanua et al. 2013) 
This dataset is titled: Molecular characterization of tumor cells from the cerebrospinal 
fluid and matched primary tumors from metastatic breast cancer patients with 
leptomeningeal disease (GSE46068). It utilized expression profiling by RT-PCR. The 
platform is the Custom Human TLDA 64-Circulating tumor cell associated gene panel 
(GPL17020). Tumor cells from CSF (n-18) vs. primary leukocytes (n=9) from metastatic 
breast cancer patients were compared.  64 genes were analyzed. 
Methylation 
Methylation occurs when a methyl group is added to a cytosine nucleotide of a DNA molecule 
by enzymes called methyltransferases. Methylation appears to occur most often in regions called 
cytosine-phosphate-guanine (CpG) islands, which can be found in gene regulatory regions. As 
such, this process plays a role in gene expression regulation by inhibiting the binding of proteins 
necessary for transcription. When methylation occurs in a promoter region, gene transcription is 
usually prohibited. Gene expression regulation is essential in different stages of cell progression. 
Certain genes need to be expressed early in development, but then are not needed again as aging 
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occurs. Methylation aids in terminating the expression of such genes once they are no longer 
needed.  
By being able to inhibit gene expression, methylation plays a key role in defending cells 
from detrimental conditions, interfering with viral-DNA expression for example. However, 
methylation can also be harmful if it occurs in the wrong area, such as silencing tumor 
suppressor genes. DNA methylation patterns can be inherited from mother cells to daughter 
cells. As such methylations can accumulate over time, thus methylation has been implicated as 
an indicator of the aging process. 
Like other array processes, methylation arrays use probes designed specifically for 
predetermined loci, hybridized to a surface. These arrays are used to measure methylation 
intensity across the genome. The following is a description of the most common methylation 
assay technology from the Illumina Infinuim Methylation Assay website 
(http://www.illumina.com/technology/beadarray-technology/infinium-methylation-assay.html):   
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Figure 12. Infinium methylation assay bead technology. The Infinium Methylation Assay 
uses two different bead types to detect CpG methylation. The U bead type matches the 
unmethylated CpG site; the M bead type matches the methylated site. In the top figure, the 
unmethylated CpG target site matches with the U probe, enabling single-base extension and 
detection. It has a single-base mismatch to the M probe, which inhibits extension. If the CpG 
locus of interest is methylated (bottom figure), the reverse occurs. 
http://www.illumina.com/technology/beadarray-technology/infinium-methylation-assay.html 
The assays work by “detecting cytosine methylation at CpG islands based on genotyping 
of bisulfite-converted genomic DNA. Following treatment with bisulfite, unmethylated cytosines 
are converted to uracil, while methylated cytosines remain unchanged. The loci are interrogated 
by using two site-specific probes (Figure 12), one for the methylated locus (M bead) and another 
for the unmethylated locus (U bead). Single-base extension of the probes incorporates a labeled 
nucleotide, which is tagged with a fluorescence reagent. The level of methylation for the 
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interrogated locus can be determined by calculating the ratio of the fluorescent signals from the 
methylated vs unmethylated sites.” An aid to the above description is provided in Figure 12, as 
the wording can be complicated. 
Methylation array technology has been utilized extensively in lung and breast cancer 
studies, with methylation signatures even being researched as possible biomarker panels. In this 
work, one breast cancer and one lung cancer methylation datasets was examined (see Table 6). 
 
Breast Cancer Methylation (Dedeurwaerder et al. 2011) 
This dataset is titled: Epigenetic portraits of human breast cancers (GSE20713). It 
utilized methylation profiling by array. The platform is the Illumina 
HumanMethylation27 BeadChip (HumanMethylation27_270596_v.1.2) (GPL8490). 
Several comparisons were performed for this analysis: Tumor vs. Normal, as well as 
Tumor grade comparisons (Grade Nv1, Nv2, Nv3, 1v2, 1v3, and 2v3). Various sample 
sizes were used for the different comparisons with the largest sample size being 238 
tumor samples vs. 8 normal. 27578 probes covering 14501 genes were analyzed. 
  
 
Lung Cancer Methylation (Shames et al. 2006) 
This dataset is titled: Genome-wide screen for hypermethylated genes in lung cancer 
(GSE5816). It utilized expression profiling by array. The platform is a commercial [HG-
U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) with in situ 
oligonucleotides. Comparisons performed were based on treatment protocol: Control 
treatment group (DMSO qod for 6 days); Low dose treatment group (5-aza-2'-
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deoxycytidine qod for 6 days); and High dose (1000nM) treatment group (5-aza-2'-
deoxycytidine qod for 6 days). 54675 probes covering 32459 genes were analyzed. 
ArrayCGH 
Array comparative genomic hybridization (aCGH) is a molecular method for comparing copy 
number variations (CNVs; gain or loss of chromosomal regions) from two DNA samples such as 
a test sample and a reference. It allows for testing all chromosomes, locus-by-locus, for deletions 
and duplications, on a high-resolution scale (Pinkel & Albertson 2005) at a level of 5–10 kb (Ren 
et al. 2005).Two approaches exist for aCGH, whole genome and targeted areas. Whole-genome 
arrays are used more often in research applications, while targeted arrays are used to target 
specific areas of interest and can be used for clinical applications.  
ACGH employs the same principles of competitive fluorescence in situ hybridization as 
traditional CGH. Equal quantities of DNA samples are labelled with different color fluorophores 
(usually red/Cyanine 5/Cy5 and green/Cyanine 3.Cy3) and are then used as probes that 
competitively hybridize to a microarray of thousands of spotted target sequences. After 
hybridization, the remaining unbound sample and fluorophore are washed away, and a digital 
imaging system is used to quantify the fluorescence intensities of each probe/target.  The ratio of 
intensities is proportional to the ratio of the copy number in the sample and reference genomes. 
When the intensities are somewhat equal, the copy number of the samples compared is assumed 
to be equal.  A yellow color on the array indicates no difference between the samples in that 
location (Strachan & Read 2010; Weiss et al 1999). A greater intensity of the sample color red 
indicates a loss of DNA, while a higher intensity of reference color green indicates a gain of 
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DNA at the given locus (Shinawi & Cheung 2008). In this work, one lung cancer methylation 
datasets was examined (see Table 6): 
 
Lung cancer ArrayCGH (Medina et al. 2009) 
This dataset is titled: Gene expression analysis & comparative genomic hybridization 
from lung cancer cell lines (GSE14079). It utilized expression and genome variation 
profiling by array. The platform is a non-commercial CNIO H. sapiens 13.6K Oncochip 1 
(GPL1998) with spotted DNA/cDNA technology. DNA samples were compared to 
matched RNA samples, from Homo sapiens lung cancer cell lines, across 13056 probes 
covering 7040 genes. 
 
Protein arrays 
A protein microarray is a molecular biology technique developed to study protein interactions, 
and function. The array is usually a slide, nitrocellulose membrane, or microtiter plate. ’Capture 
proteins’ are attached to act as the probe molecules, and protein samples labeled with fluorescent 
dye, are added as the targets. When the fluorescent dye is hit by a laser, light of a specific 
wavelength is emitted, and the intensity is read by a scanner. 
Protein arrays were developed because the quantity of mRNA in a cell doesn’t 
necessarily reflect the level of protein, and it is the proteins that are the functional entities of the 
cell. The surface coating anchors the capture proteins to the surface, as well as prevents protein 
denaturation, orients the protein for optimal binding, and inhibits non-specific binding to 
minimize background noise. The capture molecules used usually are antibodies, antigens, partial 
or full-length proteins. There are three types of protein microarrays that are commonly used: 
 90 
analytical (capture) arrays, functional (target) arrays, and reverse-phase arrays. In analytical 
arrays a library of antibodies is arrayed on the support surface as capture molecules. The array is 
probed with the sample containing proteins, and analysis provides information about the amount 
of protein as well as binding properties. In functional arrays purified proteins are used as probes 
to identify protein interactions, enzymatic activity and detect antibody specificity. Reverse phase 
arrays (RPAs) are used to study complex samples. Cell lysates is arrayed onto the surface and 
probed with antibodies to the target protein. Reference peptides are included on slides for protein 
quantification of the sample lysates. RPAs allow for the determination of the presence of altered 
proteins or other agents that may be results of a given disease. Post-translational modifications 
may also be detected using RPAs. In this work, one breast cancer protein array dataset was 
examined (see Table 6): 
 
Breast Cancer Protein (no citation) 
This dataset is titled: Evaluation of auto-antibody serum biomarkers for breast cancer 
screening (GSE34555). It utilized protein profiling by protein array. The platform is the 
Austrian Institution of Technology Protein Array 642 (GPL15009). Multiple comparisons 
were performed with this dataset: Normal vs. Benign, Normal vs. Malignant, and Benign 
vs. Malignant. Various sample sizes were used for the different comparisons with the 




3.2.2.2     Pre-processing steps     Downloaded datasets were transformed/normalized for 
comparison purposes. CaGEDA (Patel & Lyons-Weiler 2004) is a resource developed to aid in 
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data analysis. Downloaded datasets were formatted (ensuring datatype for each row and column 
was the required type) using Microsoft Excel 2010. The data was input as a text-file with the first 
column containing gene/protein IDs and subsequent columns containing data (Figure 13, A). 
Figure 13. Examples of portions of caGEDA file formats. A) Example of caGEDA Format 1 
data spreadsheet. Duplicate values for GeneID’s are averaged by caGEDA. B) Example of the 
caGEDA sample identification file. The sample name should be in column 1 and the class in 
column 2, identified as 1 (case) or 2 (control). 
 An additional file describing sample ID and group number (i.e. case = group 1; control = group 
2) is also required (Figure 13, B). All datasets underwent z-transformation, and the J5 test was
used for feature selection (to reduce the number of genes to be examined by BRL; see section 
3.2.2.4). 
The z-transformation is a function applied to every data point in a dataset that converts 
the values of a sample into z-scores using the formula  
Equation 9. Z-transformation formula 
A B 
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where   zi is the z-transformed sample observations, xi is the original values of the sample,  is the 
sample mean, and s is the standard deviation of the sample.  The z-transform of two datasets 
results in comparable distributions since both z-transformed distributions have a mean of 0.0 and 
a standard deviation of 1.0 (http://www.statistics4u.info/fundstat_eng/ee_ztransform.html). 
The J5 test is a gene-specific ratio between the mean difference in expression intensity 
between two groups, A and B, to the average mean group difference of all m genes.  
      Equation 10. The J5 formula 
The J5 test is likely to be useful in pilot studies where, due to high variance, t-tests are likely to 
exhibit unacceptably low specificity (high false discovery rates) (Patel et al. 2004). 
The z-transformed dataset containing new normalized values can be directly downloaded 
from the caGEDA website (http://bioinformatics.upmc.edu/GE2/GEDA.html; temporarily disabled) as a 
text file from the Analysis Results Page. A specific number of genes can be returned by setting a 
threshold which corresponds to the J5 Score. The dataset of retained genes can also be 
downloaded from the Results Page. To limit the number of genes that the modeling algorithm 
must examine, the feature selection cutoff was set to 1000 genes; the analyses were all performed 
at the gene-level, and thus experimental probe values pertaining to the same gene were averaged 
together to produce one value per gene per sample. 
The caGEDA results page provides some valuable analysis metrics and plots. The 
between-mean array correlation, confounding index (after normalization), sample distribution 
box-whisker plots, global correlation graph of sample means, score histogram, and score 
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Relevant information required for the modeling algorithm input file exists in different files. To 
combine all of the required information into one file, a Perl matching script named 
Matching_keep_all.pl was used. The script was provided by Haiwen Shi, Bioinformatics Core 
Labs, Genomic and Proteomic Core Labs, University of Pittsburgh. This Perl script takes two 
text files as input, and will match any common identifiers based on the user-defined columns of 
interest (Table 7). In this work, three lists (z-scores, feature selection list containing 1000 genes, 
and the normalized dataset), must be combined to obtain the necessary information, so the script 













Table 7. Input files for matching script. The feature selection list and normalized dataset are 
output from caGEDA. The informed prior list comes from the text-mining exercise described 
earlier. Files were matched by using the GeneID/Name columns. Samples are depicted below. 
 
Feature Selection List Normalized Dataset Informed Prior List 
   
 
 
Table 8. Matching script output file. Ratio+1 measure was used to eliminate any zeros from 




3.2.2.3     Transforming counts to prior probabilities     Determining the most appropriate 
method to transform the literature mining counts into prior probabilities is essential for 
understanding the modeling results. Prior information values need to be within an acceptable 
range to appropriately be incorporated into the dataset without overwhelming the remaining data.  
In this work, three different transformation methods were tested: informed prior ratio (a ratio of 
number of positive biomarker mentions/number of negative biomarker mentions + 1 to eliminate 
zeros); uniform priors (value of 0.5 for all biomarkers); and no priors (data only).  
 
3.2.2.4     Bayesian Rule Learner     In the search for biomarkers, more accurate modeling 
should increase the chances of uncovering more-likely disease-specific markers. Using a 
Bayesian approach allows for prior information to be integrated into model learning. 
Additionally, rule learning is preferred because rules are easy to interpret and are easily applied. 
The Bayesian Rule Learner (BRL) algorithm is a probabilistic method for learning rules, and has 
been described in Gopalakrishnan et al. 2010. Models optimize a Bayesian score, which can be 
used to measure model uncertainty and rank and choose models; and ultimately translate the 
Bayesian network (BN) into a set of rules with scores. 
The BRL utilizes the K2 Bayesian scoring measure and search heuristic (Cooper and 
Herskovits 1992). The K2 measure assumes discrete variables, independent cases, missing 
values, and a uniform prior probability distribution over all possible network structures. The K2 
measure assumes every possible probability distribution over the values of a node given the state 
of its parents is equally likely. Under these assumptions, the Bayesian score is given by the 
following equation (Cooper and Herskovits 1992): 
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Equation 11. K2 Bayesian score 
where M is the BN structure, D is the data used to learn M, n is the number of variables in M, qi 
is the number of parent states of child variable i, ri  is the number of values or states of variable i 
and Nijk is the number of instances in the training database D for which variable i has the value k 
and the parents of i have the value state denoted by index j. Also, Nij is the sum over k of Nijk 
(Cooper and Herskovits 1992).  
The BRL process is described by Gopalakrishnan et al. 2010, with a summary given here: 
Bayesian networks containing a target node with zero parents are created and evaluated with 
Bayesian scores. Next, the list of variables in good scoring models which cannot be improved by 
adding a parent is initialized. A greedy search is implemented due to the difficulty of searching 
all possible BN structures. Models are searched by utilizing a beam to store the highest-scoring 
BNs. Beam size is user-defined, and the BNs are stored according to score. Because of beam 
size-restrictions, only the highest scoring BN structures which possess the ability to be improved 
upon by the addition of a parent variable are further examined. Additional searches are 
performed by adding one more variable as an additional parent of the target. For each target, its 
probability given each state of possible values of its parent variables is calculated. If the score of 
the model was improved with the addition of a new parent variable to the model structure, and 
the total number of parent variables in the model does not exceed the user-defined limit, 
additional searches are performed. If not, the model is placed on a priority queue containing final 
model structures ordered according to Bayesian scores.  
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Equation 12. The BRL Score 
The algorithm retains those sets of variables that cannot be improved upon further for 
reuse as parent variables. When no further improvements can be made to any model structure, 
the highest scoring models are returned to the user in the form of a rule models, which represent 
the probability that the model is valid given the data. The assumption is that if a predictor is 
found in a final rule, then it is unlikely to be a strong predictor in another rule. 
The BRL was chosen as the modeling algorithm due to its many benefits also described 
in Gopalakrishnan et al. 2010: 1) evaluation of the entire rule set using a Bayesian score results 
in a whole model evaluation instead of a per rule evaluation; 2) creation of optimized 
probabilistic rules as opposed to the evaluation per rule; 3) incorporation of  both structure and 
parameter priors; 4) prior knowledge with conditional independencies among variables can be 
applied, specifying the network structure; 5) returns parsimonious models with fewer variables 
or markers, without sacrificing classification performance; 6) fewer variables allows for less 
biological verification and validation; 7) more statistically significant results than other rule 
learning methods; 8) very efficient as it utilizes breadth-first marker propagation to only one pass 
through the training data once.; 9) ability to quantify uncertainty about the validity of a rule 
model using a Bayesian score;  and 10) the use of prior probabilities into the rule-discovery 
process minimizes over-fitting. 
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3.2.2.5     Execution of the BRL algorithm     BRL version 1 (2010-05-29) was used for the 
structure prior modeling exercises. The BRL is run as an executable jar file. The following 
arguments are given in the command line: –LP defines the learning parameters; –rgm 1 1 is the 
rule generation method, where the first 1 represents Bayesian local rule learning (local structure 
search), and the second 1 represents the decision tree parallel greedy search (PGS); –cv 10 
represents 10-fold cross-validation;  –d 0 0.5 specifies the discretization method, where 0 means 
no discretization, and the 0.5 is the default value for the structure prior parameter lambda; –beam 
5000 specifies the size of the beam, or how many models can be retained at any one time; –PPP 
are pre-processing parameters; and –DP specifies data parameters used. So an example of the 
entire executable statement would be: java –jar BRLv1.jar –LP –rgm 1 1 –cv 10 –d 0 0.5 –beam 
5000 –PPP –DP filename. 
 
3.2.2.5.1     BRL input     The BRL algorithm requires proper dataset formatting which was 
performed using Microsoft Excel 2010. The downloaded datasets must be transposed so that the 
rows represent samples and columns represent genes (Figure 14). The second column must be a 
sample class column. The second row must be the row of prior values if utilizing uniform or 
informed prior values. This row can be omitted if prior information is not desired.  The file must 
be saved as a tab-delimited text file. 
 99 
Figure 14. Example of a portion of a BRL input file. The @class column is the sample group 
identifier. In this example Former and Current represent smoking status, but any group identifier 
could be used. 
3.2.2.5.2     BRL output     BRL exports a number of informative files (cross-validation 
performance, cross-validation rules, and training data performance, prediction, and rules files). 
The performance and rules files were examined in this work. Performance files contain accuracy, 
sensitivity, specificity, balanced accuracy, and area under the curve measurements for the cross-
validation and training data. The rules files contain the rules and attributes used to create the 
cross-validation and training models. An example of a rule is shown below. Rules were taken 
from a rules file obtained from a lung cancer microarray dataset of former vs. current smokers 
using informed priors: ((PCBP1 = 2.513..inf) (RTP4 = 1.045..inf) (TMEM161A = 1.054..1.364) 
(CBY1 = 0.661..inf) (SOD2 = 1.174..1.527) (AA654586 = 1.714..inf) (MFHAS1 = 0.627..inf) 
(WDR19 = 0.317..inf)) ==> (@class =  Current). Samples whose data values fell within the 
described ranges for the 8 attributes (genes) in the rule were classified as Current smokers.   
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3.2.2.6     Confirmatory research     The BRL modeling rules files contain the attributes 
(markers) used to create the best-scoring models. The attributes used to build the model were 
compared to the list of known disease biomarkers to look for markers common to both lists. 
When commonality was found, a potential relationship was assumed to exist (SOD2/CCL5). 
Further confirmatory research is then required to determine if the relationship is already known, 
novel, or a false-positive. 
Pathway analysis was performed by examining KEGG, PID, and BioCarta pathway 
databases for SOD2/superoxide dismutase 2 and CCL5/C-C motif chemokine ligand 5 pathways. 
The protein interaction database String DB, string-db.org/, was searched for SOD2 and CCL5 
protein interactions. Others examined include BioGRID, thebiogrid.org/, and IntAct, 
www.ebi.ac.uk/intact/main.xhtml. Entrez Gene, a genomic database 
www.ncbi.nlm.nih.gov/gene, was used to search the genes of interest. The information returned 
from this database includes gene summary, genomic context, genomic regions, transcripts, and 
products, pathways, ontology, and interactions. Lastly, a literature search of PubMed was 
performed. PubMed (www.ncbi.nlm.nih.gov/pubmed) contains more than 24 million citations for 
biomedical literature. PubMed can be searched using the marker IDs as keywords, and should 
return a somewhat comprehensive set of citations as results. Results can be further filtered by a 
number of parameters, one of which is species.  
3.2.3     Pathway analysis methodology 
Pathway analysis has become a standard step in biological data analysis. Some algorithms permit 
the user to input a set of relevant genes/proteins and their expression values, and output a 
diagram of the biological process where the input genes are highlighted. This allows the 
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researcher to visualize what genes may be altered up- or down-stream for possible disease 
manipulation (prevention and/or treatment). 
Figure 15. Diagram of the KEDA pathway analysis process. 
Prior information can be incorporated with experimental data and analyzed for pathway 
analysis, increasing the likelihood that pathway findings and subsequent conclusions are more 
accurate. Figure 15 is a diagram of the pathway analysis process used in this work. The pathway 
analysis program utilized in this work was Pathway Express (PE). 
3.2.3.1     Pathway Express     Pathway Express (PE) is a freely available pathway analysis tool 
which is incorporated into the Onto-Tools suite. PE helps researchers find the most appropriate 
pathways for their genes of interest. PE takes as input a gene list with accompanying 
differentially expressed values, compares the list to existing pathways in the KEGG database, 
and outputs valuable pathway information such as impact factor, p-values, total number of input 
genes in the pathway, and pathway diagrams.  
Khatri et al. 2005, briefly describe the impact factor calculation as follows: PE first 
calculates a perturbation factor (PF; Equation 2) for each input gene. The PF takes into account 
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the normalized fold-change of the gene and the number and amount of perturbation of upstream 
and downstream genes. The PF reflects the relative importance of each differentially regulated 
gene. The impact factor (Equation 3) of the entire pathway includes a probabilistic term that 
takes into consideration the proportion of differentially regulated genes on the pathway and gene 
perturbation factors of all genes in the pathway. Pathways are ranked by impact factor before 
presentation to the user.  
The PE p-value calculation is described in Khatri et al. 2007. PE performs a classical 
enrichment analysis based on a hypergeometric distribution in order to identify those pathways 
that contain a proportion of differentially expressed genes that is significantly different from 
what is expected by chance.  
3.2.3.2     Execution of Pathway Express algorithm     Pathway Express requires Java and is 
part of the Intelligent Systems and Bioinformatics Laboratory, found on the website 
http://vortex.cs.wayne.edu/projects.htm. Once the program is initiated, a menu will appear where 
the user chooses PE from Onto-Tools options menu. A subsequent PE input menu appears. From 
here the user enters the input file, reference file, reference array, organism, input type, and 
advanced options. 
3.2.3.2.1     Pathway Express input     Pathway Express allows the user to input a list of 
relevant genes/proteins for examination. The software assumes the entered values are fold 
change values, but any values may be used. In addition to genelists, a reference file is required, 
which is a list of all of the genes present on a given array. It uses this file for the perturbation and 
impact factor calculations described earlier. 
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Five different types of input genelists were studied to determine their effects on pathway 
results. Only a subset of the array-based experimental breast and lung cancer datasets mentioned 
earlier were examined. The first type of genelist contained differentially expressed genes and 
their accompanying J5 scores; which was considered data only. The second and third types of 
genelists contained genes with the z-scores and ratios obtained from the literature-mining 
exercises from whole blood, which were considered z-score only or ratio only. The fourth and 
fifth types of genelists used the product of the J5 score and z-score or ratios; considered data & 
z-score or data & ratio, respectively.   
 
3.2.3.2.2      Pathway Express output     Pathway Express outputs a menu of results as four 
windows (Figure 16). The upper left window orders affected pathways in decreasing order of 
their expected importance for the given condition (Khatri et al. 2005). The upper right window is 
the list of returned pathways, where the highlighted pathway is the active pathway. By clicking 
on the link, the actual pathway diagram is displayed, showing the input genes/proteins and their 
expression. The bottom right window displays the genes involved in the active pathway. The 
bottom left window displays the input genes/proteins, and the number of returned pathways that 
the genes/proteins are involved. Any particular window can be downloaded directly from the 
output menu. 
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Figure 16. Example of Pathway Express output menu. Upper left window orders affected 
pathways in decreasing order of their expected importance for the given condition. Upper right 
window is a list of relevant pathways returned. The highlighted pathway is the active pathway. 
Bottom left window is a list of the input genes/proteins and the number of returned pathways the 
gene/proteins are found. Bottom right window is a list of the genes found in active pathway. 
Figure 17 is the KEGG pathway diagram for non-small cell lung cancer created using 
lung cancer microarray smoking former vs. current data + ratio dataset. The visual diagram 
allows researchers to view gene/protein interactions, as well as look for genes that may be 
possible targets for disease prevention and/or treatment. Genes/proteins from the user-provided 
genelist are highlighted to show their expression under given conditions. 
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Figure 17. KEGG Non-small cell lung cancer diagram created using lung cancer 
microarray smoking former vs. current data + ratio dataset. Highlighted red = upregulated; 








4.0 EVALUATION OF KEDA 
The sections below present the experimentation undertaken to test the claims made above 
pertaining to literature-mining (4.1), modeling accuracy (4.2), and pathway analysis (4.3). The 
KEDA Framework was created to expedite the literature mining process to obtain values that can 
be used as prior knowledge in modeling and pathway analysis. 
 
4.1 LITERATURE-MINING RESULTS 
The goal of literature mining was to obtain prior knowledge values to aid in biomarker discovery 
via modeling and pathway exercises, while trying to acquire added new knowledge, in the form 
of disease and biofluid specific findings, in the process. Additionally, literature mining findings 
could also be utilized to identify potential biomarkers as a stand-alone process.  
Biofluid-specific markers were identified from mining the literature, assigned relevance 
scores by frequency of occurrence, and validated using known biomarker lists and/or databases 
for lung and breast cancer. Biofluid specificity for each marker was calculated, and the 
performance of the semi-automated literature mining method assessed. In the following sections 
(4.1.1 - 4.1.9) the claim that text-mining is a sufficient method of obtaining potential biomarkers 





4.1.1     Z- score threshold optimization 
Gene/protein IDs in PubMed abstracts were identified and frequency of occurrence counts were 
converted to z-scores. Z-scores were selected as a measure because they provide more 
information that counts alone. Z-scores are a relative measure that provide a general idea about 
the number of standard deviations a data point varies from its mean; counts do not. A threshold 
was sought to determine the point at which z-scores would be considered significant. Because of 
the large number of markers found, only markers considered ‘significant’ were further pursued.  
Empirical findings were used to establish said threshold. Figure 18 is a plot of the number of 
known and new markers found by varying the z-score threshold in increments of 0.5. It can be 
seen that in both breast and lung cancer that a threshold value of 1.0 allows for the maximum 












Figure 18. Number of markers identified across the range of possible Z-scores.  Decreasing 
the Z-score threshold allows for more significant markers to be identified. Sig = significant. 
4.1.2     Known markers per biofluid  
To estimate the performance of our semi-automated literature mining process, an error rate 
calculation was performed. By estimating the error rate in known biomarkers, it might be 






























biomarker lists are combinations of several lists from well-known disease databases.  The known 
breast cancer list contains 211 markers that mapped to our dictionary (Table 4; n=159), and the 
known lung cancer list has 209 markers that mapped to our dictionary (Table 5; n=145). Results 
presented in Table 9 were achieved by identifying putative biomarkers with a z-score exceeding 
the significance threshold (>1.0), and confirming the gene symbol’s existence in a known disease 
biomarker list. Table 9 also provides a summary of each biofluid, markers with significant z-
scores, the number of known markers found, and the calculated percent of new discoveries. 
Breastmilk was removed from breast cancer examination because the positive and negative 
search terms both contain the root word ‘breast’.   
4.1.3     Known markers found significant vs. non-significant 
The next question to be asked was: Out of the total known markers that were identified by our 
methods, what percentage were being identified as significant by the proposed scoring method? 
By calculating this percentage using the counts provided in Table 9, it could be determined if the 
scoring threshold was too stringent or too lenient. For breast cancer, known/significant 
percentages ranged from 5% in plasma and serum to 37.5% in stool (for biofluids with known-
significant markers; non-zero). In lung cancer the known/significant percentages ranged from 3% 
in serum to 37% in mucus. Based on these percentages, it was determined that the threshold was 
not too stringent because the it was not eliminating all of the found known markers, and it also 
was not too lenient in that it was reducing the number of markers for further study by more than 
half. 
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Table 9. Number of markers identified for disease-biofluid combinations. Known markers 
were confirmed by the presence of the gene symbol in our known biomarker lists (Tables 4 and 
5).  Significant markers have a z-score > 1.0. 
4.1.4     Newly discovered markers found significant vs. non-significant 
The percentages of newly discovered markers (markers not found in known marker list) found to 
be significant vs. those that were identified but not found to be significant was calculated to 
determine if the error rate calculation for known markers could be extrapolated to apply to newly 
discovered unknown potential markers. For breast cancer, new/significant marker percentages 
ranged from 6.67% in stool to 29.3% in bile (for biofluids with known-significant markers; non-
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zero), and in lung cancer the new/significant percentages ranged from 7.9% in plasma to 27.2% 
in synovial fluid. The newly discovered/significant percentage ranges highly correlate with the 
known/significant percentage ranges. Based on this result, it was concluded that the error rate 
from known findings could be inferred to new findings. 
 
 
4.1.5     Potential marker biofluid specificity  
The search for additional information in the literature mining process led to breast and lung 
cancer findings being further subdivided into biofluids. Biomarker commonality and specificity 
was determined across biofluids. This is a significant finding as this information is novel as 
potential biomarker comparisons across more than a few biofluids are rarely seen in the scientific 
literature. This information could also prove very beneficial to breast and lung cancer researchers 
and clinicians in the future.  Table 10 shows the known and significant biomarkers found within 





















Table 10. Identification of the significant validated potential markers found to be in 
common to several biofluids or biofluid specific for breast and lung cancer. Yellow 
highlights are breast cancer markers found in the list of validated lung cancer biomarkers (Table 
4), or lung cancer markers found in the list of validated breast cancer biomarkers (Table 5). It is 
doubtful that these markers are disease specific. Green highlights aid in identifying which 
markers were identified per biofluid. CDH1 is the only biomarker appearing in both breast and 






From Table 10, for breast cancer, nine biofluids produced known markers with 
significant scores. 21 known & significant putative markers were identified. 14 of these markers 
are only mentioned in combination with one biofluid, 3 with two biofluids, 1 with 3 biofluids 
(ERBB2; mentioned blood, plasma, and serum), 1 with 4 biofluids (NCOA3/nuclear receptor 
coactivator 3; mentioned in bile, blood, plasma, and serum), 1 with 6 biofluids (BRCA2; 
mentioned in bile, blood, mucus, saliva, serum, and sweat), and 1 with 7 biofluids (BRCA1; 
mentioned in blood, mucus, plasma, saliva, serum, sweat, and urine).  
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Also from Table 10, for lung cancer, eight biofluids produced known markers with 
significant scores. 26 known & significant putative markers were identified. 21 of these markers 
are only mentioned in combination with one biofluid, 3 with two biofluids, 1 with 3 biofluids 
(EML4/echinoderm microtubule-associated protein-like 4; mentioned in blood, mucus, and 
serum), and 1 with 4 biofluids (KRAS; mentioned in blood, breastmilk, mucus, and serum).  
As we are interested in identifying disease-specific markers, it was important to ensure 
that the markers on the list were not common cancer markers, but breast or lung cancer specific. 
To do this, markers in the breast cancer list of Table 10 were compared to the list of validated 
lung cancer biomarkers (Table 5), and lung cancer markers found in the list of Table 10 were 
compared to the list of validated breast cancer biomarkers (Table 4). In doing so, six breast 
cancer markers (ERBB2, CDH1/cadherin 1, CYP1A1/cytochrome P450 family 1 subfamily A 
member 1, PIK3CA, THBS1/thrombospondin 1, and TNFSF10/tumor necrosis factor 
superfamily member 10) and eleven lung cancer markers (CD40LG/CD40 ligand, CDH1, 
CDKN2A/cyclin-dependent kinase inhibitor 2A, CGA/glycoprotein hormones, alpha 
polypeptide, EGFR, HRAS/Harvey rat sarcoma viral oncogene homolog, KLK10/kallikrein-
related peptidase 10, PLG/plasminogen, TNFRSF1A/tumor necrosis factor receptor superfamily 
member 1A, TP53, and VEGFA/vascular endothelial growth factor A) were determined to not be 
either breast or lung cancer specific markers. However, even though they are not breast or lung 
cancer specific, most of them have been implicated in cancer biology in general, and should not 
be discarded from any cancer study. 
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4.1.6     Manual verification of findings 
Manual inspection of pertinent abstracts was performed to determine the reliability of the 
findings in Table 10. For each relevant finding in Table 10, the supporting PubMed abstracts 
were manually examined to verify that each abstract contained mention of the marker, biofluid, 
and disease. Only abstracts that mentioned all three entities were considered true positives in this 
study. The results can be seen in Table 11. In breast cancer, four known biomarkers 
(CHEK2/checkpoint kinase 2 in both plasma and urine, CDKN1B/cyclin-dependent kinase 
inhibitor 1B, PCNA/proliferating cell nuclear antigen, and THBS1/thrombospondin 1) were 
identified as false positives (red); and in lung cancer, eight known biomarkers were identified as 
false positives (KRAS, GDNF/glial cell line-derived neurotrophic factor in both breastmilk and 
plasma, MYCL1/v-myc avian myelocytomatosis viral oncogene lung carcinoma-derived 
homolog in both blood and serum, CD40LG, CGA, CTAG1A/cancer-testis antigen 1A, 
ERCC6/excision repair cross-complementation group 6, and HRAS). KRAS is interesting in that 
it produced a false positive in association with breastmilk, but had verified positive findings in 
associations with blood, mucus, and serum.  
4.1.7     Error rate estimation of new discoveries 
The manual verification step enabled calculation of the error rates across the biofluid-disease 
combinations. Table 11 displays an average error rate for breast cancer of 12.5%, and an average 
error rate for lung cancer of 29.41%. Based on these error rates, it is estimated that 87.5% of the 
breast cancer new discoveries, and 70.59% of the lung cancer new discoveries from the proposed 
method could be trusted to be true positives.  
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Table 11. Manually verified biomarker table. Biomarker specific abstracts were manually 
examined for mentions of biofluid, disease, and biomarker. Omission of any of these terms 





The following factors support the idea that (Claim 1) literature mining is a sufficient 
method of obtaining potential biomarkers: 1) the search space was exhaustive, ensuring that all 
relevant abstracts were included in the analysis (methodology 3.2.1); 2) a gene/protein dictionary 
was implemented, to allow gene/protein aliases to also be included in the counts (methodology 
3.2.4); 3) use of positive/negative abstract sets ensured that the findings were disease specific 
(methodology 3.2.4); 4) known biomarker lists were utilized as gold-standards, supporting the 
idea that the findings were true (methodology 3.2.6; experimentation 4.1.1 - 4.1.3); 5) manual 
verification allowed for further confirmation of true findings (methodology 3.2.6; 
experimentation 4.1.6); 6) an error rate was calculated to determine the number of newly 
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discovered markers that can be trusted to be true positive findings (methodology 3.2.7; 
experimentation 4.1.7). 
4.2 CLASSIFICATION MODELING RESULTS 
The goal of modeling is to predict correct classification of samples into groups based on the 
examination of specific criteria. Several different evaluation measures were assessed in order to 
determine the performance of the models: accuracy, number of attributes, informativeness of the 
attributes, sensitivity, and specificity all contributed to the understanding and assessment of the 
results. The BRL determines the best performing models and presents only the best model(s) to 
the user. Several factors exist (dataset size, weighting of priors, and data type) which could bias 
results and need to be accounted for before proper assessment can be performed. 
The following sections provide explanations of the comparisons and exercises performed. 
Sections 4.2.1 – 4.2.4 test the idea that incorporation of prior information did not on average, 
enhance or degrade the model performance (Claim 2, part A). Section 4.2.5 – 4.2.6 examine the 
claim that analyzing the attributes used to build the best-performing models may lead to possible 
new interactions (Claim 2, part B). 
4.2.1 Experimental design using literature mining results 
For the modeling exercises, the prior probabilities were incorporated into the normalized dataset. 
Figure 14 in section 3.2.2.5 provides an example of the BRL input file. The priors were 
incorporated as a column in-between the sample class column and the data columns. Each 
comparison required a separate dataset / prior combination. The customized BRL algorithm 
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tested the prior column as its own variable, and then multiplied each data point with its 
applicable prior probability for all other variables (in this case gene/protein). 
4.2.2     Dataset size effects on accuracy 
An initial experiment was performed to determine if an optimal sized dataset exists and if so, 
would it influence the modeling results. The lung cancer microarray dataset case-control 
comparison (cancer vs. normal) was chosen for this exercise. The sample size consisted of 73 
adenocarcinoma samples vs. 80 control samples. 22277 probes covering 14355 genes were 
analyzed. The dataset was Z-transformed, and feature selection was performed prior to analysis. 
Figure 19. Overall modeling accuracy and the number of attributes found using different 
dataset sizes. Accuracy measurements can be found in the 40-80% range, while the number of 
attributes can be found in the 0-20 range. Results were obtained from BRL. Ratio = informed 
priors (red); Orig = no priors (green); Uniform = uniform priors (blue). 
Smaller sized sub-datasets were manually created by randomly choosing samples to 
create datasets of pre-determined percentages of the original microarray dataset, ranging from 
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20% to 100%, in increments of 10%. For example, the 20% dataset would consist of 14 
adenocarcinoma samples (out of 73 total) and 16 control samples (out of 80 total) randomly 
chosen. The BRL was executed with the previously discussed settings. Informed priors (Ratio), 
no priors (Orig), and uniform priors were tested and examined for classification accuracy. Figure 
20 is a combined plot of the accuracy of the models tested (top group of curves), as well as the 
number of attributes tested (bottom group of curves), across the different sub-datasets. No 
consistent pattern of improvement in modeling accuracy or number of attributes is seen across 
the different dataset sizes. The greatest accuracy for the informed prior is obtained from the 30% 
dataset. 
 
4.2.3     Weighting effects on accuracy 
An experiment was performed to determine how weighting the informed prior ratio would 
influence the BRL modeling results. If the weights are too large, the prior values could 
overwhelm the data and models could be chosen based solely on the prior values, ignoring the 
data. Conversely, if the informed prior weights are too small, they might be overwhelmed by the 
data, and thus not contribute to the model either.  
The same lung cancer microarray dataset case-control comparison (cancer vs. normal) 
was chosen for this exercise. However, the 30% dataset was used, being that the greatest 
informed prior accuracy was achieved with that dataset. The dataset was z-transformed, and 
feature selection was performed prior to analysis.  
 Informed prior ratios were weighted on an increasing scale beginning with no weight, and 
adding values of 2, 3, 4, 5, 10, 25, 50, and 100. Uniform priors were scaled beginning with 0.5, 
1, 1.5, 2, 2.5, 5, 12.5, 25, and 50. 
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Figure 20. Overall modeling accuracy across various weights. Accuracy measurements are 
found in the 50-80% range, while the number of attributes can be found in the 0-20 range. 
Results were obtained from BRL. Ratio = informed priors (red); Orig = no priors (green); 
Uniform = uniform priors (blue). 
The BRL was executed with the previously described settings. Figure 21, is a combined 
plot of the accuracy of the models tested (top group of curves), as well as the number of 
attributes tested (bottom group of curves), with different weights. As before, no consistent 
pattern of improvement in modeling accuracy or number of attributes is seen using different 
weights. The greatest accuracy for the informed prior is obtained using a weight of 1 (weighted 
ratio = 1 in Figure 21). 
4.2.4 Accuracy across different types of datasets 
The possibility exists that the results obtained up to this point may be data-type specific, and that 
the results could change drastically if a different data-type is examined. To confirm that previous 
findings were not data-type specific, an experiment was performed to determine modeling 
accuracy across different data-types or platforms. Eight comparisons and four different data-
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types were examined. In this experiment, the entire datasets were used. The dataset was z-
transformed, and feature selection was performed prior to analysis.  
Figure 21. Overall modeling accuracy across different types of experimental data. Results 
were obtained from BRL. Results from breast cancer datasets found in the top plot, and lung 
cancer in the bottom. Breast cancer abbreviations: Meth = methylation; MA = microarray; Prot = 
protein; T/N = tumor vs. normal; N/1 = normal vs. grade 1; N/2 = normal vs. grade 2; N/3 = 
normal vs. grade 3; 1/2 = grade 1 vs. grade 2; H/C = healthy vs. cancer; P/N = ER+ vs. ER-; P/P 
= menopause pre vs. post; B/M = benign vs. malignant; N/B = normal vs. benign; N/M = normal 
vs. malignant; L/C = leukocyte vs. CSF. Lung cancer abbreviations: CGH = comparative gene 
hybridization; Meth = methylation; MA = microarray; H/C = high vs. control comparison; H/L = 
high vs. low comparison; L/C = low vs. control comparison; C/C = case vs. control comparison; 
Morph = morphology comparison (adenocarcinoma vs. scc; Smoke = smoking history; FvC = 
former vs. current; Ratio = informed priors; Orig = data only. 
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The BRL was executed with the previously described settings. Figure 21, is a plot of the 
accuracy of the models tested, across different data types and comparisons. Once again, no 
consistent pattern of improvement in modeling accuracy is seen across the different data types. 
The greatest accuracy for the informed prior from all of the dataset types tested is obtained from 
the microarray dataset comparing lung cancer morphology.   
4.2.5 Statistical significance 
While individual comparisons can pinpoint a few examples where informed priors increased the 
modeling accuracy (Figure 20), the accuracy of the models does not appear to improve with the 
addition of the prior information, on average. Paired student’s t-tests were performed using 
Microsoft Excel 2010 to support the conclusion of no improvement and no decrease in modeling 
accuracy with the addition of prior information. Accuracy measures from the dataset type 
comparisons in Figure 21 were used to perform the significance test. None of the test 
comparisons (informed (I) vs. uniform (U), informed vs. data only (D), uniform vs. data only) 
showed statistical significant findings based on the t-tests (Breast I-U; p=0.36; Breast I-D; 
p=0.48; Breast U-D; p=0.51; Lung I-U; p=0.89; Lung I-D; p=0.65; Lung U-D; p=0.92). 
4.2.6 Examining modeling attributes 
While the lack of improved modeling accuracy was disappointing, scientific value remains. 
Attributes from the best performing models (Appendix C.27 and C.28) were examined and 
compared to known biomarker lists (Tables 4 and 5). When two attributes from the same disease 
model were also identified in the lists of known biomarkers, an assumption was made that a 
possible disease–specific relationship may exist. Analyzing the results from the lung cancer 
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microarray dataset comparison between former vs. current smokers revealed a possible 
relationship between SOD2 and CCL5. This possible relationship was found in cross-validation 
models using both informed prior as well as a uniform prior. No similar finding was achieved 
from breast cancer models. 
4.2.7 Confirmatory research 
While the ideal scenario is that the possible relationship discovered is a novel finding, further 
research and experimentation is warranted. Pathway analysis, database searches, and literature 
searches were performed in search of further insight into the possible relationship finding. 
Several pathway databases were explored (KEGG, REACTOME, WikiPathways, BIOCYC, PID, 
and BioCarta) for pathways containing SOD2 and CCL5. No pathways were found to contain 
both SOD2 and CCL5 from the databases examined (although Di Renzo et al. 2014 refers to 
SOD in general as part of the Human Oxidatitive Stress Pathway, SOD2 in particular was not 
mentioned). Several protein interaction databases were searched (StringDB, BioGRID, IntAct) 
for known interactions and/or interacting entities of SOD2 and CCL5, and lists created for 
examination.  
There does not appear to be a documented interaction between SOD2 and CCL5, nor 
does there seem to be any direct interacting entities in common obtained from the interaction 
databases. The genomic database Entrez Gene, www.ncbi.nlm.nih.gov/gene, was investigated for 
genomic information pertaining to SOD2 and CCL5. Gene ontologies were examined in search 
of common functions, processes, and/or components. No common function, process, or 
component ontologies between SOD2 and CCL5 was found.  
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A query was performed to determine if the SOD2-CCL5 relationship has been discussed 
previously in any scientific literature. PubMed was searched using the official symbols SOD2 
and CCL5, as keywords, and implementing a filter of ‘Homo sapiens’. Seven scientific abstracts 
were returned as a result of said search. 
Kitaya et al. (2007) discussed how genes are regulated by Interferon (IFN)-gamma in 
human uterine microvascular endothelial cells. IFN-gamma plays a critical role in murine uterine 
spiral artery remodeling for successful pregnancy, and a link to a human role was sought. 
Treatment with IFN-gamma induced a significant > or =2-fold change in 29 genes in pooled 
human uterine microvascular endothelial cells; of the 20 genes that were up-regulated, was the 
chemokine CCL5, and the enzyme SOD2. The results suggest that IFN-gamma regulates the 
gene expression involved in natural killer cell recruitment, embryo and trophoblast migration, 
endometrial decidualization, angiogenesis, angiostasis, and anti-viral infection in human uterine 
microvascular endothelial cells. However, no relationship between SOD2 and CCL5 was 
discussed; and it was mentioned that the SOD2 protein is not expressed in uterine microvascular 
endothelial cells in vivo. 
 Qui et al. (2009) described a relationship not between SOD2 but between SOD1/copper-
zinc superoxide dismutase and CCR5/CCL5. They identified SOD1 as mediating CCR5/C-C 
chemokine receptor 5 activation by CCL5 in macrophages. They discussed that CCL5/CCR5 are 
known to play a vital role in regulating leukocyte trafficking, engendering the adaptive immune 
response and contributing to the pathogenesis of a variety of diseases. While SOD1 was 
discussed in great detail, SOD2 was not directly mentioned in the entire manuscript. 
Jin et al. (2010) discussed molecular signatures of maturing dendritic cells. Dendritic 
cells (DCs) are often produced by GM-CSF/granulocyte-macrophage colony-stimulating factor 
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and IL-4/interleukin 4 stimulation of monocytes. They analyzed the kinetics of DC maturation by 
LPS/lipopolysaccharide and IFN-gamma/interferon gamma induction in order to characterize the 
usefulness of mature DCs (mDCs) for immune therapy and to identify biomarkers for assessing 
the quality of mDCs. After 24 hours of LPS and IFN-gamma stimulation, Th1 attractant genes 
such as CCL5 were up-regulated during maturation. The expression of SOD2 was also up-
regulated throughout maturation. They concluded that DCs, matured with LPS and IFN-gamma, 
were characterized by increased levels of Th1 attractants and may be particularly effective for 
adoptive immune cancer therapy. However, other than mentioning that SOD2 and CCL5 are both 
classic mature dendritic cell biomarkers, no direct or indirect relationship are discussed, with 
SOD2 being rarely mentioned at all. 
Shah et al. (2011) conferred that oxidative stress and chemokines are important factors 
involved in the development of various clinical features found in patients with systemic lupus 
and arthritis, chronic inflammatory autoimmune disorders. The anti-oxidant activity of SOD was 
significantly reduced, and antioxidant molecules showed a negative association with CCL5 in 
both diseases. They concluded that excessive production of ROS/reactive oxygen species 
disturbs redox status and can modulate the expression of inflammatory chemokines leading to 
inflammatory processes, and affecting tissue damage in autoimmune diseases, as exemplified by 
their strong association with disease activity. A general term SOD was mentioned throughout the 
manuscript, but no delineation was defined between SOD 1 and SOD 2.  
Kumar et al. (2012) discussed how reactive oxygen species mediate microRNA-302 
regulation of cellular proliferation during transitions between normal cell growth phases’ 
quiescence and proliferation. They discussed CCL5 as a target for miR-302, and describe the 
best possibility of the SOD2-CCL5 relationship via miR-302. MiR-302 levels are decreased 
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significantly by overexpression of SOD2. Because SOD2 converts superoxide to hydrogen 
peroxide, overexpression of SOD2 is anticipated to increase hydrogen peroxide levels which 
may lead to ROS sensitivity of miR-302 regulation of ARID4a/AT-rich interaction domain 4A 
and CCL5 mRNA levels.  
Di Renzo et al. (2014) discussed SOD2 and CCL5 in the context of the positive effect of 
red wine intake on oxidized-LDL and gene expression. SOD2 and CCL5 were two of six genes 
examined, but no direct link between the two genes was discussed. They found that when red 
wine is taken in, values of ox-LDL are lowered (P < 0.05) and expression of antioxidant genes is 
increased, while CCL5 expression is decreased (P < 0.05). While a negative correlation in gene 
expression was revealed between SOD2 and CCL5, no direct link was mentioned. 
Kim et al. (2014) also examined miR-302’s regulation of cell proliferation and cell-cycle 
progression in adipose tissue-derived mesenchymal stem cells using microarray technology and 
other assays. They found that miR-302 induces cell proliferation and inhibits oxidant-induced 
cell death through a reduction in CCL5 expression. However, SOD2 was only mentioned once in 
the manuscript, as one of the anti-oxidant molecules being tested. Transfection of miR-302 did 
not affect the expression of SOD molecules. While treatment of the stem cells with CoCl2 
increased the gene expression of SOD1 and SOD2, transfection with miR-302 inhibited the 
CoCl2-induced increase in SOD1 and SOD2. However, no direct relationship was discussed 
between CCL5 and SOD2.   
 Results presented above support the idea that incorporation of prior information did not 
enhance or degrade the model performance, on average (Claim 2, part A; experimentation 4.2.1 – 
4.2.4). A consistent pattern of increased modeling accuracy was NOT observed when dataset 
size, weighting, and different data types were examined (experimentation 4.2.1 - 4.2.3). 
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However, these results cannot be generalized because only one dataset was tested. Statistically 
significant differences in modeling accuracy were NOT achieved (experimentation 4.2.4). An 
example is shown where analyzing the attributes used to build the best-performing models did 
lead to a possible new interaction (Claim 2, part B; experimentation 4.2.5). A very likely 
relationship may exist between SOD2 and CCL5 (experimentation 4.2.5, Kumar et al. 2012). 
While the two entities have been examined together in several studies, with miR-302 acting as an 
intermediary, it is possible that SOD2 may indirectly regulate CCL5 (experimentation 4.2.6). 
Similarly, a direct relationship has been described between CCL5 and SOD1. One would assume 
that SOD1 and SOD2 exhibit very similar molecular traits and behaviors. Additional 
confirmatory research is needed to support the idea since it is hypothesized, but not clearly 
defined in the literature (experimentation 4.2.6). The ’not so promising results’ that were 
achieved from the limited experimentation led to a change in direction of study (pathway 
analysis) as described in section 4.3.   
 
 
4.3 PATHWAY ANALYSIS RESULTS 
The goal of pathway analysis is to present a visual diagram of a biological process or pathway to 
enable researchers to better understand the process, as well as the biological entities involved in 
the process, and identify targets for altering the process. Three different evaluation measures 
were assessed in order to determine the performance from the pathway analyses: number of input 
genes in each pathway, impact factor of each pathway, and individual pathway p-values. These 
three measures contributed to the understanding and assessment of the results. Pathway Express 
allows for expression values to accompany the gene/protein name, which can be incorporated as 
an added benefit of the pathway analysis.  
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The following sections describe the various comparisons and exercises performed, 
relating to pathway analysis. Sections 4.3.1 – 4.3.1.3 test the idea that incorporation of prior 
information enhances pathway analysis results by identifying more input genes in breast cancer-
relevant pathways (Claim 2, part C). Sections 4.3.2 – 4.3.2.3 test the idea that incorporation of 
prior information enhances pathway analysis results by identifying more input genes in lung 
cancer-relevant pathways (also Claim 2, part C).  
Pathway Express returned 93 KEGG pathways from our breast and lung cancer data 
input. While a comprehensive analysis is always optimal, the study was limited to 22 pathways 
directly pertinent to breast cancer and 23 pathways directly pertinent to lung cancer. These 
pathways were chosen due to established biology relationships (ERBB2 and breast cancer); as 
being described as significant by Guille et al. 2013; or as being returned identified by a disease 
search of ‘breast cancer’ or ‘lung cancer’ using the KEGG website.  
 
4.3.1 Experimental design using literature mining results 
Prior incorporation was performed differently for pathway analysis compared to the modeling 
exercises. Pathway Express takes as input a list of gene/protein ID’s and one value. In order to 
achieve a representative value, the dataset for each comparison was analyzed first using 
caGEDA. The resulting differentially expressed value was in the form of a J5 score. The J5 score 
for each variable (gene/protein) was multiplied by the informed or uniform prior value (or by 1 





4.3.2     Breast cancer datasets 
Seven previously described (Table 6, Section 3.2.2.1) breast cancer datasets were analyzed: 1) 
copy number case vs. control (BCCNCvN); 2) microarray grade 1 vs. grade 2 (BCMA1v2); 3) 
microarray grade 1 vs. grade 3 (BCMA1v3); 4) microarray grade 2 vs. grade 3 (BCMA2v3); 5) 
microarray blood healthy vs. cancer (BCMABlood); 6) microarray ER status positive vs. 
negative (BCMAER); 7) microarray menopausal status pre vs. post (BCMAMeno). 
 Analysis results underwent post-analysis processing by one of five different methods: 
data-only (D; 835 most differentially expressed J5 scores); ratio (R; 835 genes from literature 
mining); z-scores (Z; 835 genes from literature mining); the product of data & ratio (DR; highest 
scoring 835 genes when J5 score multiplied by literature mining ratio); and the product of data & 
z-scores (DZ; highest scoring 835 genes when J5 score multiplied by literature mining z-score). 
In most cases the ratio (R) and z-score (Z) return the same genes, however, due to the 
mathematical sign of the value, (ratio always being a positive number, whereas the z-score may 
be positive or negative number), the gene expression values may be different. The same 
phenomenon applies to data & ratio (DR) and data & z-score (DZ), where the same genes are 
usually returned but the expression values and their signs may differ. Post-analysis processed 
values accompanied the gene ID’s in the genelists from the breast cancer microarray grade 1 vs. 
3 dataset and were input into Pathway Express.  
 All 22 relevant breast cancer pathways were assessed for each post-processing method. 
The Apoptosis Pathway produced from breast cancer microarray grade 1 vs. 3 dataset will be 
used as an in-depth example. The Apoptosis Pathway was chosen because 1) a steady increase in 
the number of input genes in the pathway is shown, from D (n=1) to R/Z (n=6) to DR/DZ 
(n=25); 2) the impact factor (if) increased by around a factor of 10, from D (if=3.07), R 
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(if=2.70), and Z (if=2.25) to DR (if=27.26) and DZ (if=27.64); and 3) the p-values changed from 
non-significant, D (p=0.98) and R/Z (p=0.17), to significant values of p=2.275 X 10-12 for 
DR/DZ. 
‘Data only’ results are what would normally be obtained from a typical pathway analysis 
using only experimental data array findings. Combining prior knowledge with experimental data 
array findings adds an additional layer of confidence to the reported pathway analysis findings, 
which allows the researcher more avenues to pursue in drawing conclusions, as well as more 
areas to focus on for future work. 
 
Assessment of pathway measures   
In assessing the pathway measures, the most important measure to be examined is the number of 
input genes in pathway. It is from this count that all other measures are calculated.  
 
 
Table 12. Number of input genes in pathway from breast cancer datasets. D = data only; R = 
ratio only; Z = z-score only; DR = data & ratio; DZ = data & z-score. Red highlights cases where 
the number of input genes in the pathway decreased from left (R/Z only) to right (DR/DZ). 
BCCNCvN = breast cancer copy number case vs. control; BCMA1v2 = breast cancer microarray 
grade 1 vs. grade 2; BCMA1v3 = breast cancer microarray grade 1 vs. grade 3; BCMA2v3 = 
breast cancer microarray grade 2 vs. grade 3; BCMA Blood = breast cancer microarray blood 
healthy vs. cancer; BCMAER = breast cancer microarray ESR1 status positive vs. negative; 
BCMAMeno = breast cancer microarray menopausal status pre vs. post. 
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Table 12 shows the number of input genes found in a given pathway using a given 
genelist. In general, a steady progression exists from left to right with D genelists providing the 
least amount of input genes in the returned pathways; the R/Z genelists producing more input 

















Figure 22. KEGG Apoptosis Pathway diagrams and input gene tables created using breast 
cancer microarray grade 1 vs. 3 dataset. A = data-only (D); B = z-score only (Z); C = data & 
z-score (DZ). Input genes highlighted red = upregulated and blue = downregulated. PF = 





The KEGG Apoptosis Pathway diagram, output from Pathway Express, contains 89 total 
genes (Figure 22, A). When the data only (D) genelist is analyzed, only one input gene is 
highlighted in the output Apoptosis pathway (BIRC3/baculoviral IAP repeat containing 3, in 
three different roles). When the literature mining z-score (Z) genelist is input (Figure 22, B), six 
input genes are highlighted in the output Apoptosis Pathway (AKT2/v-akt murine thyoma viral 
oncogene homolog 2, CASP10/caspase 10, CFLAR/CASP8 and FADD-like apoptosis regulator, 
PIK3CA*, PPP3CA/protein phosphatase 3 catalytic subunit alpha, and TP53*). Finally, when 
the combined DZ genelist is used as input (Figure 22, C), 25 input genes are highlighted in the 
output Apoptosis Pathway (AKT1*/v-akt murine thyoma viral oncogene homolog 1, ATM*/ATM 
serine-threonine kinase, BAD/BCL2-associated agonist of cell death, BAX/BCL2-associated X 
protein, BCL2*/B-cell CLL-lymphoma 2, BCL2L1/BCL2-like 1, BID/BH3 interacting domain 
death agonist, BIRC3, CASP8*/caspase 8, CFLAR, CYCS/cytochrome c, somatic, FADD/Fas-
associated via death domain, FAS*/Fas cell surface death receptor, IL1B/interleukin 1 beta, 
IL1R1*/interleukin 1 receptor type 1, NFKB1/nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1, PIK3CA*, PIK3CD/phosphatidylinositol-4,5-biphosphate 3-kinase 
catalytic subunit delta, PIK3CG/ phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit 
gamma, PPP3CA, PRKAR1A/protein kinase c-AMP-dependent type 1 regulatory subunit alpha, 
TNFRSF10B*/tumor necrosis factor receptor superfamily member 10b, TNFRSF1A*, 
TNFSF10*, TP53*).  
* Indicates gene/protein found in list of known breast cancer biomarkers Table 4
The actual up-regulation or down-regulation of the genes is not of great importance for 
this exercise. The z-score measure and J5 scores produce both positive and negative values, 
whereas the ratio only produces positive values.  As such, the sign of the input value will depend 
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on the two values being multiplied together, and so careful interpretation will be required of the 
researcher. The major point of emphasis here is the enriched input dataset, which produces more-
relevant results, in the output pathways, when data and prior knowledge are combined.  
 
 
Table 13. Impact factors from breast cancer datasets. D = data only; R = ratio only; Z = z-
score only; DR = data & ratio; DZ = data & z-score. Red highlights cases where the impact 
factor decreased from left (R/Z only) to right (DR/DZ). Green highlights cases where the impact 
factor increased by a factor of three or greater. BCCNCvN = breast cancer copy number case vs. 
control; BCMA1v2 = breast cancer microarray grade 1 vs. grade 2; BCMA1v3 = breast cancer 
microarray grade 1 vs. grade 3; BCMA2v3 = breast cancer microarray grade 2 vs. grade 3; 
BCMA Blood = breast cancer microarray blood healthy vs. cancer; BCMAER = breast cancer 
microarray ESR1 status positive vs. negative; BCMAMeno = breast cancer microarray 




The impact factor calculation relies on the number of differentially regulated genes in the 
pathway and perturbation factors of all genes in the pathway. Similarly to section 4.3.1.1 results, 
for most pathways examined, a steady progression exists from left to right with D genelists 
producing the smallest impact factor; the R/Z genelists producing larger impact factors than D; 
and DR/DZ combined genelists producing the largest impact factors, in general. Some 
exceptions do exist however, as can be seen in Table 13. Red highlights indicate where the 
impact factor was greater for the ratio/z-score only input genelists than it was for the combined 
DR/DZ input genelists.  
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Table 14. P-values from breast cancer datasets. D = data only; R = ratio only; Z = z-score 
only; DR = data & ratio; DZ = data & z-score. Green highlights cases where the p-values went 
from non-significant to significant in going from left (R/Z only) to right (DR/DZ). BCCNCvN = 
breast cancer copy number case vs. control; BCMA1v2 = breast cancer microarray grade 1 vs. 
grade 2; BCMA1v3 = breast cancer microarray grade 1 vs. grade 3; BCMA2v3 = breast cancer 
microarray grade 2 vs. grade 3; BCMA Blood = breast cancer microarray blood healthy vs. 
cancer; BCMAER = breast cancer microarray ESR1 status positive vs. negative; BCMAMeno = 




The p-value calculation identifies pathways that contain a proportion of differentially 
expressed genes that are significantly different from what is expected at random. A significance 
threshold of ≤ 0.05 is applied. Again, similarly to sections 4.3.1.1 and 4.3.1.2 results, for most 
pathways examined, a steady progression exists from left to right with D genelists producing the 
least significant pathway p-values; the R/Z genelists producing more significant pathway p-
values than D; and DR/DZ combined genelists producing the most significant pathway p-values, 
in general. In Table 14, green highlights cases where pathway p-values for R/Z produced 
genelists could be considered non-significant, but pathway p-values for the DR/DZ produced 





4.3.3 Lung cancer datasets  
Five previously described lung cancer datasets were analyzed: 1) microarray case vs. control 
(LCMACvC); 2) microarray smoking never vs. former (LCMANvF); 3) microarray smoking 
former vs. current (LCMAFvC); 4) microarray smoking never vs. current (LCMANvC); 5) 
microarray morphology small cell carcinoma vs. adenocarcinoma (LCMAMorph).  
 Analysis results underwent post-analysis processing by one of five different methods: 
data-only (D; 1660 most differentially expressed J5 scores); ratio (R; 1660 genes from literature 
mining); z-scores (Z; 1660 genes from literature mining); the product of data & ratio (DR; 
highest scoring 1660 genes when J5 score multiplied by literature mining ratio); and the product 
of data & z-scores (DZ; highest scoring 1660 genes when J5 score multiplied by literature 
mining z-score). Post-analysis processed values accompanied the gene ID’s in the genelists from 
the lung cancer microarray case vs. control dataset and were input into Pathway Express.  
 
 All 23 relevant lung cancer pathways were assessed for each post-processing method. 
The PPAR/peroxisome proliferator activated receptor alpha Signaling Pathways produced from 
lung cancer microarray case vs. control datasets will be used as an in-depth example. The PPAR 
Signaling Pathway was chosen because 1) a steady increase in the number of input genes in the 
pathway is shown, from D (n=6) to R/Z (n=10) to DR/DZ (n=13); 2) the impact factor (if) 
doubled, from D (if=1.27), R (if=2.21), and Z (if=2.27) to DR (if=4.59) and DZ (if=4.62); and 3) 
the p-values changed from non-significant, D (p=0.741) and R/Z (p=0.187), to significant values 




Assessment of pathway measures  
Table 15 shows the number of input genes found in a given pathway using a given genelist. In 
general, a steady progression exists from left to right with D genelists providing the least amount 
of input genes in the returned pathways; the R/Z genelists producing more input genes in the 




Table 15. Number of input genes in pathway from lung cancer datasets. D = data only; R = 
ratio only; Z = z-score only; DR = data & ratio; DZ = data & z-score. Red highlights cases where 
the number of input genes in the pathway decreased from left (R/Z only) to right (DR/DZ). 
LCMACvC = lung cancer microarray case vs. control; LCMANvF = lung cancer microarray 
smoking never vs. former; LCMAFvC = lung cancer microarray smoking former vs. current; 
LCMANvC = lung cancer microarray smoking never vs. current; LCMAMorph = lung cancer 







Figure 23. KEGG PPAR Signaling Pathway diagrams and input gene tables created using 
lung cancer microarray case vs. control. A = data-only (D); B = z-score only (Z); C = data & 
z-score (DZ). Input genes highlighted red = upregulated and blue = downregulated. PF = 





The KEGG PPAR Signaling Pathway diagram contains 70 total genes. As can be seen in 
Figure 23 when the data only (D) genelist is submitted (Figure 23, A), six input genes appear in 
the output PPAR Signaling Pathway (ACSL1/acyl-CoA synthetase long-chain family member 1, 
ACSL4/acyl-CoA synthetase long-chain family member 4, ACSL5/acyl-CoA synthetase long-
chain family member 5, CD36, GK/glycerol kinase, ILK/integrin-linked kinase). When the 
literature mining z-score (Z) genelist is used as input (Figure 23, B), ten input genes appear in 
the output PPAR Signaling Pathway (ACSL5, ANGPTL4/angiopoietin-like 4, AQP7/aquaporin 
7, DBI/diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein), 
FABP2/fatty acid binding protein 2, ME1/malic enzyme 1, NADP(+)-dependent, cytosolic, 
MMP1*/matrix metallopeptidase 1, PDPK1/3-phosphoinositide-dependent protein kinase 1, 
PPARA/peroxisome proliferator-activated receptor alpha, and UBC/ubiquitin C). Finally, when 
the combined DZ genelist is used as input (Figure 23, C), 13 input genes appear in the output 
PPAR Signaling Pathway (ACSL5, ADIPOQ*/adiponectin, C1Q and collagen domain-
containing, ANGPTL4, AQP7, CD36, DBI, FABP2, ME1, MMP1*, PDPK1, PPARA, 
SORBS1/sorbin and SH3 domain containing 1, UBC). 
* Indicates gene/protein found in list of known lung cancer biomarkers Table 5
Again, the up-regulation or down-regulation of the genes is not of great importance for 
this exercise. The major point of emphasis here is the enriched input dataset, which produces 
more-relevant results, in the output pathways, when data and prior knowledge are combined.  
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Table 16. Impact factors from lung cancer datasets. D = data only; R = ratio only; Z = z-score 
only; DR = data & ratio; DZ = data & z-score. Green highlights cases where the impact factor 
increased by a factor of two or greater. LCMACvC = lung cancer microarray case vs. control; 
LCMANvF = lung cancer microarray smoking never vs. former; LCMAFvC = lung cancer 
microarray smoking former vs. current; LCMANvC = lung cancer microarray smoking never vs. 




Similar to section 4.3.2.1 results, for most pathways examined, a steady progression 
exists from left to right with D genelists producing the smallest impact factor; the R/Z genelists 
producing larger impact factors than D; and DR/DZ combined genelists producing the largest 
impact factors, in general. In Table 16, green highlights indicate where the impact factor was 









Table 17. P-values from lung cancer datasets. D = data only; R = ratio only; Z = z-score only; 
DR = data & ratio; DZ = data & z-score. Green highlights cases where the p-values went from 
non-significant to significant in going from left (R/Z only) to right (DR/DZ). LCMACvC = lung 
cancer microarray case vs. control; LCMANvF = lung cancer microarray smoking never vs. 
former; LCMAFvC = lung cancer microarray smoking former vs. current; LCMANvC = lung 
cancer microarray smoking never vs. current; LCMAMorph = lung cancer microarray 
morphology small cell carcinoma vs. adenocarcinoma. 
 
 
Similarly to sections 4.3.2.1 and 4.3.2.2 results, for most pathways examined, a steady 
progression exists from left to right with D genelists producing the least significant pathway p-
values; the R/Z genelists producing more significant pathway p-values than D; and DR/DZ 
combined genelists producing the most significant pathway p-values, in general. In Table 17, 
green highlights cases where pathway p-values for R/Z produced genelists could be considered 
non-significant, but pathway p-values for the DR/DZ produced genelists could be considered 
significant.  
 
The idea that incorporation of prior information enhances pathway analysis results 
(Claim 2, part C), is not without merit. It is shown above that with few exceptions, consistent 
patterns emerge in quality metrics when analyzing the results. An increase in the number of input 
genes and impact factor, with a corresponding decrease in p-values, is relatively consistent when 
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comparing pathway results from data-alone, ratio/z-scores, and data + (ratio/z-score), 
respectively. 
Using the combined method of prior knowledge and experimental data array results 
returned more genes compared to either method individually. This may be beneficial to 
researchers as genes of interest may be missed using only experimental results or only literature 
mining results.   
The following factors support the idea that (Claim 2, part C; experimentation 4.3.1 - 
4.3.2) incorporation of prior information enhances pathway analysis by identifying more input 
genes in disease-relevant pathways: 1) in almost all of the breast and lung cancer datasets 
examined, the number of input genes in pathways increased with the incorporation of prior 
information (experimentation 4.3.1.1 & 4.3.2.1); 2) the impact factors increased with the 
incorporation of prior information (experimentation 4.3.1.2 & 4.3.2.2) ; and 3) the p-values 
decreased (became more significant) with the incorporation of prior information 
(experimentation 4.3.1.3 & 4.3.2.3). 
 
4.4 SUMMARY 
The first claim in this dissertation is to determine whether literature mining is a sufficient method 
of obtaining prior information for use in modeling and pathway analysis. The arguments that 
support this claim can be found in sections 4.1.2 – 4.1 5. 
 The second claim is to investigate whether incorporating prior knowledge into modeling 
and pathway analysis enhances results compared to using experimental data only. The arguments 
that support this claim can be found in the following sections: 
a) Incorporation of prior information does not degrade modeling performance, on 
average. Section 4.2.1 – 4.2.4 strongly supported this claim. 
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b) Analyzing the attributes used to build the best-performing models leads to new 
biological relationships being uncovered. Section 4.2.5 strongly supports this claim. 
c) Incorporation of prior information enhances pathway analysis results by identifying 
more input genes in disease-relevant pathways. Sections 4.3.1.1 and 4.3.2.1 strongly 
support this claim as there is robust evidence for pathway involvement in the disease 
of interest based on statistically significant standard measures such as impact factors 













5.0 CONCLUSIONS, LIMITATIONS AND FUTURE WORK 
The sections below discuss the conclusions, limitations, and future work of this dissertation. The 
benefits of using the KEDA framework are presented in section 5.1. Limitations and assumptions 
as they pertain to this dissertation are identified in section 5.2. Lastly, directions for future work 
in KEDA-related areas are addressed in section 5.3.  
5.1 CONCLUSIONS 
The age of personalized medicine is upon us. The field of pharmacogenomics is ready to explode 
by predicting via DNA analysis, individual patients that will benefit from given medications, and 
which will not. Moreover, biomarkers of all types are needed for disease prediction, diagnosis, 
and treatment. New methods for obtaining disease biomarkers are desperately needed as current 
approaches are very time-consuming, and are not producing enough reliable biomarkers at a 
sufficient rate.  
Literature mining can aid in the search for new biomarkers as it has been shown to be an 
appropriate method of obtaining prior scientific knowledge. In this work, the KEDA framework, 
which utilizes a semi-automated literature mining method to examine PubMed abstracts and establish a 
list of putative biomarkers for breast and lung cancer, is described. Biological entity mentions in the 
abstracts were tallied and used to calculate scores for use as prior knowledge. Counts were used 
to determine biomarker specificity for a biofluid, rank the biomarkers by score, and to establish 
an error rate to predict the accuracy of novel future discoveries. 
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Disease modeling can also aid in the search for new biomarkers by emulating biological 
systems. The literature mining counts were converted to prior probabilities, and incorporated into 
publicly available lung and breast cancer datasets in modeling exercises. While neither improvement nor 
degradation of modeling performance measures was observed in models incorporating prior information, 
examining the attributes of the best-performing models uncovered a new potential interaction.  
 Pathway analysis can also aid in the search for new biomarkers by presenting 
researchers with maps of biological processes. Literature mining prior probabilities were 
combined with experimental data and incorporated into pathway analysis. The combination of 
prior information and data analysis results produced far superior increases in performance 
measures such as impact factor and p-value, when compared to data analysis results and/or prior 
information alone. This is a significant finding as the use of pathway analysis results as prior 
knowledge is well-documented, however documentation of the use of prior knowledge as input 
into pathway analysis had not been found.   
 This dissertation has provided a significant contribution to the scientific and 
bioinformatics community. The KEDA literature mining results presented in this work can be 
used by breast and lung cancer researchers as a valuable source of information. The KEDA 
computational tools can be extrapolated to obtain prior knowledge for any disease, provided the 
appropriate keyword are used in the initial search. Examining the attributes used to build the 
best-performing models provides a different approach to biomarker discovery, and incorporating 







The results presented in this dissertation show that the KEDA framework is a useful approach for 
biomarker discovery. That being said, the conclusions must be drawn carefully based on the 
following limitations of the study: 
a) Aliases of biological entities continue to complicate literature-mining findings. For 
example, ceacam5 and ceacam8 were both identified with the CEA alias. Even the 
most up to date dictionary may still not contain every alias used by the scientific 
community for a given entity. 
b) Negation was not addressed in this work. Some biomarker mentions in positive 
abstract sets may actually be in a negative context.  
c) A biomarker associated with any other disease (even another type of cancer or a non-
specific cancer marker) might negate a positive finding for breast or lung cancer due 
to the scoring method used.  
d) Verification databases may be far from exhaustive. This could be a reason why the 
list of known/significant biomarkers is not as large as expected.  Also, in limiting our 
search to ‘breast or lung cancer specific’ markers, many biomarkers common to 
several or all types of cancers may have accidentally been omitted from the study.  
e) Due to lack of access to full text articles, only abstracts were examined. Access to full 
text of scientific articles remains a limiting factor for many researchers.   
f) The BRL algorithm works optimally when discretization is employed. However, 
discretization was not implemented into the described modeling process as much 
information would be lost trying to convert experimental and prior knowledge values 
into discrete ones.  
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g) Only one algorithm was used for each KEDA process. Algorithms used were chosen 
for ease-of-use or familiarity. Other available algorithms may exist which may 
improve results.   
h)  For modeling, the initial analysis only examined results from one dataset. Therefore, 
the modeling results presented cannot be generalized further. 
 
 
5.3 FUTURE WORK 
The work described in this dissertation exposes several different avenues to biomarker discovery. 
The following suggestions could be pursued for future research:   
 
5.3.1 Informatics 
Informatic resources and tools to be utilized for future research are discussed in the following 
sections. 
 
5.3.1.1     Resources     A database of disease/biofluid-associated ratios/z-scores  
For others to benefit from the work presented above, the information must be readily accessible. 
Online access to a database containing tables of putative disease biomarkers obtained using the 
KEDA framework would be extremely beneficial to other researchers. This database could serve 
as a valuable resource for scientists performing modeling or pathway analysis where prior 
information may be warranted; or as a starting point of genes/proteins that may be implicated in 
a given disease. 
Verification databases  
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The databases of known cancer biomarkers used in this dissertation may be far from exhaustive, 
as well as too specific. Constant updating of the list of known biomarkers may improves KEDA 
results. These updated lists should be posted for others to use to avoid repetitive efforts.  
 
5.3.1.2     Tools     Literature mining, modeling, and pathway analysis tools and notions are 
presented in the following sections.  
  
5.3.1.2.1     Literature mining     Further automation of the semi-automated process  
While the process performs well currently, improvements where manual intervention is currently 
required would speed up the process and reduce the chance for manual errors. Further 
automation could be added in searching for and downloading of relevant abstracts, parsing the 
abstract file to create an individual file per abstract, and calculating z-scores and ratios from final 
tallies. Ideally, one should be able to run PittCAP, enter the keywords from its execution 
window, and the algorithm should automatically perform all duties and return the list of putative 
disease markers with their z-scores and ratios.   
 
Negation 
Negation was not addressed in this work. An assumption was made that in the short amount of 
space allotted for an abstract text, writers would not write about negative findings. However that 
may not necessarily be the case and thus some of the biomarker mentions in positive abstract sets 
may actually be in a negative context. This is a well-known issue in the literature mining field, 
and is not easily fixed. Time and effort will need to be invested to tend to these issues. Adapting 
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the literature mining component to account for negation will produce more accurate prior 
estimates. 
 
Applying the KEDA framework to other datasets and diseases  
The KEDA framework can be adapted to obtain and process abstracts for any disease. Many 
diseases exist where prior information from literature mining may be useful for disease modeling 
and pathway analysis.   
 
Adapting the KEDA framework to use other resources 
While one implementation of the KEDA framework was described above, KEDA can be can be 
adapted as many other implementation possibilities exist. Alternatives can be implemented for 
the abstract resource in place of PubMed; the tagger in place of Abner; the data source in place 
of Gene Expression Omnibus; the classification modeling algorithm in place of the Bayesian 
Rule Learner; and the pathway analysis algorithm in place of Pathway Express.     
 
5.3.1.2.2     Modeling      Follow-up with BRL 
While a good deal of time and effort was invested in disease modeling using BRL, the results 
were less than expected. Classification accuracy was expected show at-least minimal 
improvement in accuracy and other quality measures. However, that was not observed in this 
work, or in several other in-house efforts which utilized structure priors. Further investigation is 





Determine how use of priors alters the search order 
The fact that the SOD2-CCL5 relationship was observed in models utilizing informed priors and uniform 
priors but not found when no prior was used speaks to the fact that the use of priors changes the order of 
the search. This is an interesting occurrence that should be investigated further. 
 
5.3.1.2.3 Pathway analysis     Pathway analysis from modeling results    
It would be interesting to perform pathway analyses based on modeling results. In this situation, 
the input file for Pathway Express could be limited to the attributes found from the best-
performing models. Another interesting concept would be to search for modeling attributes 
common to more than one pathway.         
 
5.3.2 Laboratory verification      
Confirmatory laboratory experimentation and further research  
Informatics can only take the biomarker discovery so far. Eventually, in order to verify potential 
findings, actual wet-lab experimentation will need to be performed. For example, 
experimentation seeking to identify a direct relationship between SOD2 and CCL5 is now 
warranted. Follow-up experimentation of pathway analysis findings may also prove beneficial.  
 
SOD2/CCL5 follow-up research 
It appears a possibility that a relationship may exist between SOD2 and CCL5 in lung cancer. 
While a documented direct relationship was not identified, several facts seem to support the 
theory due to SOD2 being an oxidative agent which aids in ridding the body of toxins, and CCL5 
being a chemokine involved in the immunoregulatory and inflammatory processes.   
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Shah et al. (2011) studied the SOD/CCL5 relationship in the chronic inflammatory 
autoimmune disorders, systemic lupus and arthritis. In both diseases, SOD’s anti-oxidant activity 
was significantly reduced, and antioxidant molecules showed a negative association with CCL5. 
It was concluded that excessive production of ROS disturbs redox status and can modulate the 
expression of inflammatory chemokines leading to inflammatory processes, and affecting tissue 
damage in autoimmune diseases. 
Kumar et al. (2012) studied the microRNA miR-302 and how it regulates transition 
between cellular quiescence and proliferation. SOD2, is an antioxidant enzyme well-known to 
regulate cellular reactive oxygen species levels by converting superoxide into hydrogen 
peroxide. Overexpression of SOD2 is believed to increase H2O2 levels which may lead to ROS-
sensitive regulation of CCL5 mRNA levels. SOD2 expression increases in quiescence, and it is 
suggested that SOD2-signaling activates CCL5 expression.  Moreover, miR-302 levels decreased 
significantly by overexpression of SOD2, as well as from ionizing radiation, increasing the 
CCL5 mRNA levels.  
Kim et al. (2014) also examined miR-302’s regulation of cell proliferation and cell-cycle 
progression in adipose tissue-derived mesenchymal stem cells. They found that miR-302 induces 
cell proliferation and inhibits oxidant-induced cell death through a reduction in CCL5 
expression.  
 DiRenzo et al. (2014) also discussed SOD2 and CCL5. They discussed that 
antioxidants reduced CCL5 mRNA expression, and mentioned the Human Oxidative Stress 
Pathway. The SOD2 gene related to antioxidant defense antioxidants effectively suppressed 
CCL5 mRNA expression. While more experimental evidence is required for confirmation, the 





PYTHON SCRIPTS FOR KEDA TEXT-MINING COMPONENT 
PYTHON SCRIPT ‘RANDABSTRACTMAKERV2.0’ CODE 
 





#********************** Function definition ***************************** 
#************************** Main Program ******************************** 
def main(): 
    print "Rand-Neg Abstract Maker1.0" 
    print "The DirList should contain a list of abstract files to be used" 
    print 
 
    NewAbFile = [] 
 
    # Read in abstract file 
    AbFile = raw_input("Enter the abstract file: (.txt)") 
    outfileB = open("List.txt", 'w') 
    print AbFile 
    print "Working..." 
    infile = open(AbFile, 'r') 
    things = 0 
    SepAb = [] 
    for line in infile: 
        line = string.split(line) 
        NewAbFile.append(line)       # append lines to new abstract file 
    infile.close() 
 
    # Create new abstract files 
    NewAbOut = [] 
    for line in NewAbFile: 
        key = line[0:1] 
        key = str(key) 
        ID = line[1:2] 
        ID = str(ID) 
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        NewAbOut.append(line) 
        if key == "['PMID:']": 
            name = (ID + ".txt") 
            outfile = open(name, 'w') 
            for line in NewAbOut: 
                outfile.write(str(line)) 
                outfile.close 
                NewAbOut = [] 
            outfileB.write(str(name)+'\n') 
 
    outfileB.close 











#********************** Function definition ***************************** 
#************************** Main Program ******************************** 
def main(): 
    print "CancerAbstractPicker" 
    print "The DirList should contain a list of abstract files to be used" 
    print 
 
    DIRList = [] 
 
    # Read in list of abstracts 
    AbDirFile = raw_input("Enter the list of abstracts: (.txt)") 
    Dict = raw_input("Enter the dictionary filename: (.txt)") 
    print AbDirFile 
    infile = open(AbDirFile, 'r') 
    things = 0 
    for line in infile: 
        line = string.split(line) 
        DIRList.append(line)       # list each abstract file 
        things = things + 1 
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    infile.close() 
 
    # Confirm number of abstract files 
    print ("There is(are) ", things, " abstracts in the file(s).") 
 
    # Open individual abstract files 
    j = 0 
    outfile = open('PickerResults.txt', 'w') 
    keep = [] 
    for report in DIRList: 
        A = [] 
        report = str(report) 
        report = report.rstrip("\n") 
        report = report.strip("[]") 
        report = report.strip("'") 
        report = report.strip('""') 
        A = open(report, 'r') 
        print report 
 
        # Parse the file 
        flag = 0 
        for line in A: 
             line = str(line) 
             line = string.split(line) 
             ID = "PMID:"+ report[2:-11] 
             for item in line: 
                if item == '<PROTEIN>': 
                    flag = 1 
                if item == '<CELL_LINE>': 
                    flag = 1 
                if item == '<CELL_TYPE>': 
                    flag = 1 
                if item == '<DNA>': 
                    flag = 1 
                if item == '<RNA>': 
                    flag = 1 
                if item == '</PROTEIN>': 
                    keep.append('\t') 
                    keep.append(ID) 
                    keep.append('\n') 
                    flag = 0 
                if item == '</CELL_LINE>': 
                    keep.append('\t') 
                    keep.append(ID) 
                    keep.append('\n') 
                    flag = 0 
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                if item == '</CELL_TYPE>': 
                    keep.append('\t') 
                    keep.append(ID) 
                    keep.append('\n') 
                    flag = 0 
                if item == '</DNA>': 
                    keep.append('\t') 
                    keep.append(ID) 
                    keep.append('\n') 
                    flag = 0 
                if item == '</RNA>': 
                    keep.append('\t') 
                    keep.append(ID) 
                    keep.append('\n') 
                    flag = 0 
                if flag == 1: 
                    keep.append(str(item)+' ') 
        j = j + 1 
    for line in keep: 
        outfile.write(str(line)) 
    outfile.close() 




    print "CleanerUpper" 
    print 
 
    # Read in list of abstracts 
    infile = open('PickerResults.txt', 'r') 
 
    # Clean up tags 
    firstlist = [] 
    comblist = [] 
    for line in infile: 
        line = str(line) 
        line = string.split(line) 
        if line[0] == "<PROTEIN>": 
            newline = str(line[1:])+'\n' 
            firstlist.append(newline) 
        if line[0] == "<DNA>": 
            newline = str(line[1:])+'\n' 
            firstlist.append(newline) 
        if line[0] == "<RNA>": 
            newline = str(line[1:])+'\n' 
            firstlist.append(newline) 
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        if line[0] == "<CELL_LINE>": 
            newline = str(line[1:])+'\n' 
            firstlist.append(newline) 
        if line[0] == "<CELL_TYPE>": 
            newline = str(line[1:])+'\n' 
            firstlist.append(newline) 
 
    # Remove extra characters 
    for line in firstlist: 
        line = str(line) 
        lineindex = line.index('\n') 
        n = 0 
        newstring = "" 
        while n <= lineindex: 
            if line[n]=="[": 
                n=n+1 
            elif line[n]=="'": 
                n=n+1 
            elif line[n]==",": 
                n=n+1 
            elif line[n]=="]": 
                n=n+1 
            elif line[n]=='"': 
                n=n+1 
            else: 
                newstring = newstring + line[n] 
                n = n+1 
        comblist.append(newstring) 
 
    #Remove dups 
    biodict = [] 
    for item in comblist: 
        item = str(item) 
        item = string.split(item) 
        A = item 
        A = str(A) 
        A = A.lower() 
        newA = '' 
        if A in biodict: 
            continue 
        else: 
            newA = str(A) 
        biodict.append(newA) 
 
    #Write to outfile 
    biodict.sort() 
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    outfile = open('CleanerResults.txt', 'w') 
    for line in biodict: 
        line = str(line) 
        lineindex = line.index(']') 
        n = 0 
        newstring = "" 
        while n <= lineindex: 
            if line[n]=="[": 
                n=n+1 
            elif line[n]=="'": 
                n=n+1 
            elif line[n]==",": 
                n=n+1 
            elif line[n]=="]": 
                n=n+1 
            elif line[n]=='"': 
                n=n+1 
            else: 
                newstring = newstring + line[n] 
                n = n+1 
        outfile.write(str(newstring)) 
        outfile.write('\n') 
    outfile.close() 
    print "Cleaner done." 
 
# Dictionary Checker 
 
    print "Dictionary Checker" 
    print "The dictionary list should have the gene/protein abbreviation in the first column, and 
aliases to the right - tab delimited" 
    print "The input file should have one putative biomarker per line" 
    print 
 
    Dictionary = [] 
    Biomarkerlist = [] 
 
    # Read in dictionary 
    dictfile = open(Dict, 'r') 
    for line in dictfile: 
        Dictionary.append(line)       # list each line 
    dictfile.close() 
 
    # Read in dictionary 
    biofile = open('CleanerResults.txt', 'r') 
    for line in biofile: 
        Biomarkerlist.append(line)       # list each line 
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    biofile.close() 
 
    # Match lists 
    Keeplist = [] 
    for item in Biomarkerlist: 
        item = str(item) 
        item = item.split('\t') 
        for entity in item: 
            locate = entity.index('pmid') 
            entity = entity[0:(locate-1)] 
            for line in Dictionary: 
                line = str(line) 
                line = line.lower() 
                line = line.split('\t') 
                if entity in line: 
                    Keeplist.append(line[0]) 
 
    # Tally up counts 
    Finallist = [] 
    Keeplist.sort() 
    oldcount = 1 
    oldthing = '' 
    for thing in Keeplist: 
        a = Keeplist.count(thing) 
        if thing == oldthing: 
            continue 
        else: 
            oldthing = thing 
            oldcount = a 
            b = oldthing + '\t' + str(oldcount) 
        Finallist.append(b) 
 
    # Print output 
    outfile = open('DictionaryCheckerResult.txt', 'w') 
    outfile.write("PUTATIVE BIOMARKERS") 
    outfile.write('\n') 
    for item in Finallist: 
        item = str(item) 
        outfile.write(str(item)) 
        outfile.write('\n') 
    outfile.close() 






INPUT DATASET DESCRIPTIONS FROM GEO 
Breast Cancer – Copy Number 
Series GSE27574    
Status  Public on Nov 19, 2012 
Title  High-resolution analysis of copy number changes in circulating and disseminated tumor 
cells in breast cancer patients 
Organism  Homo sapiens 
Experiment type  Genome variation profiling by array 
Summary  The aim of this study was to establish a single-cell array comparative genomic 
hybridization (SCaCGH) method providing in-depth genomic analysis of circulating tumor cells 
(CTCs) and disseminated tumor cells (DTCs). The robustness and resolution limits of the method 
were estimated with different cell amounts of the breast cancer cell line SKBR3 using 44k and 
244k arrays. Subsequent adjustments of the method were conducted analyzing the copy number 
profiles of 28 CTCs in combination with four hematopoietic cell (HC) controls from eight 
metastatic patients and of 24 DTCs, three probable HCs, and five HC controls from seven breast 
cancer patients and one healthy donor. The frequency of the major genomic gains and losses of 
the analyzed DTC revealed similarities to primary breast tumor samples with some evident 
differences. Three of the patients had available profiles for DTC and the corresponding primary 
tumor. In 2/3 of the examined DTCs, equivalent genomic changes and common aberration 
breakpoints were disclosed, both to each other and to the corresponding primary tumors. 
Interestingly, similar copy number changes were found in DTCs taken at time of diagnosis or in 
DTCs collected at 3-years relapse-free follow up. Residual immunomorphological characterized 
tumor cells showed balanced profiles with only minor aberrations. Three cells with unclear 
morphological identification showed either balanced profiles (n=2) or aberrations comparable to 
the primary tumor and DTC (n=1). SCaCGH may be a powerful tool for molecular 
characterization of immunostained and morphological identified CTCs and DTCs to explore the 
malignant potential, therapeutic targets and tumor heterogeneity of single tumor cells. 
Overall design  24 DTCs, 3 probable HCs, and 5 HCs from 7 early-stage breast cancer 
patients, 28 CTCs and 4 HCs from 8 metastatic breast cancer patients, and 1 healthy donor were 
analyzed. Comparison with the primary tumor was done in 3 patients. The reference for the 
patients was DNA from multiple anonymous female donors. This submission does not include 
the SKBR3 data obtained from the 44k array. 
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Contributor(s)  Baumbusch LO, Naume B, Speicher MR, Pantel K, Børresen-Dale A, 
Lingjærde OC, Mauermann O, Obenauf AC, Schneider IJ, Rye IH, Borgen E, Liestøl K, 
Riethdorf S, Geigl JB, Due EU, Fjelldal R, Mathiesen RR 
Citation(s)  Mathiesen RR, Fjelldal R, Liestøl K, Due EU et al. High-resolution analyses of 
copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer 
2012 Aug 15;131(4):E405-15. PMID: 21935921 
Submission date  Feb 28, 2011 
Last update date  Nov 14, 2014 
Contact name  Randi Mathiesen 
E-mail  randi.mathiesen@rr-research.no 
Phone  +4745290525 
Organization name  Institute for cancer research Oslo University Hospital Radiumhospitalet 
Department  Dept. of genetics 
Street address  Montebello 
City  Oslo 
ZIP/Postal code  0310 
Country  Norway 
Platforms (2)   
GPL8841  Agilent-014950 Human Genome CGH Microarray 4x44K (Probe Name version) 
GPL9128  Agilent-014693 Human Genome CGH Microarray 244A (Probe name version) 
Samples (79) 
Relations BioProject  PRJNA181273 
 
Breast Cancer – Microarray 
Series GSE16443   
Status  Public on Jan 15, 2010 
Title  Gene expression profiling of peripheral blood cells for early detection of breast cancer 
Organism  Homo sapiens 
Experiment type  Expression profiling by array 
Summary  Purpose: Early detection of breast cancer is key to successful treatment and 
patient survival. We have previously reported the potential use of gene expression profiling of 
peripheral blood cells for early detection of breast cancer. The aim of the present study was to 
validate these findings using a larger sample size and a commercially available microarray 
platform. 
Overall design  Experimental Design: Blood samples were collected from 121 females 
referred for diagnostic mammography following an initial suspicious screening mammogram. 
Diagnostic work-up revealed that 67 of these women had breast cancer while 54 had no 
malignant disease. Additionally, 9 samples from 6 healthy female controls (three pregnant 
women, one breast-feeding woman and two healthy controls at different time points in their 
menstrual cycle) were included. Gene expression analyses were conducted using high-density 
oligonucleotide microarrays. Partial Least Square Regression was used for model building and 
predictors were identified using a Jackknifing approach. Prediction performance was determined 
by a 20-fold double cross validation approach 
Contributor(s)  Aarøe J, Lindahl T, Dumeaux V, Sæbø S, Hagen N, Tobin D, Skaane P, 
Lönneborg A, Sharma P, Børresen-Dale A 
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Citation(s)  Aarøe J, Lindahl T, Dumeaux V, Saebø S et al. Gene expression profiling of 
peripheral blood cells for early detection of breast cancer. Breast Cancer Res 2010;12(1):R7. 
PMID: 20078854 
Submission date  Jun 04, 2009 
Last update date  Nov 12, 2012 
Contact name  Jørgen Mømb Aarøe 
E-mail  jorgen.aaroe@rr-research.no 
Phone  +4791774653 
Fax  +4722934440 
Organization name  The Norwegian Radium Hospital 
Department  Genetics 
Lab  Genetics 
Street address  Montebello 
City  Oslo 
ZIP/Postal code  N-0310 
Country  Norway 
    
Platforms (1)   
GPL2986  ABI Human Genome Survey Microarray Version 2 
Samples (130) 
Relations BioProject  PRJNA116345 
 
Breast Cancer – Methylation 
Series GSE20713    
Status  Public on Oct 19, 2011 
Title  Epigenetic portraits of human breast cancers 
Organism  Homo sapiens 
Experiment type  Expression profiling by array; Methylation profiling by array 
Summary  This SuperSeries is composed of the SubSeries listed below. 
Overall design  Refer to individual Series 
Citation(s)  Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK et al. DNA methylation 
profiling reveals a predominant immune component in breast cancers. EMBO Mol Med 2011 
Dec;3(12):726-41. PMID: 21910250 
Submission date  Mar 09, 2010 
Last update date  Jun 02, 2015 
Contact name  Benjamin Haibe-Kains 
E-mail  benjamin.haibe.kains@utoronto.ca 
Phone  +14165818626 
Organization name  Princess Margaret Cancer Centre 
Department  Princess Margaret Research 
Lab  Bioinformatics and Computational Genomics 
Street address  610 University Avenue 
City  Toronto 
State/province  Ontario 
ZIP/Postal code  M5G 2M9 
Country  Canada 
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Platforms (2)  
GPL570  [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array 
GPL8490  Illumina HumanMethylation27 BeadChip (HumanMethylation27_270596_v.1.2) 
Samples (381) 
Relations BioProject  PRJNA124907 
 
Breast Cancer – RT-PCR 
Series GSE46068    
Status  Public on Jan 09, 2014 
Title  Molecular characterization of tumor cells from the cerebrospinal fluid and matched 
primary tumors from metastatic breast cancer patients with leptomeningeal disease 
Organism  Homo sapiens 
Experiment type  Genome variation profiling by genome tiling array; Expression profiling 
by RT-PCR 
Summary  We purified tumor cells in the CSF (“CSFTC”) from 15 metastatic breast cancer 
patients diagnosed with leptomeningeal disease using a two-step method involving 
immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS). Magnetic beads 
coated with mAb to the epithelial cell adhesion marker (EPCAM) were used to enrich for tumor 
cells and were further purified by FACS analysis. 
For DNA profiling, isolated CSFTC were subjected to molecular characterization through 
genome-wide copy number analyses. Genomic analyses were then compared with those 
performed on the corresponding archival primary tumors. 
For RNA profiling, isolated CSFTC were then subjected to molecular characterization through 
gene expression profiling via QPCR analysis of 64 cancer-related genes 
Overall design  CGH: 17 CSFTC samples from 13 patients were successfully profiled, 1 
patient had 5 time points, 6 of 13 patients had matched to copy number data archival tumors 
RNA: 18 samples from 5 patients had successful gene expression data of the 64 genes measured 
in triplicates. For non-tumor controls, 9 of the samples had matching gene expression data from 
sorted leuckocytes (+CD45 cells) obtained from the same draw. 
 Contributor(s)  Magbanua MJ, Scott JH, Hauranieh L, Melisko M, Sosa EV, Kablanian A, 
Roy R, Park JW 
Citation(s)  Magbanua MJ, Melisko M, Roy R, Sosa EV et al. Molecular profiling of tumor 
cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients 
with leptomeningeal carcinomatosis. Cancer Res 2013 Dec 1;73(23):7134-43. PMID: 24142343 
Submission date  Apr 15, 2013 
Last update date  Jan 09, 2014 
Contact name  Mark Magbanua 
Organization name  UCSF/Helen Diller Family Comprehensive Cancer Center 
Department  HemOnc 
Lab  Park 
Street address  1450 3rd Street, PO Box 589001 
City  San Francisco 
State/province  CA 
ZIP/Postal code  94158-9001 
Country  USA 
Platforms (2)   
 162 
GPL6359  UCSF Cancer Center HumArray3.2 
GPL17020  Custom Human TLDA 64-Circulating tumor cell associated gene panel 
Samples (57) 
Relations BioProject  PRJNA197197 
 
Breast Cancer – Protein 
Series GSE34555    
Status  Public on Dec 21, 2011 
Title  Evaluation of auto-antibody serum biomarkers for breast cancer screening 
Organism  Homo sapiens 
Experiment type  Protein profiling by protein array 
Summary  Using protein microarrays, derived from 642 His-tag proteins, we could 
distinguish sera from breast-nodule positive patients and healthy control individuals. 
Overall design  Each Protein microarray was divided in to 4 sub-arrays. Each protein was 
spotted in duplicates in each sub-array. For evaluation 24 malignant, 16 benign breast cancer 
serum samples and 20 healthy control serum samples were used. 
Contributor(s)  Weinhäusel A, Syed P 
Citation missing  Has this study been published? Please login to update or notify GEO. 
Submission date  Dec 19, 2011 
Last update date  Mar 23, 2012 
Contact name  Parvez Syed 
E-mail  parvez.syed@ait.ac.at 
Organization name  Austrian Institution of Technology 
Street address  Muthgasse 11 
City  Vienna 
ZIP/Postal code  1180 
Country  Austria 
Platforms (1)  
GPL15009  Austrian Institution of Technology Protein Array 642 
Samples (60) 
Relations BioProject  PRJNA151535 
 
Lung Cancer – Microarray 
Series GSE20189    
Status  Public on Sep 23, 2011 
Title  A gene expression signature from peripheral whole blood for stage I lung 
adenocarcinoma 
Organism  Homo sapiens 
Experiment type  Expression profiling by array 
Summary  Affordable early screening in subjects with high risk of lung cancer has great 
potential to improve survival from this deadly disease. We measured gene expression from lung 
tissue and peripheral whole blood (PWB) from adenocarcinoma cases and controls to identify 
dysregulated lung cancer genes that could be tested in blood to improve identification of at-risk 
patients in the future. Genome-wide mRNA expression analysis was conducted in 153 subjects 
(73 adenocarcinoma cases, 80 controls) from the Environment and Genetics in Lung cancer 
Etiology (EAGLE) study using PWB and paired snap-frozen tumor and non-involved lung tissue 
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samples. Analyses were conducted using unpaired t-tests, linear mixed effects and ANOVA 
models. The area under the receiver operating characteristic curve (AUC) was computed to 
assess the predictive accuracy of the identified biomarkers. We identified 50 dysregulated genes 
in stage I adenocarcinoma versus control PWB samples (False Discovery Rate ≤0.1, fold change 
≥1.5 or ≤0.66). Among them, eight (TGFBR3, RUNX3, TRGC2, TRGV9, TARP, ACP1, 
VCAN, and TSTA3) differentiated paired tumor versus non-involved lung tissue samples in 
stage I cases, suggesting a similar pattern of lung cancer-related changes in PWB and lung tissue. 
These results were confirmed in two independent gene expression analyses in a blood-based 
case-control study (n=212) and a tumor-non tumor paired tissue study (n=54). The eight genes 
discriminated patients with lung cancer from healthy controls with high accuracy (AUC=0.81, 
95% CI=0.74-0.87). Our finding suggests the use of gene expression from PWB for the 
identification of early detection markers of lung cancer in the future. 
Overall design  Samples from 164 subjects were initially included in the study. Two 
samples with poor quality profile based on quality assessment (described in Supplemental 
Material 2) were excluded before normalization. The remaining 162 samples were processed and 
normalized with the Robust Multichip Average (RMA) method. Nine additional subjects were 
excluded after data normalization because of reclassification to non-adenocarcinoma 
morphology during histologic review. The final analyses were based on 73 adenocarcinoma 
cases and 80 controls. All 22,277 probe sets based on RMA summary measures were used in the 
analyses. 
Contributor(s)  Rotunno M, Hu N, Su H, Wang C, Goldstein AM, Bergen AW, Consonni 
D, Pesatori AC, Bertazzi P, Wacholder S, Shih J, Caporaso NE, Taylor PR, Landi M 
Citation(s)   Rotunno M, Hu N, Su H, Wang C et al. A gene expression signature from 
peripheral whole blood for stage I lung adenocarcinoma. Cancer Prev Res (Phila) 2011 
Oct;4(10):1599-608. PMID: 21742797 
Submission date  Feb 04, 2010 
Last update date  Mar 06, 2015 
Contact name  Melissa Rotunno 
E-mail  rotunnom@mail.nih.gov 
Phone  301-402-1622 
Fax  301-402-4489 
Organization name  NIH/NCI 
Department  DCEG 
Lab  GEB 
Street address  6120 Executive Blvd 
City  Rockville 
State/province  MD 
ZIP/Postal code  20892 
Country  USA 
Platforms (1)   
GPL571  [HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array 
Samples (162) 
Relations BioProject  PRJNA125685 
 
Lung Cancer – ArrayCGH 
Series GSE14079    
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Status  Public on Mar 03, 2009 
Title  Gene expression analysis & Comparative genomic hybridization from Lung cancer Cell 
lines 
Organism  Homo sapiens 
Experiment type  Expression profiling by array; Genome variation profiling by array 
Summary  Gene expression and Comparative genomic hybridization (CGH) microarrays 
performed in a set of 8 Lung cancer Cell lines. 
Overall design  The search for oncogenes is becoming increasingly important in cancer 
genetics because they constitute suitable targets for therapeutic intervention. To identify novel 
oncogenes, activated by gene amplification, we performed high-resolution CGH (Comparative 
Genome Hybridization) analysis on cDNA microarrays and compared DNA copy number and 
mRNA expression levels in lung cancer cell lines. We have performed both microarrays 
(expression and CGH) in a set of 8 human lung cancer cell lines: Calu3, H23, H441, A427, 
H522, A549, H1299, and H2126. 
Contributor(s)  Medina PP, Castillo S, Sanchez-Cespedes M 
Citation(s)  Medina PP, Castillo SD, Blanco S, Sanz-Garcia M et al. The SRY-HMG box 
gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet 
2009 Apr 1;18(7):1343-52. PMID: 19153074 
Submission date  Dec 21, 2008 
Last update date  Mar 20, 2012 
Contact name  Pedro P Medina-Vico 
E-mail  ppmedinavico@gmail.com 
Organization name  Yale University 
Street address  266 Whitney Ave, 938 KBT 
City  New Haven 
State/province  CT 
ZIP/Postal code  06511 
Country  USA 
Platforms (1)   
GPL1998  CNIO H. sapiens 13.6k Oncochip 1 
Samples (16) 
Relations BioProject  PRJNA112505 
 
Lung Cancer – Methylation 
Series GSE5816   
Status  Public on Jan 03, 2007 
Title  A Genome-wide Screen for Hypermethylated Genes in Lung Cancer 
Organism  Homo sapiens 
Experiment type  Expression profiling by array 
Summary  Abstract 
Background: Promoter hypermethylation coupled with loss of heterozygosity at the same locus 
results in loss of gene function in many tumor cells. The “rules” governing which genes are 
methylated during the pathogenesis of individual cancers, how specific methylation profiles are 
initially established, or what determines tumor-type specific methylation are unknown. However, 
DNA methylation markers that are highly specific and sensitive for common tumors would be 
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useful for the early detection of cancer, and those required for the malignant phenotype identify 
pathways important as therapeutic targets. 
Methods and Findings: In an effort to identify new cancer-specific methylation markers, we 
employed a high throughput global expression profiling approach in lung cancer cells. We 
identified 132 genes that have 5’ CpG islands, are induced from undetectable levels by 5-aza-2’-
deoxycytidine (5-aza) in multiple non-small cell lung cancer cell lines, and are expressed in 
immortalized human bronchial epithelial cells. As expected, these genes were also expressed in 
normal lung, but often not in companion primary lung cancers. Methylation analysis of a subset 
(45/132) of these promoter regions in primary lung cancer (N=20) and adjacent non-malignant 
tissue showed that 31 genes had acquired methylation in the tumors, but did not show 
methylation in normal lung or lymphocytes. We studied the eight most frequently and 
specifically methylated genes from our lung cancer data set in breast cancer (N=37), colon 
cancer (N=24), and prostate cancer (N=24) along with counterpart non-malignant tissues. We 
found that seven loci were frequently methylated in both breast and lung cancers, with four 
showing extensive methylation in all four epithelial tumors. 
Conclusions: By using a systematic biological screen we identified multiple genes that are 
methylated with high penetrance in primary lung, breast, colon, and prostate cancers. The cross-
tumor methylation pattern we observed for these novel markers suggests that we have identified 
a partial promoter hypermethylation signature for these common malignancies. These data 
suggest that while tumors in different tissues vary substantially with respect to gene expression, 
there may be commonalities in their promoter methylation profiles that represent potential targets 
for early detection screening or therapeutic intervention. 
Keywords  Cell line comparison 
Overall design  Drug treatment: control, 100 nM, 1 uM 
Cancer vs. Normal Comparison: NSCLC vs. Normal 
Contributor(s)  Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang 
A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CD, Wong M, Shyr Y, Nanda R, Olopade 
OL, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD 
Citation(s)     Shames DS, Girard L, Gao B, Sato M et al. A genome-wide screen for promoter 
methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS 
Med 2006 Dec;3(12):e486. PMID: 17194187 
Submission date  Sep 12, 2006 
Last update date  Mar 20, 2015 
Contact name  David S Shames 
E-mail  shames.david@gene.com 
Phone  650-225-7559 
Organization name  Genentech Inc. 
Department  Oncology Biomarker Development 
Lab  Shames 
Street address  1 DNA Way 
City  South San Francisco 
State/province  CA 
ZIP/Postal code  94080 
Country  USA 
Platforms (1)      
GPL570  [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array 
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Samples (42) 
Relations BioProject  PRJNA97201 
 
Lung cancer – Copy Number 
Series GSE31800    
Status  Public on Sep 12, 2011 
Title  DNA copy number and gene expression profiles of resected non-small cell lung cancer 
tumors 
Organism  Homo sapiens 
Experiment type  Genome variation profiling by genome tiling array; Expression profiling 
by array 
Summary  This SuperSeries is composed of the SubSeries listed below. 
Overall design  Refer to individual Series 
Citation(s)  Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R et al. TRAF6 is an 
amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Invest 
2011 Oct;121(10):4095-105. PMID: 21911935 
Submission date  Aug 31, 2011 
Last update date  Jan 18, 2013 
Contact name  Raj Chari 
E-mail  rchari@bccrc.ca 
Organization name  BC Cancer Research Centre 
Department  Cancer Genetics and Developmental Biology 
Lab  Wan Lam Lab 
Street address  675 West 10th Avenue 
City  Vancouver 
State/province  BC 
ZIP/Postal code  V5Z 1L3 
Country  Canada 
Platforms (2)   
GPL14189  Custom Rosetta-Affymetrix Human platform [rmhu01aa520485] 
GPL14360  BCCRC whole genome tilling path array v2 (March 2006 build) 
Samples (320) 
This SuperSeries is composed of the following SubSeries: 
GSE31798  DNA copy number profiles of NSCLC tumors 
GSE31799  Gene expression profiles of NSCLC tumors 
Relations BioProject  PRJNA145473 
 
Series GSE31798    
Status  Public on Sep 12, 2011 
Title  DNA copy number profiles of NSCLC tumors 
Organism  Homo sapiens 
Experiment type  Genome variation profiling by genome tiling array 
Summary  Whole genome tiling path array CGH was used to measure the copy number 
profiles of 271 NSCLC tumors 
Overall design  271 microdissected NSCLC tumors 
Contributor(s)  Chari R, Lockwood WW, Lam WL 
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Citation(s)  Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R et al. TRAF6 is an 
amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Invest 
2011 Oct;121(10):4095-105. PMID: 21911935 
Submission date  Aug 31, 2011 
Last update date  Mar 23, 2012 
Contact name  Raj Chari 
E-mail  rchari@bccrc.ca 
Organization name  BC Cancer Research Centre 
Department  Cancer Genetics and Developmental Biology 
Lab  Wan Lam Lab 
Street address  675 West 10th Avenue 
City  Vancouver 
State/province  BC 
ZIP/Postal code  V5Z 1L3 
Country  Canada 
Platforms (1)   
GPL14360  BCCRC whole genome tilling path array v2 (March 2006 build) 
Samples (271) 
This SubSeries is part of SuperSeries: GSE31800 DNA copy number and gene expression 
profiles of resected non-small cell lung cancer tumors 
Relations BioProject  PRJNA155045 
 
Series GSE31799    
Status  Public on Sep 12, 2011 
Title  Gene expression profiles of NSCLC tumors 
Organism  Homo sapiens 
Experiment type  Expression profiling by array 
Summary  A custom microarray was used to measure the gene expression of NSCLC tumors. 
This represents a subset of samples which also have matched DNA copy number profiles from 
array CGH experiments 
Overall design  49 microdissected NSCLC tumor samples 
Contributor(s)  Chari R, Lockwood WW, Lam WL 
Citation(s)  Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R et al. TRAF6 is an 
amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Invest 
2011 Oct;121(10):4095-105. PMID: 21911935 
Submission date  Aug 31, 2011 
Last update date  Jan 18, 2013 
Contact name  Raj Chari 
E-mail  rchari@bccrc.ca 
Organization name  BC Cancer Research Centre 
Department  Cancer Genetics and Developmental Biology 
Lab  Wan Lam Lab 
Street address  675 West 10th Avenue 
City  Vancouver 
State/province  BC 
ZIP/Postal code  V5Z 1L3 
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Country  Canada 
Platforms (1)   
GPL14189  Custom Rosetta-Affymetrix Human platform [rmhu01aa520485] 
Samples (49) 
This SubSeries is part of SuperSeries: GSE31800  DNA copy number and gene expression 
profiles of resected non-small cell lung cancer tumors 






























BIOMARKERS FOUND BY KEDA LITERATURE-MINING COMPONENT 
 
































































































































































































































































































































































Table C.27.   Breast cancer modeling results 
 








Normal Uniform 100 
100           
100 
100          
100 
100       
100 2 




Normal Orig 100 
100      
100 
100       
100 
100       
100 1 




Normal Ratio 100 
100      
100 
100        
100 
100          
100 2 
WAS, KRTHB1 ,PJA1, AK125051 
Methylation Tumor vs. Normal Ratio 96.37 
100              
0 
0             
100 
50                
50 5 
CLDN19, KCNJ14, MUC15, TGFBR1, OR2H1, 
C1orf118,  ITIH2, KCNC1, CLDN15, KCNJ14, 
SLFN3, C4orf8, DNASE1L2, MGC35048 
Methylation Tumor vs. Normal Uniform 96.77 100           
0 
11.11        
100 
55.56            
50 
6 
MUC15, TGFBR1, ADRA1A, KRTAP19-5, 
KCNJ14, CLDN19, C1orf177, MGC35048, 
C4orf8, C1orf118, CLDN15, PLXDC1, KCNC1, 
SLFN3, DNASE1L2 
Methylation Tumor vs. Normal Orig 96.76 100           0 
0            
100 50              50 
5 
KCNJ14, ITIH2, MUC15, CLDN19, TGFBR1, 
MGC35048, C1orf177, KRTAP19-5, C4orf8, 
C1orf118, CLDN15 
Methylation Grade 1 vs 2 Ratio 71.21 86.79        0 
15.39         
100 
51.09           
50 9 
C20orf177, CEACAM7, POT1, GJB6, CKMT2, 
TSPAN32, SH3BGRL3, FLJ44881, MUC17, HRC, 
C3orf22, THPO, KLHL6, CUEDC1, IL27, DYDC1, 
CPT1B, POP2,  IBRDC1, PRODH2, IAPP, 
SEC61A2, LRMP, DOK5, PRKCDBP,  TMC8,  
IL22, UTS2, FLJ90579, VWCE,  IL10 
Methylation Grade 1 vs 2 Uniform 65.15 79.25           0 
15.39         
100 
47.32            
50 9 
C20orf177, POP2, CKMT2, FLJ90579, IBRDC1, 
SH3BGRL3, FLJ44881, GJB6, THPO, ABCA3, 
CUEDC1, DTL,  LRMP, DOK5, MUC17, HYI, 
CPT1B, FLJ42486, NALP8, PRODH2, TSPAN32, 
IAPP,  SEC61A2, POT1, TMC8, NOX1, RASIP1, 
VWCE, C3orf22,  ST6GALNAC3 
Methylation Grade 1 vs 2 None 20 1.89         100 
100         
1.89 
50.94      
50.94 10 
POP2, LRMP, CKMT2, VWCE, GJB6, DTL, 
FLJ90579, NOX1, FLJ00060, CUEDC1,  THPO, 
FLJ44881, SH3BGRL3, CEACAM7, FLJ42461, 
C3orf22, IAPP,  C20orf177,  INHBE,, CASP10,  
PROKR2, TSPAN32, PRODH2, DOK5, MFSD7, 
FLJ34922, PRKCDBP, C20orf177 
Methylation Grade N vs 1 Ratio 75.81 86.79          0 
11.11        
100 
48.95          
50 3 
ZP4, GPR141, C1orf177, CLDN15, CHST3, 
C4orf8,  FLJ10781, FOLR1, SLC4A11, SPARCL1, 
REM1 
Methylation Grade N vs 1 Orig 18.03 5.66        100 
100         
5.66 
52.83        
52.83 1 
CHST3, DDAH2, C4orf8, FOLR1 
Methylation Grade N vs 1 Uniform 75.81 86.79         
0 
11.11         
100 
48.95         
50 
3 
ZP4, CLDN19, ZBTB7B, CLDN15, CHST3, 
C4orf8, SPARCL1, FLJ10781,  PDE9A, CYTL1, 
GPR141, REM1, SETBP1, HOM-TES-103 
Methylation Grade Nv2 Ratio 66.67 100        
12.5 
22.22           
100 
61.11       
56.25 
3 
FLJ30058, LIMS3, DMBX1, PRKCB1,  PCOLCE, 
SGCB,  CLDN15 
Methylation Grade Nv2 Uniform 66.67 100        
12.5 
22.22           
100 
61.11       
56.25 
3 
FLJ30058, LIMS3, DMBX1, PRKCB1, SGCB, 
PCOLCE, CLDN15 
Methylation Grade Nv2 Orig 100 100         
100 
100         
100 
100         
100 
1 
LIMS, PRKCB1, FLJ30058, CLTB, ANGPTL2, 
LIMS3, CLDN15, PDPN 
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Methylation GradeNv3 Orig 95.53 100             0 
0              
100 
50                
50 2 
CLDN19, GPR132, CLDN15, C4orf8 
Methylation GradeNv3 Uniform 95.56 100             0 
11.11              
100 
55.56                
50 2 CLDN19, FLJ23657, CLDN15, C4orf8, GPR132 
Methylation GradeNv3 Ratio 99.44 100          
100 
100          
99.42 
100        
99.71 
3 
KCNC1, CLDN19, C1S,  C1orf118, C4orf8, 
GPR132, CLDN15 
Microarray Blood Orig 57.025 100         3.7 
3.7        
100 
51.85         
51.85 15 
AIF1, hCG2023505, LOC56181, ST8SIA4, CA1, 
CDK5R1, CD22, AJ223366.1, ZNF638, OR56B4, 
ACPT, P2RY14, KIAA0196, hCG1787898.2, 
hCG2007944, SPATA11,   PF4V1, TBRG1,  
RPS23,  HBQ1,   SRRM2,  hCG1642749.1, 
FBXO3, KIAA0196, TESK2,   GGA2,  
hCG2014315, BCL2A1,  DXYS155E, SCRN1,  
hCG1983348, USP10,  RPS25,  hCG1642170.3 ,  
FLJ20160, ZNF638, Cep192,  hCG2041718,  
ANXA3,  hCG2041813 
Microarray Blood Ratio 54.92 100               0 
0                
100 
50            
50 22 
USP52, ZNF3, UCN, WIRE, NELL2, ZFP91, 
Z27499.1_CDS_1, ZMAT2, ZFP36L2, 
XM_373795, ZSWIM3, unk91, unk90, unk97, 
TBX21, unk59, PARC, ZNF638, ZNF652, 
LOC91526, ZCCHC14, ZC3HDC7, USP10, USP3, 
TM4SF13, DXYS155E, unk163,  unk173, WSB2, 
TRAP1, ZNFN1A1, unk47, GFOD1, URP, UTRN, 
UGT2A1, TM4SF9, TRIM23, USP10, 
hCG1747327.2, ZF,  RPS23, WARS,  TUBB6, 
YWHAQ,  SYK,  TTBK1, unk57,  SPN, UPK3B, 
UCP2, CA1, UNQ5783, ORM1, unk68, PPARA, 
SLC2A3,  FLJ42953, unk113, C10orf33,  IL2RB, 
NCOR2, UBAP2L 
Microarray Blood Uniform 54.92 100               0 
0                
100 
50            
50 22 
USP52, ZNF3, UCN, WIRE, NELL2, ZFP91, 
Z27499.1_CDS_1, ZMAT2, ZFP36L2, 
XM_373795, ZSWIM3, unk91, unk90, unk97, 
TBX21, unk59, PARC, ZNF638, ZNF652, 
LOC91526, ZCCHC14, ZC3HDC7, USP10, USP3, 
TM4SF13, DXYS155E,   unk163, unk173, ZF, 
URP, UTRN, ZNFN1A1, unk47, WSB2, TRAP1,   
GFOD1,  RPS23,  hCG1747327.2, LOC221091, 
UGT2A1, UPK3B, TRIM23,  TM4SF9, UNQ5783, 
UBXD1, UCP2, WSB2, ORM1,  YWHAQ,  CA1, 
unk68, PPARA, TRAP1,   FLJ42953, ZNF3, 
C10orf33, SLC2A3, unk113, UBAP2L,   TTBK1, 
unk58,  TP53BP2, VDP, NCOR2,  WARS,  
TM4SF13 
Microarray ER Orig 90.2 100           37.5 
37.5         
100 
68.75        
68.75 9 
CDK5R1, AJ223366.1, OR56B4, 438146_rc, 
ACPT, Cep192, P2RY14, HBQ1, hCG2007944, 
PTGER2, ST8SIA4, ZNF638,  hCG17621.3, 
FUSIP1,  YWHAQ, KIAA0196, ASAHL, TRAP1, 
hCG2015808, TSC, DDX46, hCG1787791.2, 
ELMO2 
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Microarray ER Ratio 98.08 100        100 
88.89       
100 
94.44        
100 8 
ACPT, hCG2007944, AJ223366.1, OR56B4, 
438146_rc, hCG1787898.2, SRRM2, CDK5R1, 
KIAA0196, hCG37981.3, ST8SIA4, TSC,  
P2RY14, IARS, hCG1789070.2, TBRG1, 
C10orf47, TRAP1, FBXO3, ZNF638, HBQ1, 
AF386301.1_CDS_1, SPATA11,  TPSG1, MBC2, 
ZNF638, PLEK2, FUSIP1,  LOC56181, 
hCG2014315, hCG1813545.1, Cep192, FUSIP1, 
hCG1644254.2, hCG1787791.2,    
hCG1747327.2, hCG1812838.1, 
hCG1642170.3,  hCG1642749.1 
Microarray ER Uniform 98.08 100        100 
88.89       
100 
94.44        
100 8 
ACPT, hCG2007944, AJ223366.1, OR56B4, 
438146_rc, hCG1787898.2, SRRM2, ST8SIA4, 
TSC, CDK5R1, hCG37981.3, KIAA0196,  
hCG1789070.2, IARS, P2RY14, TBRG1, 
C10orf47, ZNF638,HBQ1, Cep192, FBXO3,  
SPATA11, TRAP1, PLEK2, FUSIP1, TPSG1, 
MBC2, hCG2014315,  LOC56181, 




Microarray Grade1v2 Ratio 61.54 100         6.67 
6.25        
100 
53.13                    
53.33 10 
hCG2040108,  hCG40931.2, "hCG2041203, 
hCG2039305", "hCG20704.2,  hCG2015359", 
"SNRPEL1, SNRPE", KIAA0020, Name, 
"hCG32985.2, hCG2042652", "hCG2001464.2, 
hCG2001453.1", "hCG27168.2, hCG2030721", 
"LOC440607, FCGR1A", hCG33299.3, 
hCG2026261,  "hCG2041203,  hCG2033271.2, 
hCG1989403, "hCG2032253, hCG1999251", 
"hCG40614.2, hCG1985370", ChGn, 
"hCG2038936, hCG2029987.1, hCG2003479",  
"hCG2040657, hCG1645925.2", unk179, 
hCG2042652", hCG38189.3, hCG1990955.1, 
"hCG2020044, hCG2043429", TOMM20,  
"hCG27618.3, hCG1640125.2",  "hCG21570.3, 
hCG1783417.1", "hCG27168.2, SEC63, 







Microarray Grade1v2 Uniform 61.54 100         6.67 
6.25        
100 
53.13                    
53.33 10 
hCG2040108,  hCG40931.2, "hCG2041203  
,hCG2039305", "hCG20704.2,  hCG2015359", 
"SNRPEL1,  SNRPE", KIAA0020, Name, 
"hCG32985.2,  hCG2042652", "hCG2001464.2,  
hCG2001453.1", "hCG27168.2,  hCG2030721", 
"LOC440607,  FCGR1A", hCG33299.3,  
hCG2026261, hCG38189.3,  hCG1990955.1,  
KIAA0746, "hCG2020044,  hCG2043429",  
"hCG27618.3,  hCG1640125.2", "hCG2040657,  
hCG1645925.2", unk179,   hCG2030721", 
hCG40931.2", hCG14638.4,  "hCG40614.2,  
hCG1985370", "hCG21570.3,  hCG1783417.1", 
,  SEC63, "hCG32985.2, ZNF350,  hCG1981858, 
hCG2042652", hCG1989403", "hCG2033271.2, 
"hCG1642357.4, hCG28108.2",  "hCG2017355, 
hCG1733583.1, hCG1983954.1", hCG16179.4, 
"hCG1984513, hCG2014440", "hCG1728885.2, 
hCG1739047.2" 
Microarray Grade1v2 Orig 60.53 95.65                      6.67 
6.67         
95.65 
51.16          
51.16 12 
hCG40614.2, hCG1985370, "LOC440607, 
FCGR1A", "SNRPEL1, SNRPE", hCG2041031, 
"hCG2015869, hCG2015868.1", "hCG27618.3, 
hCG1640125.2", "hCG27168.2, hCG2030721", 
"hCG32985.2, hCG2042652", "hCG33299.3, 
hCG2026261", "hCG20704.2, hCG2015359", 
"LOC283922, PDPR", "hCG2038936 
,hCG2029987.1, hCG2003479",  ChGn, 
hCG2041203,  hCG2039305, "hCG2040657, 
hCG1645925.2", "hCG38189.3,  
hCG1990955.1", ,hCG1646386.3,  
"hCG27168.2,  "hCG2040108, hCG40931.2", 
"hCG21570.3, hCG1783417.1",  "HIST2H2AA, 
HIST2H2AC", KIAA0020, , TXNRD2,  
hCG1746597.1, ZNF350, "hCG2033271.2, 
hCG1989403", RPS26,  ,hCG1990955.1", 
hCG1985370",  hCG2015359", "LOC440607,   
hCG14638.4, CX3CR1, "hCG2039500, 
hCG1737371.3", , "hCG2033271.2 
,hCG1989403" 
Microarray Grade1v3 Orig 42.11 4.35        100 
100        
4.35 
52.17       
52.17 10 
FNBP4, TRPV4, SPATA5L1, MLL5, RAD21, 
hCG2039309.1, DNAJB9, hCG1747328.2,  
hCG17415.3, TMEM40, EIF4G3, hCG2014776,  
DPP9,  DDX5, C19orf25, FBXO7,  hCG2039497,  
hCG2023112.1, MGST2,  hCG2010443,  
LOC55924, hCG24651.4, hCG2027440, PISD, 
hCG2039309.1,  ANKRD11, SESTD1, RAB2B, 
ABCB7, SAP30, IPLA2(GAMMA), AGL, PISD 
Microarray Grade1v3 Uniform 71.8 100         33.33 
31.25        
100 
65.63           
66.67 10 
FNBP4, FBXO7, TRPV4, hCG2039309.1, 
hCG1747328.2, RSN, RAD21, LOC55924, 
hCG17415.3, PISD, hCG2040593, DNAJB9,  
TMEM40,  hCG17415.3,  hCG2039497, HERC1, 
MLL5, unk133,  DPP9, RAB2B, MGST2, 
FLJ11171, hCG2027440, ATR, ANKRD11, MLL5,  
HOM-TES-103, EIF4G3, hCG2014776 
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Microarray Grade1v3 Ratio 79.49 100       53.33 
50         
100 
75         
76.67 11 
FNBP4, MGST2, TRPV4, hCG2023112.1, 
hCG2039309.1, hCG1747328.2, ANKRD11, 
RSN, RAD21, hCG17415.3, PISD, TMEM40, 
DNAJB9,    hCG2040593, FBXO7, hCG2039497, 
LOC55924,  hCG2039309.1,  FLJ11171, RAB2B,  
TMEM40, hCG2027440, ATR, MLL5, HOM-TES-
103, DPP9,  SESTD1, hCG2014776,  EIF4G3 
Microarray Grade2v3 Orig 69.57 100       39.13 
39.13         
100 
69.57        
69.57 13 
PTGS2, SRP14, CKLFSF8, CCDC5, SESN2, 
hCG2041826, TM4SF9, PF4, hCG2009487, 
POLR2A, RAB43, ITGB2, PSMB9,  GPR155, 
hCG1820921.1, unk9, hCG2039161, 
hCG2010471.1, ZNF206,   hCG1642482.3, 
CD79A,  MGC29814, FHIT, CAMK2G, ADAR, 
ALOX5AP, DKFZp762O076,   EDG8, 
hCG2042923,  MTF1,   FLJ23091, hCG22325.2, 
PAK1 
Microarray Grade2v3 Ratio 59.57 82.61               39.13 
37.5           
83.33 
60.05                  
61.23 12 
CAMK2G, MGC32065, PSMB9, PYGL, TM4SF9, 
ZNF206, hCG1781673.1, ITGB2, hCG2039161, 
GPR155, C20orf178, hCG2039498, 
hCG2041220, CD79A, CKLFSF8, TIZ, IRF7, 
MGC32065, hCG1782892.2, hCG2009487, 
hCG2041826,   CCDC5, hCG16179.4,  
hCG20164.2, hCG1781894.2,  SRP14, C1orf24,  
PF4, SESN2, FHIT,  ProSAPiP2, ALOX5AP, 
PTGS2, hCG1642482.3,  F13A1, AMPD2, 
HMGB1,  ZNF206,  EDG8,  hCG26831.3,   
413154_rc 
Microarray Grade2v3 Uniform 59.57 82.61               39.13 
37.5           
83.33 
60.05                  
61.23 12 
CAMK2G, MGC32065, PSMB9, PYGL, TM4SF9, 
ZNF206, hCG1781673.1, ITGB2, hCG2039161, 
GPR155, C20orf178, hCG2039498, 
hCG2041220, CD79A, CKLFSF8, TIZ,  IRF7, 
hCG2009487, hCG2041826, hCG1782892.2, 
PFKFB3, hCG16179.4, PF4, SRP14, EDG8, 
PTGS2, C1orf24, FHIT, SESN2, ProSAPiP2, 
ALOX5AP, hCG1642482.3, AMPD2,  F13A1k, 
413154_rc, HMGB1, KLFSF8, CCDC5, 
hCG26831.3 
Microarray Menopause Orig 29.41 2.70        100 
100         
2.70 
51.35         
51.35 9 
SNRPD2, TRIM46, XPC, 41886, hCG1772363.3, 
SLC31A1, hCG1790688.1, hCG1820954.2, 
DEPC-1, NUSAP1, UNG, NTAN1, POR, 
FLJ10374, GTF2E2,  STX17, ARID4B, SLC22A4, ,  
LENG4, hCG1744783.2, hCG22538.3, 
hCG1790802.3 
Microarray Menopause Uniform 26.92 0               100 
100                 
0 
50                 
50 11 
SLC31A1, 41886, XPC, SNRPD2, 
hCG1790688.1, DEPC-1, SLC22A4, NTAN1, 
hCG1772363.3, hCG1820954.2, INCA, AGGF1, 
UNG, PKM2, PMM2, NUSAP1, STX17, 
hCG1820954.2, FLJ10374, hCG1991671.2, 
FLJ10374, hCG2040754, hCG22964.3, 
RARRES3, TMSB10, hCG1820528.1, POR, SIT, 
RASGRP4, BZW2, hCG22538.3, SCGB1A1, 
TRIM46, NUSAP1, ST3GAL5, STX17 
Microarray Menopause Ratio 26.92 0               100 
100                 
0 
50                 
50 11 
SLC31A1, 41886, XPC, SNRPD2, 
hCG1790688.1, DEPC-1, SLC22A4, NTAN1, 
hCG1772363.3, hCG1820954.2, NUSAP1, 
PMM2,  PKM2, INCA,  AGGF1, UNG, STX17, 
FLJ10374,  NUSAP1, hCG1820954.2, POR,  
TRIM46, ARID4B, TMSB10, RASGRP4, LENG4, 
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SIT, hCG1820528.1, INCA, SCGB1A1, 
hCG22538.3,  BZW2, ST3GAL5 
Protein BM Ratio 68.29 100         18.75 
23.53       
100 
61.77            
59.38 5 
SMARCA1, MLLT6, UNK63, BZRAP1, FADD, 
HSPD1, IK, C17ORF65, CCR6, JPH3, EXOSC10, 
NARF, C4B 
Protein BM Orig 60 100             0 
0            
100 
50                
50 8 
EBNA1BP2, RNF130, CCR6, HDAC2, JPH3, 
TUBA1A, CCND1, ING2, FADD, HSPD1, IK, 
C17ORF65, TOMM70A, MRPL28, ING2, 
TERF2IP, UNK26, PKLR, DYNLL1, EGFL6, 
SAMD14, TANK, CCR6, CREBBP,  XIRP1, FDFT1, 
NR4A3, XIRP1, EXOSC10, TUBA1A, MUC16, 
CCDC109B, C11ORF2, CCND1, SARNP, ZNF629, 
NUMA1 
Protein BM Uniform 68.29 100          18.75 
23.53       
100 
61.77            
59.38 5 
SMARCA1, NARF, MLLT6, BZRAP1, FADD, 
HSPD1, IK, C17ORF65, CCR6, JPH3, EXOSC10, 
C4B, COQ4, NAP1L4, HSPD1 
Protein NB Ratio 56.76 100               0 
5.88        
100 
52.94       
50 1 
RAB24, CREBBP, JPH3, MPHOSPH8, 
EBNA1BP2, FADD, UNK11, MLLT6, UNK63, 
BZRAP1 
Protein NB Uniform 56.76 100               0 
5.88        
100 
52.94       
50 1 
RAB24, CREBBP, JPH3, MPHOSPH8, 
EBNA1BP2, FADD, UNK11, C4B, UNK63, 
BZRAP1 
Protein NB Orig 66.67 100          25 
25          
100 
62.5         
62.5 7 
CCR6, JPH3, CAP1, CBX5, EBNA1BP2, 
TOMM70A, HSPD1, NOP2, CREBBP, FADD, 
RPS3A, IK, TERF2IP, ZNF48, ZNF238, 
ARHGEF18, SPAG7, TBC1D9, ZNF629, 
ZNF658B, XIRP1, PKLR, TANK, NOP2, YBX1,  
JPH3, UNK60, VPS13D 
Protein NM Ratio 55.56 100             0 
4.76         
100 
52.38        
50 1 
TANK, CCR6, JPH3, CAP1, CBX5, EBNA1BP2, 
FADD, ARPP21, HSPD1, MUC16 
Protein NM Uniform 55.56 100             0 
4.76         
100 
52.38        
50 1 
TANK, CCR6, JPH3, CAP1, CBX5, EBNA1BP2, 
FADD, ARPP21, HSPD1, MUC16 
Protein NM Orig 50 91.67               0 
0           
91.67 
45.83        
45.83 7 
CBX5, EBNA1BP2, FADD, CCR6, ARPP21, 
CREBBP, HSPD1, JPH3, CAP1, IK, EXOSC10, 
TERF2IP, CAP1, ARPC2, HDAC6, C11ORF2, 
LILRB1, CBX5, TANK, POLR2G, EXOSC10, YBX1, 
MRPL28, HDAC6, NPEPL1, GAPDH, RPL5, 
GSPT2 
RT-PCR   Orig 88.89 100          66.67 
66.67        
100 
83.33        
83.33 4 
CD68, FOXC2, PTPRC, TFRC, KLK3, JUN 
RT-PCR   Ratio 89.29 100          66.67 
70           
100 
85           
83.33 5 
CD68, TFRC, ABCB1, PTPRC, BCL2, AR, FOXC2,  
FOLH1, KLK3 
RT-PCR   Uniform 89.27 
100          
66.67 
70           
100 
85           
83.33 5 











Table C.28.   Lung cancer modeling results 
 
Data type Comparison Prior Accuracy SN SP Balanced Accuracy 
Model 
Size Union of variables used 
ArrayCGH RNA vs.                          DNA Informed 50 
100            
0 
0                  
100 
50              
50 2 
unk96, ZNFN1A1, MCAM, PP, 
VTN, GAS7, unk574, AA454543, 
ORM1, unk493, KIAA0934, 
MSL3L1, AA460731, MRPL35 
ArrayCGH RNA vs.                          DNA Uniform 47.06 
100                
0 
0                  
100 
50             
50 3 
unk96, ZNFN1A1, SFRP2, PP, VTN, 
IRF4, GAS7, AA454543, ORM1, 
TNNI3K, KIAA0934, MSL3L1, 
ARGBP2, F8A1 
ArrayCGH RNA vs.                          DNA None 50 
100             
0 
0               
100 
50            
50 2 
unk96, ZNFN1A1, MCAM, PP, 
VTN, GAS7, unk574, AA454543, 
ORM1, unk493, KIAA0934, 
MSL3L1, AA460731, MRPL35 
Copy Number Adeno vs. Squamous Informed 64 
100                      
10 
14.29          
100 
57.14            
55 11 





C1orf181, GLIS2, CENPO, 
LOC644285, FGFR1OP2, ESAM, 
merck-AL049252_a_at, merck-
BQ446551_at, ALPK3, merck-
AK024690_at, PRO0456, CGN, 




Copy Number Adeno vs. Squamous Uniform 62 
100                 
5 
9.5                  
100 






BM979827_at, C1orf181, GLIS2, 
LOC644246, CGN, SLC28A3, 









Copy Number Adeno vs. Squamous None 63.26 
100                
10 
10                     
100 






BM979827_at, PXMP4, ESAM, 





AK001128_at, PRO0456, POT1, 
LONRF2, SGCD, SLC39A10, CENPO 
Methylation High vs. Control Informed 68.97 
100                   
30.77 
35.71             
100 
67.85             
65.39 7 
DBF4, VKORC1, IMPDH2, ANP32B, 
EIF4A2, AC005011, MRPL24, 
PRIM1, H2AFV, MRPL37, MRPL24, 
CTNNAL1, RPL37A, HAUS1, 
COPS2, HNRNPA3 /// 
HNRNPA3P1, HMGN2, OAT, 
RPL29, TPD52L2, HSPD1, ZNF593, 
MEST, FN1, SLC3A2, C5orf32, 
LOC100510735 /// RPL29, 
HMGN2, UQCR10  
Methylation High vs. Control Uniform 55.17 
100               
0 
7.14              
100 
53.17               
50 8 
PRIM1, CLNS1A, TNNT1, RPL37A, 
VKORC1, AC005011, UBE2Q2, 
MRPL24, TMEM97, LGTN, OAT, 
HAUS1, COPS2, RPL37A, FOXM1, 
DBF4, RPLP0 /// RPLP0P6, EIF4A2, 
MYEOV2, CDKN1B, MRPL37, DH2, 
BOLA2 /// LOC440354 /// 
LOC595101, H2AFV, MYEOV2, 
MEST, CKMT1A /// CKMT1B, 
RAD21, ZNF593, SRI, IMPDH2, 
AC005011, HMGN2 
Methylation High vs. Control None 85.71 
100            
69.23 
69.23            
100 
84.62                  
84.62 9 
PRIM1, H2AFV, HEBP2, VKORC1, 
YWHAB, MRPL24, RPL37A, ND2, 
FOXM1, ITGAV, MYL12A, HDAC1, 
UBE2E2, CYC1, ZNF721, ITGB3BP, 
SERINC3, METTL5, NDUFB9, 
CACYBP, FAM96A, MOBKL1A, 
STOM, PRSS3, DCBLD2, PPL, HN1, 
C14orf156, ITGB4, TMEM14C, 
AFFX-HUMGAPDH/M33197_5_at, 
TRNP1, JAG1, CBR1, TJP1, CD164, 
PRICKLE4 /// TOMM6, RTN4, 
ACTR3, PLSCR3, NOP56, 
LOC100506727, FAM127A, PRC1, 
AC004544 
Methylation High vs. Low Informed 73.91 100                33.33 
40           
100 
70           
66.67 6 
HN1, RRAS, ASNS, POLB, ITGAV, 
LOC100506727, CYC1, ZNF721, 
METTL5, ITGAV, PRSS3, YWHAB, 
XRCC6, PLSCR3, ATP6V1F, 
CDK11A, RPA3, UBE2E2, 
C14orf156, TMEM50A, C1orf103, 
RNASEK, KRT18, TIMP1, HDAC1, 
PPP3CA, GPRC5A, ASNS, CD164, 
C14orf156, PTTG1IP, UBE2S, 
CAPRIN2 
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Methylation High vs. Low Uniform 69.57 100           22.22 
30                  
100 
65                    
61.11 6 
ACTR3, ZNF721, SLC38A2, ASNS, 
SHMT2, CES2, CD164, PRICKLE4 
/// TOMM6, MYL12A, CYC1, 
METTL5, PRSS3, ITGB3BP, 
TMEM50A, HMGB2, ITGAV, 
AY094612, ATP6V1F, CDK11A, 
RPA3, UBE2E2, C14orf156, RRAS, 
ITGB4, PTTG1IP, PPP3CA, TIMP1, 
LOC100506727, HDAC1, UCHL1, 
GPRC5A, XRCC6, ZNF721, STUB1, 
NIT2, HN1, KRT18, BRD9, PLSCR3, 
BLCAP, XRCC6, COPS8 
Methylation High vs. Low None 77.27 100           44.44 
44.44            
100 
72.22         
72.22 8 
DCBLD2, HN1, MBOAT2, 
C14orf156, PRICKLE4 /// TOMM6, 
ITGAV, UBE2E2, ZNF721, MYL12A, 
HDAC1, CYC1, ITGB3BP, SERINC3, 
ZNF721, METTL5, NDUFB9, 
CACYBP, FAM96A, MOBKL1A, 
STOM, PRSS3, PPL, ITGAV, ITGB4, 
TMEM14C, AFFX-
HUMGAPDH/M33197_5_at, 
TRNP1, JAG1, CBR1, TJP1, CD164, 
RTN4, ACTR3, PLSCR3, NOP56, 
LOC100506727, ND2, FAM127A, 
PRC1, AC004544 
Methylation Low vs. Control Informed 48 
66.67                   
11.11 
30              
93.75 
48.33         
52.43 8 
DEPDC1B, DAP3, CCDC142 /// 
MRPL53, RSRC2, ADNP, NDUFB8, 
RPL18A /// RPL18AP3, MGST1, 
NME4, GAS5, EIF3K, CENPW, 
MGST1, NRAS, CUTA, 
LOC100499177, TMEM126A, 
SYPL1, FKBP1A, SRP14, AFFX-
BioDn-5_at, AV724183, DLGAP5, 
RBX1, TOMM22, RAD51AP1, 
H2AFV, TRAPPC5, FIBP, SEC24B, 
NCAPD2, GNG5, CDCA4, JAG2, 
RSRC2, PTPRO, FOXM1, AFFX-
HSAC07/X00351_3_at, PABPC1 
Methylation Low vs. Control Uniform 76 
100             
33.33 
40          
100 
70        
66.67 7 
CCDC142 /// MRPL53, AFFX-
BioDn-5_at, NCAPD2, EIF4A2, 
NDUFB8, NRAS, H3F3B, GAS5, 
NDUFB11, PAICS, EIF3G, RSRC2, 
FOXM1, PABPC1 /// RLIM, 
LOC100505603 /// PNRC2, PHB, 
DLGAP5, DAP3, AV724183, 
MRPL51 /// SPTLC1, EIF3K, NRAS, 
H3F3B, H2AFV, DEPDC1B, AFFX-
BioDn-5_at, PTPRO, GNAI3, ADNP, 
SRP14, LOC100499177, NCAPD2, 
XRCC6, RSRC2, LOC647979, RBX1, 
FZD6, GNG5, RAD51AP1, PSMD10, 
LUZP6 /// MTPN, ECEP55 
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Methylation Low vs. Control None 37.5 
100                
0 
0                
100 
50                   
50 8 
CCDC142 /// MRPL53, RSRC2, 
ADNP, AFFX-
HUMGAPDH/M33197_3_at, 
DLGAP5, MRPL51 /// SPTLC1, 
RPL29, EI24, TOMM22, FKBP1A, 
YWHAB, HNRNPA1, 
LOC100499177, DAP3, XRCC6, 
C19orf53, EI24, CAP1, NRAS, 
ITGB1, EIF3K, TXNDC12, TXNDC17, 
NDUFB8, TMEM126A, 
LOC647979, AFFX-BioDn-5_at, 
KIAA1949, PTPRO, PSAT1, SRSF6, 
RPL28, AFFX-
HUMGAPDH/M33197_3_at, 
PPP3CA, STARD4, RSRC2, 
TMEM147, CDCA4, XRCC6, GAS5, 
FKBP1A, CENPW 
Microarray Case vs. Control Informed 50 
93.75         
1.37 
12.16            
100 
52.96            
50.69 20 
FLJ20006, AP2M1, SLC25A46, 
GSR, WLS, C21orf59, FLJ10246, 
41888, ASAP2, AL121916, 
FLJ20700, ZNF562, 
DKFZp547P082, AU147295, 
PRO1995, F13A1, TRIM68, AFFX-
BioB-M, ING3, DDX27 /// SS18, 
KIAA1033, BE999967, VPREB3, 
PRO1995, F13A1, LTF, FLJ21272, 
NAE1, ING3, WBSCR22, RPL36, 
PEBP1, AL121916, PIGP, 
AU147295, NCL, PJA1, KLHL28, 
TNFAIP6, 41700, MTPAP, RPL27, 
AGFG1, RNASE6, ROGDI, GNA15, 
PTGDR, ZNF721,  LONP2, FSTL1, 
DRAM1, RALGPS2, JAK2, NXT1, 
FLJ11786, PRPF19, CHIC2, HIRA, 
OGFOD1, C1QB, RPL3, NFATC2IP, 
ARF4, NEU1, DEFA1 /// DEFA1B 
/// DEFA3, RPL34, IGHA1 /// 
IGHA2 /// IGHG1 /// IGHG2 /// 
IGHG3 /// IGHM /// IGHV4-31 /// 
LOC100126583 /// 
LOC100290036, RCBTB2, 
COL4A3BP, PEBP1, TBX21, 
FLJ11786, TM7SF3, CXCL5,FSTL1,  
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Microarray Case vs. Control Uniform 55.2 
100        
5.48 
6.76        
100 
53.38                
52.74 18 
PRO1995, FLJ20700, FLJ21272, 
FLJ20006, CHIC2, 41888, 
AL121916, FLJ10246, SLC25A46, 
RPL36, AU147295, RPL3, RNASE6, 
PRIM1, ASAP2, NFATC2IP, WLS, 
ING3, COL4A3BP, CNPY2, SRSF11, 
AFFX-BioB-M, IGHA1 /// IGHA2 
/// IGHG1 /// IGHG2 /// IGHG3 /// 
IGHM /// IGHV4-31 /// 
LOC100126583 /// 
LOC100290036, NCL, 
DKFZp547P082, 41700, HLA-DQA1 
/// HLA-DQA2, FLJ20700, 
CCDC90A, AP2M1, FLJ13197, 
TM7SF3, FLJ10246, SPARC, 
OGFOD1, 41700, ARF4, OSBPL10, 
AGFG1, RPL27, ROGDI, GNA15, 
PTGDR, ZNF721, LTF, MTPAP, 
LONP2, FSTL1, DRAM1, TMX2, 
ZNF562, C21orf59, FLJ21272, 
KIAA0182, ARHGEF18, SMOX, 
NKTR, AGFG1, RPS18, SORT1, 
C17orf60,FTSJD2, BBX, GPR89A 
/// GPR89B /// GPR89C, ANK1, 
JAK2, PIGP, NCL 
Microarray Case vs. Control None 56.86 
95           
15.07 
15.07          
95 
55.03           
55.03 17 
NKTR, DKFZp547P082, TMX2, 
C21orf59, 41700, PRO1995, 
FLJ20700, FLJ21272, FLJ20006, 
FLJ11786, EGF, AP2M1, AFFX-
BioB-M, FLJ10246, 41888, 
SLC25A46, RNASE6, TM7SF3, 
KIAA0182, AU147295, FLJ13197, 
PEBP1, C21orf59, WLS, FLJ11786,  
TBX21, AL121916, NELL2, 41700, 
PJA1, FLJ11786, PIGP, ANK1, 
ING3, PLGLA /// PLGLB1 /// 
PLGLB2, BF984434, ASAP2, 
TRAF3IP3 
Microarray Adeno vs. SCC Informed 97.53 100          83.33 
75          
100 
87.5                       
91.67 8 
PCBP1, TMBIM1, HSDL2, 
FLJ21272, IER3, DEFA1 /// DEFA1B 
/// DEFA3, AFFX-r2-Ec-bioC-3, 
FLJ23556, ATP6V1A, HEBP2, 
TBXAS1, AFFX-r2-Ec-bioB-3, 
CDC42EP3, AFFX-BioB-3, C7orf42, 
TM6SF1,  ASGR1, DAZAP2, DPM1, 
RNF130, FBXO11, PRO1412, 
TIMM8B, BRP44L 
Microarray Adeno vs. SCC Uniform 92.59 98.63               33.33 
37.5               
98.67 
68.07                        
66 7 
FLJ21272, IER3, ATP6V1A, 
BRP44L, DEFA1 /// DEFA1B /// 
DEFA3, PCBP1, TMBIM1, AFFX-
BioC-5, AFFX-BioC-3, AFFX-r2-Ec-
bioB-3, AFFX-r2-Ec-bioB-5, 
LMBRD1, CAB39, FLJ23556, PGCP, 
DAZAP2, KCNJ15, AFFX-r2-Ec-
bioC-3, PPP3CA, DPM1, PRO1412, 
HADHB, AFFX-r2-Ec-bioC-5, AFFX-
BioB-5, AFFX-BioDn-5, FBXO11 
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Microarray Adeno vs. SCC None 93.75 100         33.33 
28.57          
100 




CDC42EP3, TMBIM1, BRP44L, 
AFFX-r2-Ec-bioB-5, AFFX-r2-Ec-
bioC-3, AZIN1, FLJ21272, AFFX-
BioB-5, ATP6V1A, AFFX-BioDn-5, 
HSDL2, DEFA1 /// DEFA1B /// 
DEFA3, PRO1412, FLJ23556, 
NAPA, TBXAS1, AFFX-BioC-5, 
TFEC, FBXO11, DAZAP2, TM6SF1, 
ASGR1, PRO1412, BRP44L, DPM1, 








Informed 55 100          1.82 
3.57        
100 
51.79               
50.91 16 
RTP4, OLFR89, FLJ23556, RTN3, 
SLC22A8, JUNB, COL9A2, EFNA3, 
PDLIM1, POLL, OSGEP, C7orf28B 
/// CCZ1, CLEC2D, TBC1D12, 
FLJ11117, NDUFB8, SFPQ, 
MFHAS1, OR7E37P, SOD3, 
RPS6KA1, RAPGEF2, HSAF000381, 
PXN, AFFX-M27830_5, SV2A, 
SFRS15, SFPQ, CRAT, 
HSAF000381, TMEM161A, 
UBE2D3, C16orf71, PXN, 
DKFZp547P082, UBR2, C6orf62, 
AU148154, AA654586, RAB14, 
PCNP, CHMP1B, SFMBT1, XPO1, 
MAPKAPK5, NRGN, OSGEP, LSR68, 
EML4, AW150065, DPM2, NUDT3, 
POLL, RBPJ, PPP4C, NUPL1, IGLC7 
/// IGLV1-44, KIAA0317, SYNE1, 
FAM129A, MEF2A, TBC1D12,  
VCL, PXN, ANKRD28, NUSAP1, 
HNRNPA1 /// HNRNPA1L2 /// 
HNRNPA1P10 /// LOC728643, 
MEF2A, NAB1, CCL5, RPLP0 /// 
RPLP0P6, GGA1, ACTR2, SOD2, 








Uniform 55 100        3.64 
3.57         
100 
51.79                    
51.82 11 
OLFR89, RTP4, LSM2, AA654586, 
HSAF000381, C7orf28B /// CCZ1, 
SLBP, RAPGEF2, EFNA3, SFPQ, 
FLJ23556, NOD2, MAPKAPK5, 
NUSAP1, HSAF000381, TBC1D12, 
BF448531, C16orf71, IGKV1-5, 
DKFZp547P082, DPM2, XCL1 /// 
XCL2, MRP63, AFFX-M27830_5, 
PPP4C, OSGEP, RPS6KA1, SOD2, 
RBM16, NDUFB8, PGAP3, LSR68, 
CEP57, IGK@ /// IGKC /// IGKV1-
5, RPS24, CLEC2D, FLJ11117, 
NPHS2, AL080190, COL9A2, 
FANCG, CTTN, FLJ23556, FPR2, 
DPM2, AU148154, IGKV1D-8, 
RPLP0 /// RPLP0P6, AV742010, 
ANKRD28, LSR68, SYNE1, CRAT, 
FAR2, IGLL3P, KIAA0317, 
C17orf101, PELI1, CHMP1B, 
M85256, PCBP1, SOD2, 







None 53.78 100               0 
0              
100 
50                 
50 16 
OLFR89, MAPKAPK5, OSGEP, 
C16orf71, LSR68, EML4, 
DKFZp547P082, RTP4, C14orf56, 
FLJ23556, HSAF000381, IGF2BP2, 
AFFX-M27830_5, CLEC2D, 
TBC1D12, FLJ11117, IGKV1D-8, 
RPS6KA1, EFNA3, NRGN, 
C7orf28B /// CCZ1, RTN3, CRAT, 
RFWD3, ANKRD28, SNRNP40, 
EML4, EHD3, GPRC5C, SFPQ, 
COL9A2, SOD2, LSM2, 
HSAF000381, LSR68, CLCN2, 
IGF2BP2, UBXN6, AL080190, 
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